<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005117.pub2" GROUP_ID="MUSKEL" ID="366304050918521942" MERGED_FROM="" MODIFIED="2014-02-07 09:19:59 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C028-R" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.8">
<COVER_SHEET MODIFIED="2014-02-07 09:19:59 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE>Diacerein for osteoarthritis</TITLE>
<CONTACT>
<PERSON ID="D333AF6682E26AA20080535F106A5F7A" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Tania</FIRST_NAME>
<MIDDLE_INITIALS>S.A.</MIDDLE_INITIALS>
<LAST_NAME>Fidelix</LAST_NAME>
<SUFFIX/>
<POSITION>MD</POSITION>
<EMAIL_1>tsafidelix@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine and Therapeutic</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Mediterraneo, 290 sl 13</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Bernardo</CITY>
<ZIP>09750 420</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2>+55 11 41255840</PHONE_2>
<FAX_1>+55 11 43303676</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-02-07 09:19:59 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="D333AF6682E26AA20080535F106A5F7A" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Tania</FIRST_NAME>
<MIDDLE_INITIALS>S.A.</MIDDLE_INITIALS>
<LAST_NAME>Fidelix</LAST_NAME>
<SUFFIX/>
<POSITION>MD</POSITION>
<EMAIL_1>tsafidelix@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine and Therapeutic</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Mediterraneo, 290 sl 13</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Bernardo</CITY>
<ZIP>09750 420</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2>+55 11 41255840</PHONE_2>
<FAX_1>+55 11 43303676</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="62E0491B82E26AA201F801F7BD1071A6" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cristiane</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Macedo</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher/Trials Search Co-ordinator</POSITION>
<EMAIL_1>crisrufa@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION>
<ADDRESS_1>Rua Borges Lagoa 564 cj 63</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04038-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5575 2970</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17387" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Lara</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Maxwell</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor, Cochrane Musculoskeletal Group</POSITION>
<EMAIL_1>lmaxwell@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613 562 5800 ext: 1977</PHONE_1>
<PHONE_2/>
<FAX_1>613 562 5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14973" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Virginia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fernandes Moça Trevisani</LAST_NAME>
<SUFFIX/>
<POSITION>Prof. Emergency Medicine and Evidence Based Medicine</POSITION>
<EMAIL_1>vmoca@uol.com.br</EMAIL_1>
<EMAIL_2>cochrane.dmed@epm.br</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Rheumatology/Internal Medicine and Therapeutics</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Marie Satzke 119</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04664-150</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 55752970</PHONE_1>
<PHONE_2>+55 11 38314161</PHONE_2>
<FAX_1>+55 11 55790496</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-01-22 10:01:18 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2014-02-04 05:52:24 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-02-04 05:52:24 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>With the addition of three new trials including 141 participants, the updated review now reports findings of a total of 10 studies including 2,210 participants. New tools used in the review downgraded the quality of the evidence.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-01-22 10:05:20 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Two new review authors, Cristiane Rufino Macedo and Lara Maxwell, were included in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-10-04 16:46:02 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-04 16:46:02 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID C028-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-25 11:20:58 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-11-26 22:04:56 -0500" MODIFIED_BY="Dolores Matthews">
<INTERNAL_SOURCES MODIFIED="2013-11-26 22:04:56 -0500" MODIFIED_BY="Dolores Matthews">
<SOURCE MODIFIED="2013-11-26 22:04:56 -0500" MODIFIED_BY="Dolores Matthews">
<NAME>UNIFESP Escola Paulista de Medicina</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Brazilian Cochrane Centre</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-02-06 16:15:10 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-02-06 12:49:34 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-04-23 10:59:00 -0400" MODIFIED_BY="[Empty name]">Diacerein for osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2014-02-06 12:49:34 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>What is osteoarthritis and what is diacerein? </B>
</P>
<P>Osteoarthritis (OA) is the most common form of arthritis. In OA, the cartilage that protects the ends of the bones breaks down, causing pain and swelling. OA can affect any joint, but the knees, hips and hands are the joints most often studied in clinical trials. In all, 10% of the world&#8217;s population aged 60 or older have pain or disability from OA.</P>
<P>Diacerein is a slow-acting drug taken as a pill that may slow the breakdown of cartilage and relieve pain and swelling.</P>
<P>The review searched for studies up to March 2013 about primary osteoarthritis affecting men and women (18 years and older) of any disease severity.</P>
<P>
<B>The review shows that in people with osteoarthitis:</B>
</P>
<P>- Pain may improve slightly more in people taking diacerein.</P>
<P>- Improvement in physical function is about the same for people taking diacerein,- or a placebo (fake pill). This may have happened by chance.</P>
<P>- Diacerein may slow the process of joint space narrowing slightly of the hip but may have little or no difference on the knee joint as it is seen on an x-ray.</P>
<P>- Diacerein may cause side effects in the lower digestive tract, such as diarrhoea.</P>
<P>Further research is very likely to have an important impact on our confidence in these findings and is likely to change the estimates.</P>
<P>
<B>Best estimate of what happens to people with osteoarthritis who take diacerein</B>
</P>
<P>
<B>Pain after three to 36 months</B>
</P>
<P>- People who took diacerein rated their pain to be 9 points lower on a scale of 0 (no pain) to 100 (extreme pain) after taking the medication for three to 36 months (9% absolute improvement).</P>
<P>- People who took diacerein rated their pain to be 34 on a scale of 0 to 100 after taking the medication compared to people who took a fake pill and rated their pain to be 43 points on a scale of 0 to 100.</P>
<P>
<B>Physical function after two to 36 months (lower score means worse function)</B>
</P>
<P>- People who took diacerein rated their physical function to be 0.30 points lower on a scale of 0 to 24 after taking the medication for two to 36 months (0% absolute improvement).</P>
<P>- People who took diacerein rated their physical function to be 9.3 on a scale of 0 to 24 after taking the medication compared to people who took a fake pill and rated their physical function to be 9 points on a scale of 0 to 24.</P>
<P>
<B>Radiographic progression - how the joint looks on an x-ray (reduction in joint space narrowing of at least 0.5 mm)</B>
</P>
<P>- Seven more people who took placebo had radiographic progression (absolute difference of 7%).</P>
<P>- 42 of every 100 people who took diacerein experienced reduction in joint space narrowing of at least 0.5 mm compared to 49 of every 100 people who took a fake pill.</P>
<P>
<B>Quality of life</B>
</P>
<P>- The review authors found no studies about quality of life of people who took diacerein compared with placebo.</P>
<P>- There was no difference in quality of life of people who took diacerein compared with non-steroidal anti-inflammatory drugs (NSAIDs). This may have happened by chance.</P>
<P>
<B>Side effects</B>
</P>
<P>- Twenty-six more people who took diacerein experienced diarrhoea as a side effect (absolute difference of 26%).</P>
<P>- 36 of every 100 people who took diacerein experienced diarrhoea as a side effect compared to 10 of every 100 who took a fake pill.</P>
<P>Diarrhoea was the most common side effect and usually occurred during the first two weeks after the start of diacerein.</P>
<P>People who took diacerein were not more likely than people who took a placebo to stop taking the medication because of side effects.</P>
<P>In November 2013, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the marketing authorisation of diacerein should be suspended across Europe because of harms outweighing benefits. However, this guidance is not final as the PRAC recommendation will be re-examined.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-02-06 12:30:15 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-02-05 13:37:09 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. There is currently no consensus on what is the best treatment to improve OA symptoms and slow disease progression. Diacerein is an anthraquinone synthesised in 1980 that interferes with interleukin-1, an inflammatory mediator. It has been proposed that diacerein acts as a slow-acting, symptom-modifying and perhaps disease-structure-modifying drug for OA. This is an update of a Cochrane review first published in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-02-04 06:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of diacerein for the treatment of adults with OA when compared with placebo and other pharmacologically active interventions (nonsteroidal anti-inflammatory drugs (NSAIDs) and other symptom-modifying, slow-acting drugs) for OA. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-01-31 07:20:19 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) - <I>The Cochrane Library</I>, Issue 10, 2013, MEDLINE (1966 to 2013), EMBASE (1980 to 2013), LILACS (1982 to 2013), and ACP Journal Club, and we handsearched reference lists of published articles. We also searched the World Health Organization International Clinical Trials Platform ( <A HREF="http://www.who.int/trialsearch/Default.aspx">http://www.who.int/trialsearch/Default.aspx</A>) to identify ongoing trials and screened reference lists of retrieved review articles and trials to identify potentially relevant studies. All searches were up to date as of March 2013. Pharmaceutical companies and authors of published articles were contacted. We searched the websites of the regulatory agencies using the keyword &#8216;diacerein&#8217; in November 2013. No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-12-01 18:32:31 -0500" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were randomised or quasi-randomised controlled trials that compared diacerein with placebo or another active pharmacological intervention in participants with OA.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-02-05 14:11:49 -0500" MODIFIED_BY="[Empty name]">
<P>Data abstraction and quality assessment were performed by two independent investigators, and their results were compared. The Cochrane risk of bias tool was used. The quality of evidence obtained was assessed using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-02-06 12:30:15 -0500" MODIFIED_BY="[Empty name]">
<P>We identified three new trials (141 participants), and this updated review now includes 10 trials, totalling 2,210 participants. The most frequent risk of bias was incomplete outcome data, identified in approximately 80% of the studies. Allocation concealment and random sequence generation were unclear in 90% and 40% of the studies, respectively, because of poor reporting.</P>
<P>Low-quality evidence from six trials (1,283 participants) indicates that diacerein has a small beneficial effect on overall pain (measured on a 100 mm visual analogue scale) at three to 36 months (mean difference (MD) -8.65, 95% confidence interval (CI) -15.62 to -1.68), which is equivalent to a 9% pain reduction in the diacerein group (95% CI -16% to -2%) compared with the placebo group. This benefit may not be clinically significant.</P>
<P>No statistically significant differences in physical function (4 studies, 1006 participants) were noted between the diacerein and placebo groups (Lequesne impairment index, 0 to 24 points) (MD -0.29, 95% CI -0.87 to 0.28).</P>
<P>Low-quality evidence from two trials (616 participants) on slowing of joint space narrowing (a decrease greater than 0.50 mm) in the knee or hip favoured diacerein over placebo (risk ratio (RR) 0.85, 95% CI 0.72 to 0.99), with an absolute risk difference of -6% (95% CI -15% to 2%) and a number needed to treat for an additional beneficial outcome (NNTB) of 14 (95% CI 8 to 203). Analysis of the knee joint alone (1 study, 170 participants) did not reach statistical significance (RR 0.94, 95% CI 0.51 to 1.74).</P>
<P>None of the trials of diacerein versus placebo measured quality of life. According to one trial (161 participants), which compared diacerein versus non-steroidal anti-inflammatory drugs (NSAIDs), the quality of life of participants in the two groups (as assessed by the Short Form (SF)-36 health survey questionnaire (0 to 800 sum score)) did not differ significantly (MD -40.70, 95% CI -85.20 to 3.80).</P>
<P>Low-quality evidence from seven trials showed significantly more adverse events in the diacerein group compared with the placebo group after two to 36 months, mainly diarrhoea (RR 3.52, 95% CI 2.42 to 5.11), with an absolute risk increase of 24% (95% CI 12% to 35%), and a number needed to treat for an additional harmful outcome (NNTH) of 4 (95% CI 3 to 7).</P>
<P>No statistically significant differences in participant withdrawal due to adverse events were seen at two to 36 months for diacerein compared with placebo (RR 1.29, 95% CI 0.83 to 2.01).</P>
<P>A search of regulatory websites found a recommendation from the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) that the marketing authorization of diacerein should be suspended across Europe because of harms (particularly the risk of severe diarrhoea and potentially harmful effects on the liver) outweighing benefits. However, this guidance is not final as the PRAC recommendation will be re-examined.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-01-31 07:18:45 -0500" MODIFIED_BY="[Empty name]">
<P>In this update, the strength of evidence for effectiveness outcomes was low to moderate. We confirmed that symptomatic benefit provided by diacerein in terms of pain reduction is minimal. The small benefit derived in terms of joint space narrowing is of questionable clinical relevance and was observed only for OA of the hip. With respect to adverse effects of diacerein, diarrhoea was most frequent. Given the recent guidance issued by the EMA recommending suspension of diacerein in Europe, the EMA website should be consulted for further recommendations regarding the use of diacerein.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-02-06 16:15:10 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-01-15 10:36:35 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-01-15 10:36:35 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis (OA) is the most prevalent musculoskeletal disease (<LINK REF="REF-ACR-2000" TYPE="REFERENCE">ACR 2000</LINK>; <LINK REF="REF-Picavet-2003" TYPE="REFERENCE">Picavet 2003</LINK>). The World Health Organization (WHO) Scientific Group on Rheumatic Diseases estimates that 10% of the world&#8217;s population aged 60 or older have significant clinical problems attributed to OA (<LINK REF="REF-Woolf-2003" TYPE="REFERENCE">Woolf 2003</LINK>). As the incidence and prevalence of OA increase with age, the increase in life expectancy will result in an increase in OA in the future (<LINK REF="REF-Sun-2007" TYPE="REFERENCE">Sun 2007</LINK>; <LINK REF="REF-Woolf-2003" TYPE="REFERENCE">Woolf 2003</LINK>), making this disease an ever growing public health problem. More than 10% of the US adult population had clinical OA in 2005, and in 2009, OA was the fourth most common cause of hospitalisation. OA is the leading indication for joint replacement surgery; 905,000 knee and hip replacements were performed in 2009 at a cost of $42.3 billion (<LINK REF="REF-Murphy-2012" TYPE="REFERENCE">Murphy 2012</LINK>). Obesity is a strong risk factor for OA of the knee and hip (<LINK REF="REF-Murphy-2012" TYPE="REFERENCE">Murphy 2012</LINK>).</P>
<P>OA remains an enigmatic disease. It is defined as a condition characterised by focal areas of loss of articular cartilage within the synovial joints, associated with hypertrophy of the bone (osteophytes and subchondral bone sclerosis) and thickening of the capsule (<LINK REF="REF-Lawrence-1998" TYPE="REFERENCE">Lawrence 1998</LINK>; <LINK REF="REF-Zhang-2001" TYPE="REFERENCE">Zhang 2001</LINK>). Recently, OA has been relabeled as a whole organ disease because pathological abnormalities such as periarticular muscle weakness, lax ligaments, low-grade synovitis, meniscal degeneration and neurosensory system alteration are often present in these patients (<LINK REF="REF-Bijlsma-2012" TYPE="REFERENCE">Bijlsma 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Treatments for OA include pharmacological and non-pharmacological therapies and surgical procedures. Pharmacological therapies consist of topical agents, oral (systemic) agents, adjunct therapies and nutraceuticals (<LINK REF="REF-Bellamy-2006" TYPE="REFERENCE">Bellamy 2006</LINK>; <LINK REF="REF-Towheed-2006" TYPE="REFERENCE">Towheed 2006</LINK>; <LINK REF="REF-Towheed--2008" TYPE="REFERENCE">Towheed 2008</LINK>).</P>
<P>Although some drugs and/or compounds have been available for several decades and are integrated as standard practice in many countries, their efficacy has been demonstrated only over the past decade. Revision of drug registries by health authorities in various European countries in the 1990s led to appropriate clinical trials for available drugs (such as avocado extract), as well as drugs in development at that time (such as diacerein). This action of health authorities greatly improved knowledge regarding the level of evidence and characteristic treatment effects of these drugs (onset of action, carry-over effect) (<LINK REF="REF-Hochberg-2001" TYPE="REFERENCE">Hochberg 2001</LINK>).</P>
<P>Current therapies for OA, including non-steroidal anti-inflammatory drugs (NSAIDs), although effective against symptoms of the disease, are palliative and do not stop disease progression. However, promising agents and compounds have been shown to reduce the severity of the disease, as well as the symptoms. Among them is diacerein, an oral interleukin (IL)-1beta inhibitor. Its active derivative, rhein, is an anthraquinone found in plants of the genus <I>Cassia</I>. It has moderate anti-inflammatory and analgesic activities (<LINK REF="REF-Spencer-1997" TYPE="REFERENCE">Spencer 1997</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Although OA is considered a non-inflammatory disease, numerous studies have shown that inflammatory cytokines provide essential biochemical signals that simulate chondrocytes to release cartilage-degrading enzymes. In addition, cytokines can be produced by synovial tissue cells and subchondral osteoblasts. IL-1beta and tumour necrosis factor (TNF)-alfa are key cytokines in the catabolic process of cartilage (<LINK REF="REF-Berembaum-2010" TYPE="REFERENCE">Berembaum 2010</LINK>).</P>
<P>In vitro and in vivo studies have demonstrated that diacerein acts not only on cartilage but in all tissues involved in the pathogenesis of OA, including synoviocytes, the synovial membrane, subchondral bone and chondrocytes. Besides its inhibitory effects on IL-1, diacerein reduces other important mediators such as metalloproteinases, nitric oxide, ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-4 and ADAMTS-5 (<LINK REF="REF-Pelletier-2010" TYPE="REFERENCE">Pelletier 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-11-26 20:59:24 -0500" MODIFIED_BY="[Empty name]">
<P>Currently, clinical management of OA typically entails a combination of treatment options to reduce pain and improve tolerance to functional activity. Existing pharmacological therapies for OA help to reduce symptoms but are only moderately effective and leave patients with substantial pain and functional burden (<LINK REF="REF-Hunter-2011" TYPE="REFERENCE">Hunter 2011</LINK>).</P>
<P>Starting in 1982 (<LINK REF="REF-Lingetti--1982" TYPE="REFERENCE">Lingetti 1982</LINK>), several trials tested diacerein for the treatment of OA, and since 1994, the drug has been marketed around the world, except in the United States of America. Based on the findings of several studies, it has been proposed that diacerein is a slow-acting, symptom-modifying and perhaps disease/structure-modifying drug for OA. However, the importance of diacerein as an option for the treatment of OA needs to be clarified. Despite the long time elapsed since its discovery, published studies have not defined a clear place for the use of diacerein in the treatment of this disease as a symptom modifier or as a disease-modifying agent that could retard the loss of cartilage.</P>
<P>We performed a review of these studies to gather up-to-date evidence to clarify the role of diacerein in the treatment of OA.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-02-05 11:44:42 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of diacerein for the treatment of adults with OA when compared with placebo and other pharmacologically active interventions (nonsteroidal anti-inflammatory drugs (NSAIDs) and other symptom-modifying, slow-acting drugs) for OA.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-02-06 14:29:50 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Studies with the following characteristics were eligible for inclusion in the review.</P>
<OL>
<LI>Randomised controlled trials (RCTs) evaluating the benefits and harms of diacerein for OA.</LI>
<LI>Both placebo-based and comparative studies were eligible.</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>All adults (age 18 years and older) with a diagnosis of primary OA at any site, including the axial and peripheral skeleton, who fulfilled the American College of Rheumatology (ACR) criteria (<LINK REF="REF-Altman-1986" TYPE="REFERENCE">Altman 1986</LINK>; <LINK REF="REF-Altman-1990" TYPE="REFERENCE">Altman 1990</LINK>) were eligible for inclusion. Primary OA is any OA for which a definite etiology (cause) is not found. Secondary OA is diagnosed when a specific cause for the disease can be identified, such as trauma or hypermobility; this type of OA was not included in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Studies evaluating benefits and/or harms of diacerein compared with:</P>
<OL>
<LI>placebo; and</LI>
<LI>other active treatments (non-steroidal anti-inflammatory drugs or other slow-acting arthritis drugs).</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Seven important outcomes were selected for reporting.</P>
<OL>
<LI>For benefit, the outcomes<B> </B>were (1) pain, (2) physical function, (3) radiographic joint structure changes and (4) quality of life.</LI>
<LI>For safety, the outcomes were (5) number of participants experiencing any adverse event, (6) number of participants who withdrew because of adverse events and (7) number of participants experiencing any serious adverse event.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Benefits</HEADING>
<P>
<B>1. Pain.</B>
</P>
<P>The measure of effectiveness was pain relief. To assess this outcome in accordance with the latest review of the OMERACT (international initiative to improve outcome measurement in rheumatology)-3 (<LINK REF="REF-Bellamy-1997" TYPE="REFERENCE">Bellamy 1997</LINK>), the OMERACT-6 (<LINK REF="REF-Pham-2003" TYPE="REFERENCE">Pham 2003</LINK>) recommends the use of standardised, validated instruments such as visual analogue scales (VASs) (<LINK REF="REF-Carlsson-1983" TYPE="REFERENCE">Carlsson 1983</LINK>), the Lequesne Functional Severity Index (<LINK REF="REF-Lequesne-1987" TYPE="REFERENCE">Lequesne 1987</LINK>) or the pain scales included in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (<LINK REF="REF-Bellamy-1988" TYPE="REFERENCE">Bellamy 1988</LINK>).</P>
<P>If data on more than one pain scale were provided for a trial, data were extracted on the pain scale that is highest in the following list, according to a previously described hierarchy of pain related outcomes.</P>
<OL>
<LI>Pain overall.</LI>
<LI>Pain on walking.</LI>
<LI>WOMAC pain subscale.</LI>
<LI>Pain on activities other than walking.</LI>
<LI>WOMAC global scale.</LI>
<LI>Lequesne Osteoarthritis Index global score.</LI>
<LI>Other algofunctional scale.</LI>
<LI>Patient&#8217;s global assessment.</LI>
<LI>Physician&#8217;s global assessment.</LI>
<LI>Other outcome.</LI>
<LI>No continuous outcome reported.</LI>
</OL>
<P>
<B>2. Physical function.</B>
</P>
<P>If data on more than one physical function scale were provided for a trial, data were extracted according to the hierarchy presented in the following list.</P>
<OL>
<LI>Global disability score.</LI>
<LI>Walking disability.</LI>
<LI>WOMAC disability subscore.</LI>
<LI>Composite disability scores other than WOMAC.</LI>
<LI>Disability other than walking.</LI>
<LI>WOMAC global scale.</LI>
<LI>Lequesne Osteoarthritis Index global score.</LI>
<LI>Other algofunctional scale.</LI>
</OL>
<P>
<B>3. Radiographic joint structure changes.</B>
</P>
<P>Radiographic progression of OA in studies lasting longer than one year include the following.</P>
<OL>
<LI>Minimum joint space width.</LI>
<LI>Median joint space width.</LI>
<LI>Semi-quantitative measurement.</LI>
</OL>
<P>
<B>4. Quality of life.</B>
</P>
<P>Quality of life data were extracted from the following instruments.</P>
<OL>
<LI>Short Form (SF)-12.</LI>
<LI>Short Form (SF)-36.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>The toxicity of diacerein was also considered a relevant outcome and was measured by the following.</P>
<P>
<B>5. Number of participants experiencing any adverse event.</B>
</P>
<P>
<B>6. Number of participants who withdrew because of adverse events.</B>
</P>
<P>
<B>7. Number of participants experiencing any serious adverse event.</B>
</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-01-22 15:49:55 -0500" MODIFIED_BY="[Empty name]">
<P>For identification of relevant studies, detailed search strategies were developed for each specific database to be searched. These strategies were based on the search strategy developed for MEDLINE (OVID) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and revised appropriately for each database. The following databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 3, 2013) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (1966 to March 2013), EMBASE (1980 to March 2013) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), ACP Journal Club (1991 to 2013) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), LILACS (1982 to March 2013) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) and International Clinical Trials Register (World Health Organization, March 2013) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>The reference lists of all identified citations were manually searched. In addition, letters were sent to study authors and to content experts to ask for assistance in retrieving additional RCTs, especially those that were unpublished. The manufacturers of diacerein (Negma-Lerads and TRB-Pharma) were contacted for additional trials. For this version of the Cochrane Review, the search was updated to March 2013.</P>
<P>For safety assessments, we searched the websites of the regulatory agencies (US Food and Drug Administration-MedWatch (<A HREF="http://www.fda.gov/Safety/MedWatch/default.htm">http://www.fda.gov/Safety/MedWatch/default.htm</A>) , European Medicines Evaluation Agency (<A HREF="http://www.ema.europa.eu">http://www.ema.europa.eu</A>), Australian Adverse Drug Reactions Bulletin (<A HREF="http://www.tga.gov.au/safety/ews-monitoring.htm">http://www.tga.gov.au/safety/ews-monitoring.htm</A>), and UK Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance and drug safety updates (<A HREF="http://www.mhra.gov.uk/Safetyinformation/index.htm">http://www.mhra.gov.uk/Safetyinformation/index.htm</A>) using the keyword &#8216;diacerein&#8217; on 26 November 2013.</P>
<P>No language or date of publication restrictions were applied.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-02-06 14:29:50 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-11-26 20:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors (TSAF and CRM) independently reviewed the references identified through the search strategy and selected those that fulfilled the selection criteria. Differences regarding selection were solved by a third review author (VFMT).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-02-06 14:29:50 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors (TSFA and CRM) independently extracted data from eligible studies. Review authors were not masked to report authors, journals, dates of publication, sources of financial support or results. Any disagreements were resolved through discussion with or by seeking the opinion of a third review author (VFMT). Data extracted included study characteristics and outcome data. For studies with more than one publication, the main trial report was used as the reference, and additional details were derived from secondary papers.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>This updated version of the review assessed independently and in duplicate the risk of bias in included studies using the risk of bias tool described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of interventions, </I>version 5.1.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The domains investigated included the following.</P>
<OL>
<LI>Sequence generation.</LI>
<LI>Allocation concealment.</LI>
<LI>Blinding of participants.</LI>
<LI>Blinding of outcome assessment.</LI>
<LI>Incomplete outcome data addressed.</LI>
<LI>Selective outcome reporting.</LI>
</OL>
<P>Each domain was classified as having 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-26 21:00:07 -0500" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes, results were expressed as a risk ratio (RR), that is, the proportion of events in the treatment group in relation to the proportion of events in the control group, with 95% confidence intervals (95% CIs). When overall results were significant, the number needed to treat for an additional beneficial outcome (NNTB) was calculated. The NNTB is the number of participants who need to be treated with the intervention to prevent one event. The NNTB was also calculated for radiographic progression. Continuous outcomes were analysed according to standardised mean differences (SMDs), using an inverse variance with random approach.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-01-15 10:50:50 -0500" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the participant. For studies containing more than two intervention groups, to make multiple pair-wise comparisons between all possible pairs of intervention groups, we included each group of participants only once in the meta-analysis, in accordance with the procedure recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-11-26 22:07:54 -0500" MODIFIED_BY="[Empty name]">
<P>As far as possible, data were analysed on an intention-to-treat (ITT) basis, and attempts were made to obtain missing data from the original trial lists. When some data were unavailable, only the available data were analysed.</P>
<P>For dichotomous outcomes that measured adverse events (e.g. number of withdrawals due to adverse events), the withdrawal rate was calculated using the number of participants who received treatment as the denominator (worst-case analysis). For dichotomous outcomes that measured benefits, the worst-case analysis was calculated using the number of randomly assigned participants as the denominator. For continuous outcomes (e.g. pain), we calculated mean difference (MD) or the SMD using the number of participants analysed at the time point. If the number of participants analysed was not presented for each time point, the number of randomly assigned participants in each group at baseline was used.</P>
<P>When possible, missing standard deviations were computed from other statistics such as standard errors. CIs or P values were calculated according to the methods recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If it was not possible to calculate standard deviations, we imputed them, for example, from other studies in the meta-analysis (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was measured by Tau<SUP>2 </SUP>and I<SUP>2 </SUP>and by calculating a Chi<SUP>2</SUP> test with P &lt; 0.10 considered significant. The I<SUP>2</SUP> cutoff point for considering substantive heterogeneity is 50% (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>In future updates, if sufficient numbers of studies (more than 10) are eligible for inclusion, a funnel plot (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) will be used to assess publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>For clinically homogeneous studies, we pooled outcomes in a meta-analysis using the random-effects model as a default.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>When possible, subgroup analysis was done as follows: different doses of diacerein, hip OA versus knee OA versus spine OA versus hand OA and different functional classes of OA. Studies analysing knee and hip OA were separated to assess whether results changed in the meta-analysis graphics (subgroup analyses). In this update, subgroup analyses for spine versus hand OA and for different functional classes of OA were not performed because RCTs included in this review did not provide these data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-02-05 13:17:51 -0500" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was carried out to explore heterogeneity. Studies of longer than six months' duration were pooled together to explore effect size differences and robustness of the results. Sensitivity analysis according to length of follow-up was not included in the original protocol because it was decided post hoc that this would be performed.</P>
<P>In future updates, if sufficient studies are eligible, other sensitivity analyses could be carried out. Heterogeneity in the results of the meta-analysis should be assessed both by inspecting graphical presentations (funnel plot) (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) if more than 10 studies are included and by calculating a Chi<SUP>2</SUP> test with P values &lt; 0.1 considered as significant. In future updates of this review, differences in populations, interventions and assessments of outcomes could be explored in analyses of heterogeneity.</P>
<SUBSECTION>
<HEADING LEVEL="3">Grading of Evidence</HEADING>
<P>The Cochrane Collaboration has adopted the principles of the GRADE approach for evaluating the quality of evidence for outcomes reported in systematic reviews (<LINK REF="REF-Grade-2008" TYPE="REFERENCE">Grade 2008</LINK>). The GRADE approach specifies four levels of quality. The highest quality rating is for randomised trial evidence. However, review authors can downgrade randomised trial evidence to moderate, low or even very low quality evidence, depending on the presence of the five factors. Usually, quality ratings will fall by one level for each factor, up to a maximum of three levels for all factors. If very severe problems are noted for any one factor (e.g. when assessing limitations in design and implementation, all studies were unconcealed, were unblinded and lost more than 50% of their participants to follow-up), randomised trial evidence may fall by two levels because of that factor alone.</P>
<P>These five factors that constitute the GRADE approach include the following.</P>
<OL>
<LI>Limitation in the design or implementation of available studies, suggesting high level of bias.</LI>
<LI>Indirecteness of evidence (indirect population, intervention, control and outcomes).</LI>
<LI>Unexplained heterogeneity or inconsistency of results (including problems with subgroup analysis).</LI>
<LI>Imprecision of results (wide confidence intervals).</LI>
<LI>High probability of publication bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>The summary of findings tables present the main findings in this updated review. They provide key information concerning quality of the evidence, magnitude of effect of the interventions examined and the sum of available data on the main outcomes. Seven important outcomes were included in the summary of findings tables.</P>
<OL>
<LI>Pain.</LI>
<LI>Physical function.</LI>
<LI>Radiographic joint structure changes.</LI>
<LI>Quality of life.</LI>
<LI>Number of participants experiencing any adverse event.</LI>
<LI>Number of participants who withdrew because of adverse events.</LI>
<LI>Number of participants experiencing any serious adverse event.</LI>
</OL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-02-06 16:14:52 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-01-15 11:04:06 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>The search retrieved 324 (25 Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 10, 2013), 184 MEDLINE, 90 EMBASE, 24 LILACS, 1 ACP Journal) references, and nine additional reports were obtained through other sources (eight reference lists and one abstract from a conference meeting), which after de-duplication resulted in 272 citations. After the titles and abstracts of these references were screened, 40 full-text articles were selected; 30 of these studies were excluded, and 10 fulfilled the selection criteria. Three new studies were included in this updated version of the 2006 systematic review. See the study flow diagram for further details (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>The 10 identified studies are listed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Years of publication ranged from 1994 to 2009. All were double-blinded, randomised, parallel-group trials and included a total of 2,210 adults with a mean age of 59.69 (± 8.90) years. A total of 996 participants were randomly assigned to treatment with diacerein, and 1,214 were randomly assigned to one of the comparator groups (NSAIDs or placebo or other symptom-modifying, slow-acting drugs for OA). These studies were performed in France (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>), the UK (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>), Canada (<LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>), Israel (<LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>), China (<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>), the Czech Republic (<LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>), Thailand (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>) and India (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>). Seven of the ten studies compared diacerein with placebo (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> ), two compared diacerein with other symptom-modifying, slow-acting drugs for OA&#8212;Harpadol and the hyaluronic acid compound NRD101 (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) and three compared diacerein with NSAIDs: tenoxicam (<LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>), diclofenac (<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) and piroxicam (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>).</P>
<P>Only knee or hip OA was evaluated in the 10 included studies. None of the studies evaluated OA in other segments such as hands or spine. In two studies, only the hip joint was evaluated (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>). The knee was evaluated in six RCTs (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>), and two RCTs (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>) assessed both knee and hip joints.</P>
<P>Participants with primary OA were evaluated in all studies, and radiographs of the target joint were obtained in nine of the ten studies. In all included studies, the diagnosis of OA was based on valid clinical and radiographic findings in accordance with the ACR criteria; one study also included the Lequesne criteria (<LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>). The Kellgren and Lawrence radiographic gradation of OA was used to evaluate the radiographic diagnosis of OA (<LINK REF="REF-Kellgren-1957" TYPE="REFERENCE">Kellgren 1957</LINK>).</P>
<P>Duration of the studies ranged from two months to three years. Six studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>) mentioned the duration of disease, and the mean was 4.69 years. The number of participants randomly assigned ranged from 64 (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>) to 521 (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>), and the number of dropouts in the diacerein groups ranged from three of 86 (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>) to 65 of 262 (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>).</P>
<P>Five trials analysed treatment carry-over effect (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) for up to two months after cessation of the intervention. The carry-over effect refers to the remaining effect of the drug after its discontinuation.</P>
<P>Good overall agreement was reached between two investigators (TSAF and CRM) regarding data extracted from the 10 RCTs. Consensus was reached for all discrepancies.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-01-15 11:04:06 -0500" MODIFIED_BY="[Empty name]">
<P>A total of 30 studies were excluded for the following reasons: inadequate study design for this review (<LINK REF="STD-Adami--1985" TYPE="STUDY">Adami 1985</LINK>; <LINK REF="STD-Bogliola--1991" TYPE="STUDY">Bogliola 1991</LINK>; <LINK REF="STD-Carrabba--1987" TYPE="STUDY">Carrabba 1987</LINK>; <LINK REF="STD-Delcambre--1994" TYPE="STUDY">Delcambre 1994</LINK>; <LINK REF="STD-Fagnani--1998" TYPE="STUDY">Fagnani 1998</LINK>; <LINK REF="STD-Kay-1980" TYPE="STUDY">Kay 1980</LINK>; <LINK REF="STD-Linguetti--1982" TYPE="STUDY">Linguetti 1982</LINK>; <LINK REF="STD-Mantia-1987" TYPE="STUDY">Mantia 1987</LINK>; <LINK REF="STD-Marcolongo--1988" TYPE="STUDY">Marcolongo 1988</LINK>; <LINK REF="STD-Mathieu-1999" TYPE="STUDY">Mathieu 1999</LINK>; <LINK REF="STD-Mazzaro--1989" TYPE="STUDY">Mazzaro 1989</LINK>; <LINK REF="STD-Renapurkar--2010" TYPE="STUDY">Renapurkar 2010</LINK>; <LINK REF="STD-Sharma--2008" TYPE="STUDY">Sharma 2008</LINK>), duplicate publication (<LINK REF="STD-Delcambre--1996" TYPE="STUDY">Delcambre 1996</LINK>; <LINK REF="STD-Leblan--2000" TYPE="STUDY">Leblan 2000</LINK>; <LINK REF="STD-Tang-2004" TYPE="STUDY">Tang 2004</LINK>; <LINK REF="STD-Valat-1997" TYPE="STUDY">Valat 1997</LINK>), incomplete data and unsuccessful personal contact with authors (<LINK REF="STD-Ascherl-1994" TYPE="STUDY">Ascherl 1994</LINK>; <LINK REF="STD-Fioravanti-1985" TYPE="STUDY">Fioravanti 1985</LINK>; <LINK REF="STD-Mattara-1985" TYPE="STUDY">Mattara 1985</LINK>; <LINK REF="STD-Mordini-1986" TYPE="STUDY">Mordini 1986</LINK>; <LINK REF="STD-Pietrogrande-1985" TYPE="STUDY">Pietrogrande 1985</LINK>; <LINK REF="STD-Portioli-1987" TYPE="STUDY">Portioli 1987</LINK>; <LINK REF="STD-Schulitz-1994" TYPE="STUDY">Schulitz 1994</LINK>; <LINK REF="STD-Seisenbayev-2012" TYPE="STUDY">Seisenbayev 2012</LINK>) and inappropriate inclusion criteria (<LINK REF="STD-Baliga-2010" TYPE="STUDY">Baliga 2010</LINK>; <LINK REF="STD-Singh-2012" TYPE="STUDY">Singh 2012</LINK>). The studies <LINK REF="STD-Vignon--2002" TYPE="STUDY">Vignon 2002</LINK>, <LINK REF="STD-Villani--1998" TYPE="STUDY">Villani 1998</LINK> and <LINK REF="STD-Villermay-1994" TYPE="STUDY">Villermay 1994</LINK> are not clinical trials. Reasons for exclusion are listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>One study (<LINK REF="STD-Shin-2013" TYPE="STUDY">Shin 2013</LINK>) is awaiting classification depending on the response of the study authors regarding information necessary to the process of inclusion.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-01-15 11:06:43 -0500" MODIFIED_BY="[Empty name]">
<P>Pre randomisation inclusion and exclusion criteria were provided by all 10 RCTs. Study authors and pharmaceutical companies were contacted to provide data.</P>
<P>The most frequent risk of bias was incomplete outcome data, identified in approximately 80% of the studies, followed by lack of blinding of clinical outcome assessment in about 20% and selective reporting in 10% of the studies. Almost all (90%) studies did not provide details on allocation concealment (unclear).</P>
<P>Approximately 40% of the included studies were unclear about random sequence generation. See the risk of bias graph and the risk of bias summary for additional details (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>Allocation sequences were adequately described with low risk of bias in six studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>). Three studies used computer-generated number lists as their randomisation method (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>), two studies used blocked randomisation (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>) and one study used central randomisation (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>).</P>
<P>Four studies (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) were classified as having unclear risk of bias for this domain.</P>
<P>Allocation concealment was not described (unclear risk of bias) in any of the studies, except one. The author of <LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK> replied to our contact and informed that he had used sealed opaque envelopes.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-01-15 11:06:43 -0500" MODIFIED_BY="[Empty name]">
<P>Six studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) were classified as having low risk of bias for blinding of participants and personnel. Four of these studies (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) described adequate double-blinding processes. <LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK> blinded only participants.</P>
<P>Four studies provided no information on blinding of participants and personnel and therefore were categorised as having unclear risk of bias (<LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>). No studies were categorised as having high risk of bias for performance bias.</P>
<P>Seven studies provided no information on blinding of clinical outcome assessors and therefore were categorised as having unclear risk of bias (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>). Two studies were categorised as having high risk of bias for detection bias (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>).</P>
<P>Two studies (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) were classified as having low risk of bias for blinding of radiographic outcome assessment because they described adequate blinding processes for radiographic outcomes: The radiologists were unaware of the identity of the participants when they read their X-rays to evaluate structural outcomes. The other eight studies, which did not evaluate radiographic outcomes, were classified as having low risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>Two studies (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>) were classified as having low risk of bias on this item because all randomly assigned participants were included in the ITT analyses.</P>
<P>Seven studies were classified as having high risk of bias (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>). In three of these studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>), ITT analysis was used for all participants who took at least one dose of the medication, and the last observation carried forward (LOCF) method was used for those with missing values.</P>
<P>
<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> evaluated efficacy outcomes using ITT analysis (all randomly assigned participants); however, radiographic evaluation was done only for participants who had at least two different X-rays to compare.</P>
<P>Two studies (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>) reported different numbers of participants in the baseline and outcomes tables. These studies provided no information on the reasons for exclusion of these participants at the end of the study.</P>
<P>
<LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK> evaluated pain using a 0 to 100-mm VAS for all randomly assigned participants. The number of participants for the second effectiveness outcome in this study (Lequesne Impairment Index) was different, and the authors provided no explanation for this discrepancy.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-11-26 20:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>All proposed outcomes were evaluated in nine studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>). One study (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>) was classified as having high risk of bias on this domain because it did not provide data for the outcome "patient evaluation of the treatment" using a 0 to 5 Likert scale .</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-02-06 16:14:52 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: diacerein compared with placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Benefits</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1. Pain.</HEADING>
<UL>
<LI>
<B>Visual analog scale for pain (0 to 100 mm); 1,283 participants from six studies: </B>
<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</LI>
</UL>
<P>The pooled summary MD (random effect) of these six studies was -8.65 (95% CI -15.62 to -1.68), with high heterogeneity (I<SUP>2 </SUP>= 84%). A negative MD in this case means that diacerein was superior to placebo in reducing pain. The absolute risk difference was -9% (95% CI -16% to -2%), and the relative percentage change was -19% (95% CI -34% to -4%).</P>
<P>The effect of diacerein was similar to that of placebo in the two studies that followed participants for longer than six months, according to the post hoc sensitivity analysis. The pooled MD of these two studies was 0.48 (95% CI -3.90 to 4.86) with no heterogeneity (I<SUP>2</SUP> = 0%). See <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Physical function.</HEADING>
<UL>
<LI>
<B>Lequesne Impairment Index (0 to 24 points); 1,006 participants from four studies:</B> <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</LI>
</UL>
<P>The pooled summary MD (random effect) of these four studies was -0.29 (95% CI -0.87 to 0.28). A negative MD in this case means that diacerein was superior to placebo in terms of its ability to improve Lequesne Index scores, but this effect did not reach statistical significance.<B> </B>The absolute risk difference was 0% (95% CI -4% to 1%), and the relative percentage change was -4% (95% CI -11% to 4%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Radiographic joint structure changes.</HEADING>
<UL>
<LI>
<B>Minimum joint space width decreased over 0.50 mm during the study period; 616 participants from two studies: </B>
<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</LI>
</UL>
<P>When diacerein was compared with placebo for changes in minimum joint space width for the knee or hip, the summary RR (random effect) was 0.85 (95% CI 0.72 to 0.99). Diacerein slowed the radiological progression for hip OA (the most representative study was <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>, with RR 0.84, 95% CI 0.71 to 0.99) but not for knee OA (RR 0.94, 95% CI 0.51 to 1.74). The number needed to treat for an additional beneficial outcome (NNTB) was 14 (95% CI 8 to 203). The absolute risk difference was -6% (95% CI -15% to 2%), and relative percentage change was -15% (95% CI -28% to -1%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Quality of life.</HEADING>
<P>This outcome was not reported by the studies included in this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Number of participants experiencing any adverse event.</HEADING>
<P>The pooled RR (random effect) for diarrhoea was 3.52 (95% CI 2.42 to 5.11) in six studies (726 participants taking diacerein and 736 taking placebo). The RR for dyspepsia was 0.98 (95% CI 0.61 to 1.58) when 526 participants in the diacerein group were compared with 533 participants in the placebo group (four studies). See <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>. The number needed to treat for an additional harmful outcome (NNTH) for diarrhoea was 4 (95% CI 3 to 7). The absolute risk difference was 24% (95% CI 12% to 35%), and the relative percentage change was 252% (95% CI 142% to 411%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Number of participants who withdrew because of adverse events.</HEADING>
<P>The pooled RR (random effect) for withdrawals due to adverse effects was 1.29 (95% CI 0.83 to 2.01) in 733 participants taking diacerein versus 743 participants using placebo (seven studies). See <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>. The NNTH was not calculated, as the result was not statistically significant. The absolute risk difference was 0% (95% CI -3% to 4%), and the relative percentage change was 0% (95% CI -29% to 41%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Number of participants experiencing any serious adverse event.</HEADING>
<P>This outcome was not described in the studies included in this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: diacerein compared with non-steroidal anti-inflammatory drugs (NSAIDs)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Benefits</HEADING>
<P>Three RCTs (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) with 150, 184 and 161 participants, respectively, compared diacerein with NSAIDs. The Nguyen study evaluated hip OA, and the other two studies evaluated knee OA.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1. Pain.</HEADING>
<UL>
<LI>
<B>Visual analog scale for pain (0 to 100 mm); 150 participants from one study: </B>
<LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>.</LI>
</UL>
<P>No statistically significant differences were noted between the two interventions. Only one study (<LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>) evaluated pain reduction according to a 0 to 100-mm VAS scale and reported no differences between the two interventions. The summary MD was 2.00 (95% CI -6.48 to 10.48).</P>
<UL>
<LI>
<B>WOMAC pain subscale; 184 participants from one study: </B>
<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>.</LI>
</UL>
<P>One study evaluated this outcome over 16 weeks of treatment by comparing diacerein versus piroxicam; no statistically significant difference was observed between the two interventions. The summary MD was 14.00 (95% CI -10.15 to 38.15).</P>
<UL>
<LI>
<B>Pain on walking 20 m; 231 participants from one study: </B>
<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>.</LI>
</UL>
<P>One study did not show statistically significant differences between diacerein and diclofenac. The summary MD was 1.30 (95% CI -3.81 to 6.41).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Physical function.</HEADING>
<UL>
<LI>
<B>WOMAC disability subscore; 345 participants from two studies: </B>
<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK> (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</LI>
</UL>
<P>The summary MD was 29.50 (95% CI -23.17 to 82.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Radiographic joint structure changes.</HEADING>
<P>No study assessed this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Quality of life.</HEADING>
<UL>
<LI>
<B>SF-36 (sum score 0-800): 374 participants in two studies: </B>
<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>.</LI>
</UL>
<P>Only one study provided data on SF-36 results allowing analysis <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>. Afer 16 weeks of active treatment, there were no statistically significant differences between the groups. At the end of the treatment, both groups had similar variations in the scores for each dimension of the SF-36 health survey questionnaire. MD was -40.70 (95% confidence interval; -85.20 to 3.80) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>
<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK> informed that there were no statistically significant differences between both intervention groups without reporting specific numerical data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Number of participants experiencing any adverse event.</HEADING>
<P>The pooled RR (random effect) for diarrhoea was 3.20 (95% CI 1.58 to 6.49) with 77 of 253 participants in the diacerein group versus 23 of 252 participants in the NSAIDs group (three studies). The RR for dyspepsia was 0.69 (95% CI 0.29 to 1.61) in three studies (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Participants who withdrew because of adverse events.</HEADING>
<P>The pooled RR (random effect) for withdrawals due to adverse events was 0.96 (95% CI 0.38 to 2.44) in three studies with 534 participants (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Participants experiencing any serious adverse event.</HEADING>
<P>None of the studies analysed this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: diacerein compared with other symptomatic slow-acting drugs for osteoarthritis (SYSADOA)</HEADING>
<P>Two RCTs (<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) consisting of 338 participants compared diacerein versus two SYSADOA drugs: intra-articular NRD101 (a hyaluronic acid high-molecular-weight, -1.900 kDa polysaccharide) for 12 months versus Harpadol or devil's claw (a perennial South African herbaceous plant with anti-inflammatory and analgesic effects attributed to its iridoid glycoside) for four months.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Benefits</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1. Pain.</HEADING>
<UL>
<LI>
<B>Visual analog scale for pain (0 to 100 mm); 338 participants from two studies: </B>
<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</LI>
</UL>
<P>For pain assessed through a VAS scale, the comparison between diacerein and NRD101 resulted in a subgroup MD (random effect) of 4.50 (95% CI -4.67 to 0.13.67), and the comparison between diacerein and Harpadol resulted in a subgroup MD (random effect) of 0.40 (95% CI -7.73 to 6.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Physical function.</HEADING>
<UL>
<LI>
<B>Lequesne Impairment Index (0 to 24 points); 338 participants from two studies: </B>
<LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</LI>
</UL>
<P>For the Lequesne Index, comparison between diacerein and NRD101 yielded a pooled MD (random effect) of 0.27 (95% CI -1.17 to 1.71), and for the comparison between diacerein and Harpadol, the pooled MD (random effect) was 1.20 (95% CI -3.01 to 5.41).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Radiographic joint structure changes.</HEADING>
<UL>
<LI>
<B>MInimum joint space width decreased by more than 0.50 mm during the study period; 216 participants from one study: </B>
<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>.</LI>
</UL>
<P>Radiographic progression was assessed in one study (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>), and no statistically significant difference was noted between diacerein and NRD101: RR (random effect) 1.07 (95% CI 0.60 to 1.91) after one year of observation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Quality of life.</HEADING>
<P>None of the studies assessed this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Number of participants experiencing any adverse event.</HEADING>
<P>The most frequent adverse event was diarrhoea, with RR 4.26 (95% CI 2.54 to 7.16) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Participants who withdrew because of adverse events.</HEADING>
<P>The proportion of dropouts in the diacerein groups was similar to that in the SYSADOA group; RR was 1.42 (95% CI 0.78 to 2.58) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Participants experiencing any serious adverse event.</HEADING>
<P>This outcome was not reported by the studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis: carry-over effect</HEADING>
<P>Five studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) analysed the carry-over effect. The time for outcome measurement without the drug was four weeks (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>), eight weeks (<LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>), four weeks (<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>), 12 weeks (<LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>) and four weeks (<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Pain.</HEADING>
<UL>
<LI>
<B>Visual analog scale for pain (0 to 100 mm); 470 participants from three studies: </B>
<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK> (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</LI>
</UL>
<P>The summary MD was -13.19 (95% CI -24.25 to -2.13).</P>
<UL>
<LI>
<B>WOMAC Index subscale pain; 339 participants from two studies: </B>
<LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK> (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</LI>
</UL>
<P>The summary MD was -80.37 (95% CI -153.26 to -7.47).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Physical function.</HEADING>
<UL>
<LI>
<B>WOMAC Index subscale physical function; 381 participants from three studies: </B>
<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK> (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</LI>
</UL>
<P>The summary MD was -233.30 (95% CI -363.30 to -103.30).</P>
<P>Only one study (<LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>) studied different doses of diacerein, and the only reported difference between groups was related to adverse events. Participants who received 50 mg/d had significantly fewer adverse effects than the group treated with 100 mg; participants treated with 150 mg/d had the highest overall rate of withdrawals (20% in the 150-mg diacerein group vs 10 % in the placebo group). This is why we did not perform this subgroup analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Results from search of regulatory websites:</HEADING>
<P>The FDA MedWatch, Australian Adverse Drug Reactions Bulletin, and UK Medicines and Healthcare products Regulatory Agency, did not have any warnings regarding diacerein. However, a notice on the European Medicines Agency (EMA) website, dated November 8, 2013, from the Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the marketing authorization of diacerein should be suspended across Europe because of harms (particularly the risk of severe diarrhoea and potentially harmful effects on the liver) outweighing benefits (<LINK REF="REF-PRAC-2013" TYPE="REFERENCE">PRAC 2013</LINK>). This guidance is not final and the EMA website should be consulted for future guidance on this issue.</P>
<P>Liver adverse effects was not an outcome pre-specified for this review. However, after becoming aware of the PRAC recommendation, we re-assessed the included studies for this outcome. We did not find evidence of liver adverse effects in the studies included in this review. Blood samples were collected to evaluate liver function in all studies, except two (<A HREF="http://archie.cochrane.org/sections/documents/view?document=366304050918521942&amp;format=REVMAN#STD-Chantre-2000">Chantre 2000</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=366304050918521942&amp;format=REVMAN#STD-Lequesne-1998">Lequesne 1998</A>). Only one patient discontinued the diacerein treatment due to deterioration in hepatic function (ALT up to 97 U/L) in the Zheng study (<A HREF="http://archie.cochrane.org/sections/documents/view?document=366304050918521942&amp;format=REVMAN#STD-Zheng-2006">Zheng 2006</A>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-02-06 16:15:10 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-02-04 05:36:38 -0500" MODIFIED_BY="[Empty name]">
<P>This updated systematic review identified 10 randomised controlled trials. We found that the symptomatic benefit of diacerein in participants with OA of the knee or hip was minimal or none when compared with placebo. Minimal benefit was noted in terms of joint space narrowing for hip OA, and was uncertain for knee OA. Adverse effects related to the gastrointestinal tract (diarrhoea) were frequent, and safety concerns could make use of this drug non-beneficial.</P>
<P>This review included trials published between 1994 and 2009 that allocated and analysed 2,210 participants with knee or hip OA. The average age of participants was 60 years, and 63% of them were women. These participants were treated with diacerein (996 participants) compared with placebo or other active interventions (1,214 participants).</P>
<P>Six studies were pooled for analysis of pain reduction assessed through a 0 to 100-mm VAS. When diacerein and placebo were compared, the MD was -8.65 (95% CI -15.62 to -1.68, P &lt; 0.01), supporting mild efficacy of diacerein as opposed to placebo. This result is based on studies with large heterogeneity (I<SUP>2 </SUP>= 84%). No significant reduction in heterogeneity was observed when the previously described sensitivity analysis was performed. Diacerein was statistically non-significant in reducing the Lequesne Index score according to five comparisons: MD was -0.29 (95% CI -0.87 to 0.28) without heterogeneity (I<SUP>2</SUP> = 0%).</P>
<P>Radiographic progression of disease was less pronounced for hip OA (RR 0.84, 95% CI 0.71 to 0.99) than for knee OA (RR 0.94, 95% CI 0.51 to 1.74).</P>
<P>Diacerein compared with NSAIDs was statistically non-significant for physical function measured by the WOMAC Index, with MD 29.50 (95% CI -23.17 to 82.17).</P>
<P>According to studies that analysed the carry-over effect (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>), diacerein remains effective for at least two months after treatment interruption. Reasons for this were not explained. Pooled results of three of these studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Lequesne-1998" TYPE="STUDY">Lequesne 1998</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) for pain reduction produced MD of -13.19 (95% CI -24.25 to -2.13) on a 0 to 100-mm VAS.</P>
<P>A statistically significant increase in the risk of adverse effects was noted for participants allocated to diacerein compared with those given placebo, mainly diarrhoea. The NNTH for diarrhoea was 4, but this did not lead to a statistically significant increase in withdrawals due to adverse events (RR 1.29, 95% CI 0.83 to 2.01).</P>
<P>No difference between diacerein and placebo was reported in terms of upper gastrointestinal symptoms. The second most prevalent adverse effect was urine discolouration (25% in the diacerein group vs 1.7% in the placebo group)&#8212;a clinically irrelevant effect. It should be noted that this effect is unrelated to renal function. Allergic events affecting the skin (pruritus, rash) were more frequent in the diacerein groups (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>In November 2013, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the marketing authorization of diacerein should be suspended across Europe because of harms (particularly the risk of severe diarrhoea and potentially harmful effects on the liver) outweighing benefits (<A HREF="http://archie.cochrane.org/sections/documents/view?document=366304050918521942&amp;format=REVMAN#REF-PRAC-2013">PRAC 2013</A>). However, the website states that this recommendation will be re-examined.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-11-26 20:46:56 -0500" MODIFIED_BY="[Empty name]">
<P>This review has several limitations. First of all, most of the included studies were small and were too short in duration, given that the therapeutic effects of diacerein start after approximately six to eight weeks of use. Only three of the 10 studies lasted longer than 24 weeks. Second, all studies allowed participants to take analgesics and even NSAIDs during the trial, and this could have influenced the results related to pain and evaluation of adverse effects. Finally, in daily clinical practice, OA can affect other joints besides the knees and hips, but these other joints were not evaluated in the included studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-11-26 21:22:43 -0500" MODIFIED_BY="[Empty name]">
<P>All studies included in this review had some type of risk of bias: selection bias or detection bias or attrition bias. Five randomised trials had lower risk of bias in most of the categories (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>), but their primary outcomes were different. <LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK> evaluated the primary efficacy and safety of diacerein compared with placebo over a short time; <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK> evaluated the non-inferiority of <I>Harpagophytum procumbens</I> compared with diacerein for pain and functional disability improvement; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> evaluated the efficacy and safety of a hyaluronic acid intra-articular compared with placebo and diacerein in a long-term study; <LINK REF="STD-Nguyen-1994" TYPE="STUDY">Nguyen 1994</LINK> evaluated the efficacy and safety of diacerein compared with non-steroidal anti-inflammatory drugs; and <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK> analysed the carry-over effect after three months of therapy. This diversity of bias can reduce the meaning of the results.</P>
<P>Only one (<LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>) of the 10 studies blinded assessors for clinical outcomes; all studies were classified as having low risk for radiographic outcomes. Radiological progression of OA is evaluated in long-term studies, and this review retrieved two studies that included this analysis. Radiographic joint space width, measured in millimetres, is currently considered the preferred technique to evaluate the structural progression of OA, which is required by regulatory agencies (<LINK REF="REF-Hellio-2009" TYPE="REFERENCE">Hellio 2009</LINK>). Unfortunately, the studies evaluated different joints. Radiological progression of knee OA was evaluated after one year (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) with no statistically significant differences noted, and hip OA was evaluated after three years, with a small difference favouring diacerein over placebo (<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>).</P>
<P>Compliance gives an indication of drug tolerability and acceptability by participants. Although all studies described in their Methods section that compliance was assessed by pill counting, investigators did not analyse this parameter, thereby hindering estimations of drug tolerability. Included studies do not provide information on how often or what doses of analgesics or NSAIDs were used by randomly assigned participants. This information would be important in assessing the overall effectiveness and safety of the treatment.</P>
<P>Only one of the 10 studies (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>) had adequate allocation concealment, and six (<LINK REF="STD-Brahmachari-2009" TYPE="STUDY">Brahmachari 2009</LINK>; <LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>; <LINK REF="STD-Louthrenoo-2007" TYPE="STUDY">Louthrenoo 2007</LINK>; <LINK REF="STD-Pavelka-2007" TYPE="STUDY">Pavelka 2007</LINK>; <LINK REF="STD-Pelletier-2000" TYPE="STUDY">Pelletier 2000</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) used an adequate method to generate a random sequence. Eight of ten studies had high risk of bias for incomplete outcome data. Only one study<B> (</B>
<LINK REF="STD-Dougados-2001" TYPE="STUDY">Dougados 2001</LINK>) was selective in its reporting of results and data. Consequently, evidence was downgraded to moderate for physical function/Lequesne impairment and to low for all other outcomes, using the GRADE assessment of quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-11-26 20:46:56 -0500" MODIFIED_BY="[Empty name]">
<P>Strengths of this review include the detailed electronic search strategy; all important databases were included in the search. At least two independent investigators were involved in all steps of the review, from screening of retrieved references, to reading, abstraction and quality assessment of included studies. An additional investigator was consulted to solve discrepancies until consensus was reached.</P>
<P>Weaknesses of this review include a low response rate when attempts were made to contact authors of the included studies. In addition, the pharmaceutical companies contacted (TRB Chemedica, Negma Lerads) did not reply to our questions regarding missing data.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-02-06 16:15:10 -0500" MODIFIED_BY="[Empty name]">
<P>Eight studies retrieved from the reference list of another review (<LINK REF="REF-Rintelen-2006" TYPE="REFERENCE">Rintelen 2006</LINK>) were excluded from our review. They were unpublished reports (<LINK REF="STD-Mantia-1987" TYPE="STUDY">Mantia 1987</LINK>; <LINK REF="STD-Portioli-1987" TYPE="STUDY">Portioli 1987</LINK>) or presentations from the Italian Society of Rheumatology (<LINK REF="STD-Mattara-1985" TYPE="STUDY">Mattara 1985</LINK>; <LINK REF="STD-Mordini-1986" TYPE="STUDY">Mordini 1986</LINK>; <LINK REF="STD-Pietrogrande-1985" TYPE="STUDY">Pietrogrande 1985</LINK>), except one study that did not show data consistent with other studies (<LINK REF="STD-Mattara-1985" TYPE="STUDY">Mattara 1985</LINK>) and two others that were already excluded in the first version of this review (2006) because they compared diacerein associated with other effective drugs versus standard treatment (<LINK REF="STD-Fagnani--1998" TYPE="STUDY">Fagnani 1998</LINK>; <LINK REF="STD-Marcolongo--1988" TYPE="STUDY">Marcolongo 1988</LINK>). Over the past three years, we have repeatedly contacted authors of those eight studies and representatives of the pharmaceutical industry to ask for additional details and unpublished data, but we have received no reply. The pharmaceutical company that sponsored several of these studies did not send us the complete data for analyses. Bartels et al (<LINK REF="REF-Bartels-2010" TYPE="REFERENCE">Bartels 2010</LINK>) also did not include these studies in their meta-analyses.</P>
<P>Results of this updated review coincide with those reported by Bartels (<LINK REF="REF-Bartels-2010" TYPE="REFERENCE">Bartels 2010</LINK>), who analysed six of these studies and reported a small beneficial effect of diacerein in the treatment of OA. As in our review, those authors found a small reduction in pain and lower efficacy in the studies of longest duration.</P>
<P>As mentioned in our Results, the EMA PRAC recommended that the marketing authorization of diacerein should be suspended because of harms related to the risk of severe diarrhoea and potentially harmful effects on the liver (<LINK REF="REF-PRAC-2013" TYPE="REFERENCE">PRAC 2013</LINK>). While the results of this review found evidence of an increased risk of diarrhea, a post-hoc assessment of the included studies for liver adverse effects was not found in these RCTs.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-02-04 05:37:15 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-02-04 05:37:15 -0500" MODIFIED_BY="[Empty name]">
<P>There is low quality evidence that diacerein provides a small symptomatic benefit in pain improvement that may not be clinically significant. Another small benefit (of low quality, as assessed by GRADE) in terms of joint space narrowing was noted in hip OA while the result for knee OA was not statistically significant. There was low quality of evidence indicating that diacerein can cause adverse effects such as diarrhoea, which was described as the most frequent adverse event by all studies that documented and analysed this outcome.</P>
<P>The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) recommended the suspension of diacerein-containing medicines across Europe because of harms outweighing benefits. However, this guidance is not final as the PRAC recommendation will be re-examined.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-11-26 20:46:56 -0500" MODIFIED_BY="[Empty name]">
<P>This review provides the most recent evidence on (1) the clinical effectiveness of diacerein for pain reduction and physical function improvement in patients with OA and (2) the effect of this drug on the radiographic progression of hip and knee OA.</P>
<P>This evidence, however, is based on studies with methodological shortcomings, qualifying the evidence as low and moderate. These findings show that additional trials are needed to further assess the effectiveness of this drug for pain reduction and physical function. These outcomes are better measured by WOMAC scales and/or the Lequesne Index, as well as by patient global evaluation (<LINK REF="REF-Dworkin-2011" TYPE="REFERENCE">Dworkin 2011</LINK>).</P>
<P>Structural variables usually assess the rate and extent of cartilage breakdown revealed by radiographic space width or cartilage volume, as measured by magnetic resonance imaging. Such outcome variables are accurate, have high intrinsic validity and are usually considered as the primary outcome to be assessed in studies of disease-modifying OA drugs (<LINK REF="REF-Dougados-2004" TYPE="REFERENCE">Dougados 2004</LINK>).</P>
<P>It is very important that researchers design studies of good methodological quality, lasting longer than six months and providing blinding of outcome assessors, including radiographic progression and symptomatic improvement. In addition to the VAS pain scale, the quality of life index and global assessment by participants and investigators should be included in future studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-01-15 13:48:21 -0500" MODIFIED_BY="[Empty name]">
<P>We would like to thank the Cochrane Musculoskeletal Editorial Team, mainly Ms Elizabeth Ghogomu, for their thoughtful comments and suggestions of ways to minimise bias in the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-01-15 13:48:50 -0500" MODIFIED_BY="[Empty name]">
<P>Tania Sales de Alencar Fidelix (TSAF), Cristiane Rufino Macedo (CRM), Lara Maxwell (LM) and Virginia Fernandes Moça Trevisani (VFMT) contributed to the updated version of this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-02-04 06:03:59 -0500" MODIFIED_BY="[Empty name]">
<P>No differences were noted between the objectives and methods described in the protocol and those included in the first published review. In this updated version, the review authors adhered to the current recommendations of the <I>Cochrane Handbook for Assessment of Methodological Quality of Studies</I> and included post hoc sensitivity analyses of studies with follow-ups lasting longer than six months. Therefore, the Jadad scores described in the protocol were not used. As well, the search included a search of four main regulatory agency websites as per the current CMSG guidance.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-01-06 14:03:27 -0500" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-01-23 14:14:32 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-01-14 14:54:34 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-01-14 14:53:02 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brahmachari-2009" MODIFIED="2013-11-26 21:30:56 -0500" MODIFIED_BY="[Empty name]" NAME="Brahmachari 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-11-26 21:30:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brahmachari B, Chatterjee S, Ghosh A</AU>
<TI>Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial</TI>
<SO>Clinical Rheumatology</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>1193-1198</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chantre-2000" MODIFIED="2013-11-26 21:38:41 -0500" MODIFIED_BY="Dolores Matthews" NAME="Chantre 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-26 21:38:41 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B</AU>
<TI>Efficacy and Tolerance of <I>Harpagophytum Procumbens</I> versus Diacerhein in Treatment of Osteoarthritis</TI>
<SO>Phytomedicine</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>177-183</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-2001" MODIFIED="2013-11-26 21:39:08 -0500" MODIFIED_BY="Dolores Matthews" NAME="Dougados 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-11-26 21:39:08 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M</AU>
<TI>Evaluation of Structure-Modifying Effects of Diacerein in Hip Osteoarthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>11</NO>
<PG>2539-2547</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lequesne-1998" MODIFIED="2013-11-26 21:39:25 -0500" MODIFIED_BY="Dolores Matthews" NAME="Lequesne 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-26 21:39:25 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lequesne M, Berdah L, Gérentes I</AU>
<TI>Efficacy and Safety of Diacerein for the treatment of Knee and Hip Osteoarthritis</TI>
<TO>Efficacité et tolérance de la diacerhéine dans le traitment de la gonarthrose et de la coxarthrose</TO>
<SO>La Revue du Praticien</SO>
<YR>1998</YR>
<VL>48</VL>
<PG>S31-S35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louthrenoo-2007" MODIFIED="2013-11-26 21:39:45 -0500" MODIFIED_BY="[Empty name]" NAME="Louthrenoo 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-26 21:39:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S</AU>
<TI>The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthitis: a randomised, double-blind, NSAID-controlled study</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2007</YR>
<VL>15</VL>
<PG>605-614</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen-1994" MODIFIED="2013-11-26 21:39:56 -0500" MODIFIED_BY="Dolores Matthews" NAME="Nguyen 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-26 21:39:56 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ngyen M, Dougados M, Berdah L, Amor B</AU>
<TI>Diacerhein in The Treatment of Osteoarthritis of The Hip</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1994</YR>
<VL>37</VL>
<NO>4</NO>
<PG>529-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2007" MODIFIED="2013-11-26 21:40:16 -0500" MODIFIED_BY="[Empty name]" NAME="Pavelka 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-26 21:40:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Trc T, Karpas K, Vítek P, Sedlacková M, Vlasáková V, Böhmová J, Rovenský J</AU>
<TI>The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>4055-4064</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-05-06 18:26:22 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelletier-2000" MODIFIED="2013-11-26 21:40:27 -0500" MODIFIED_BY="Dolores Matthews" NAME="Pelletier 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-26 21:40:27 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir M A, Choquette D, et al</AU>
<TI>Efficacy and Safety of Diacerein in Osteoarthritis of the Knee</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>10</NO>
<PG>2339-2348</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pham-2004" MODIFIED="2014-01-14 14:53:02 -0500" MODIFIED_BY="Dolores Matthews" NAME="Pham 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-01-14 14:53:02 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Henanff AL, Ravaud P, Dieppe P, et al</AU>
<TI>Evaluation of symptomatic and structural efficacy of a new hyaluronic acid (HA) compound, (NRD101), when compared to diacerein and placebo in one-year randomized controlled study in symptomatic knee osteoarthritis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>12</NO>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2006" MODIFIED="2013-11-26 21:40:48 -0500" MODIFIED_BY="[Empty name]" NAME="Zheng 2006" YEAR="2004">
<REFERENCE MODIFIED="2013-11-26 21:40:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zheng Wen-Jie, Tang Fu-Lin, Li Jun, Zhang Feng-Chun, Li Zhan-Guo, Su Yin, Wu Dong-Hai, Ma Li, Zhou Hui-Qiong , Huang Feng, Zhang Jiang-Lin, Liang Dong-Feng, Zhou Yi-Xiong, Xu Hui</AU>
<TI>Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China</TI>
<SO>APLAR Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>9</VL>
<PG>64-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-01-14 14:54:34 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adami--1985" MODIFIED="2013-11-26 21:41:05 -0500" MODIFIED_BY="Dolores Matthews" NAME="Adami  1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-26 21:41:05 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adami S, Bortolotti R, Guarrera G, Marini G, Rosini S, Zampieri A, Lo Cascio V</AU>
<TI>Diacerein in the Treatment of Degenerative Arthropathy</TI>
<TO>La Diacetilreina nel Trattamento delle Artropatie Degenerative</TO>
<SO>La Clinica Terapeutica</SO>
<YR>1985</YR>
<VL>112</VL>
<PG>439-443</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ascherl-1994" MODIFIED="2013-11-26 21:41:17 -0500" MODIFIED_BY="[Empty name]" NAME="Ascherl 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-26 21:41:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Ascherl R</AU>
<TI>Double blind, placebo-controlled multicentre, phase III study of the efficacy and tolerability of diacerein (DA39) in patients with osteoarthritis of the knee (University of Lubeck). Köln, Germany:Madaus AG;</TI>
<SO>unpublished final clinical study report</SO>
<YR>October 10, 1994. Madaus Report DA39KO.13</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baliga-2010" MODIFIED="2013-12-01 19:37:44 -0500" MODIFIED_BY="[Empty name]" NAME="Baliga 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-01 19:37:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baliga VP, Bolmall CS, Jagiasi JD, Kumar MSA, Sankaralingam K, Veerappan V</AU>
<TI>Efficacy, safety and tolerability of diacerein MR 100 mg versus diacerein 50 mg in adult patients with osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2010</YR>
<VL>18 SUPPL 2</VL>
<PG>S252</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogliola--1991" MODIFIED="2013-11-26 21:41:43 -0500" MODIFIED_BY="Dolores Matthews" NAME="Bogliola  1991" YEAR="1991">
<REFERENCE MODIFIED="2013-11-26 21:41:43 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogliolo A, Loi A, Perpignano G</AU>
<TI>"Fangobalneotherapy" and Diacerein in the Treatment of Hip and Knee Osteaoarthrosis</TI>
<TO>Fangobalneoterapia e Diacereina nel Trattamento dell'Osteoartrosi dell'Anca e del Ginocchio</TO>
<SO>La Clinica Terapeutica</SO>
<YR>1991</YR>
<VL>137</VL>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba--1987" MODIFIED="2014-01-14 14:53:24 -0500" MODIFIED_BY="Dolores Matthews" NAME="Carrabba  1987" YEAR="1987">
<REFERENCE MODIFIED="2014-01-14 14:53:24 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrabba M, Mele G, Chevallard M, Angelini M</AU>
<TI>Diacereine, an "original"approach to the treatment of degenerative and/or extra-articular rheumatism.</TI>
<TO>Diacereina: un approccio "originale" nel trattamento dei reumatismi degenerativi e/o extra-articolari</TO>
<SO>Minerva Medica</SO>
<YR>1987</YR>
<VL>78</VL>
<PG>179-185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delcambre--1994" MODIFIED="2013-11-26 21:42:02 -0500" MODIFIED_BY="Dolores Matthews" NAME="Delcambre  1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-26 21:42:02 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delcambre B, Taccoen A</AU>
<TI>ART 50 Study in the Update Rheumatologic Practice</TI>
<TO>Étude D'ART 50 en Pratique Rhumatologique Courante</TO>
<SO>Revue Du Rhumatisme</SO>
<YR>1994</YR>
<VL>61</VL>
<PG>142S-146S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delcambre--1996" MODIFIED="2013-11-26 21:42:14 -0500" MODIFIED_BY="Dolores Matthews" NAME="Delcambre  1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-26 21:42:14 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delchambre B, Taccoen A</AU>
<TI>Study of ART 50 in the rheumatologic daily practice</TI>
<TO>Étude d'ART 50 en pratique rhumatologique quotidienne</TO>
<SO>Le Revue du Praticien</SO>
<YR>1996</YR>
<VL>46</VL>
<PG>S49-S52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagnani--1998" MODIFIED="2013-11-26 21:42:27 -0500" MODIFIED_BY="Dolores Matthews" NAME="Fagnani  1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-26 21:42:27 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagnani F, Bouvenot G, Valat J-P, Bardin T, Berdah L, Lafuma A, Bono I, Escchwege E, Dreiser R-L</AU>
<TI>Medico-Economic Analysis of Diacerein With or Without Standard Therapy in the Treatment of Osteoarthritis</TI>
<SO>Pharmacoeconomics</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>135-146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fioravanti-1985" MODIFIED="2014-01-14 14:53:43 -0500" MODIFIED_BY="[Empty name]" NAME="Fioravanti 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-01-14 14:53:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fioravanti A, Marcolongo R.</AU>
<TI>Therapeutic effectiveness of diacerhein (DAR) in arthrosis of the knee and hip</TI>
<SO>Report presented at: The Toscana Medicina Symposuim on Diacereina</SO>
<YR>October 1, 1985</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kay-1980" MODIFIED="2013-11-26 21:42:53 -0500" MODIFIED_BY="Dolores Matthews" NAME="Kay 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-11-26 21:42:53 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kay AGL, Griffiths LG, Volans GN, Grahame R</AU>
<TI>Prelimirary experience with diacetylrhein in the treatment of osteoarthritis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>8</NO>
<PG>548-551</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leblan--2000" MODIFIED="2013-11-26 21:43:06 -0500" MODIFIED_BY="Dolores Matthews" NAME="Leblan  2000" YEAR="2000">
<REFERENCE MODIFIED="2013-11-26 21:43:06 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leblan D, Chantre P, Fournié B</AU>
<TI>
<I>Harpagophytum procumben</I>s in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein</TI>
<SO>Join Bone Spine</SO>
<YR>2000</YR>
<VL>67</VL>
<PG>462-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linguetti--1982" MODIFIED="2013-11-26 21:43:16 -0500" MODIFIED_BY="Dolores Matthews" NAME="Linguetti  1982" YEAR="1982">
<REFERENCE MODIFIED="2013-11-26 21:43:16 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linguetti M, D'Ambrosio PL, Di Grezia F, Sorrentino P, Lingetti E</AU>
<TI>A Controlled Study in the Treatment of Osteoarthritis with Diacetylrhein (ARTRODAR)</TI>
<SO>Current Therapeutic Research</SO>
<YR>1982</YR>
<VL>31</VL>
<NO>3</NO>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mantia-1987" MODIFIED="2012-04-24 15:59:08 -0400" MODIFIED_BY="[Empty name]" NAME="Mantia 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-04-24 15:59:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Mantia C</AU>
<TI>A controlled study of the efficacy and tolerability of diacetylrhein in the functional manifestations of osteoarthritis of the hip and the knee: a double-blind study versus diclofenac</TI>
<SO>Palermo Hospital, Palermo, Italy; 1987</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcolongo--1988" MODIFIED="2013-11-26 21:43:32 -0500" MODIFIED_BY="Dolores Matthews" NAME="Marcolongo  1988" YEAR="1988">
<REFERENCE MODIFIED="2013-11-26 21:43:32 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A</AU>
<TI>Efficacy and Tolerability of Diacerhein in the Treatment of Osteoarthrosis</TI>
<SO>Current Therapeutic Research</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>5</NO>
<PG>878-887</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathieu-1999" MODIFIED="2013-11-26 21:43:42 -0500" MODIFIED_BY="Dolores Matthews" NAME="Mathieu 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-11-26 21:43:42 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathieu P</AU>
<TI>Interleucine 1 - Results of a pilot study with diacerein (ART 50) for Knee Osteoarthrosis</TI>
<TO>L'interleukine 1 - Résultats d'une étude "pilote" avec la diacerhéine (ART 50) dans la gonarthrose</TO>
<SO>La Revue du Praticien</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>S15-S18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattara-1985" MODIFIED="2013-11-26 21:43:53 -0500" MODIFIED_BY="[Empty name]" NAME="Mattara 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-26 21:43:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mattara L</AU>
<TO>DAR: indagini "controllate" nel trattamento della osteoartosi </TO>
<SO>Relazione presentata al LXXXVI Congresso Naz. Società Ital. Medicina Interna - Sorrento</SO>
<YR>1985</YR>
<VL>S</VL>
<PG>59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzaro--1989" MODIFIED="2013-11-26 21:44:02 -0500" MODIFIED_BY="Dolores Matthews" NAME="Mazzaro  1989" YEAR="1989">
<REFERENCE MODIFIED="2013-11-26 21:44:02 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzaro C, Bocchieri E, Tesolin FG, Ventre L, Romagnoli A</AU>
<TI>Clinical Evaluation of Diacereine in Osteoarthrosis Treatment</TI>
<TO>Valutazione clinica della Diacereina nel Trattamento dell'osteoartrosi</TO>
<SO>Minerva Medica</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>9</NO>
<PG>1025-1027</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mordini-1986" MODIFIED="2013-12-01 19:40:03 -0500" MODIFIED_BY="[Empty name]" NAME="Mordini 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-12-01 19:40:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mordini M, Nencioni C, Lavagni A, Camarri E. Diacerhein vs naproxen in coxo-gonarthrosis: double-blind randomized study.</AU>
<SO>Abstract presented at: The 27th Congress of the Italian Society of Rheumatology</SO>
<YR>October 30-November 2, 1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietrogrande-1985" MODIFIED="2013-11-26 21:44:19 -0500" MODIFIED_BY="[Empty name]" NAME="Pietrogrande 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-11-26 21:44:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pietrogrande V, Leonardi M, Pacchioni C</AU>
<TI>Results of a clinical trial with a new drug, diacerhein in arthrosic patiens.</TI>
<SO>Report presented at: The LXXXVI Congress of the Italian National Society of Internal Medicine;</SO>
<YR>September 24, 1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Portioli-1987" MODIFIED="2013-11-26 21:44:29 -0500" MODIFIED_BY="[Empty name]" NAME="Portioli 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-26 21:44:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Portioli IA</AU>
<TI>Naproxen-controlled study on efficacy and tolerability of diacetylrhein in the functional manifestations of osteoarthritis of the knee and hip: a double blind study versus naproxen</TI>
<SO>unpublished clinical study report; Santa Maria Nuova Hospital, Reggio Emilia, Italy</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renapurkar--2010" MODIFIED="2012-08-28 11:37:31 -0400" MODIFIED_BY="[Empty name]" NAME="Renapurkar  2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-28 11:37:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renapurkar DK. Mathur S, Rao KLJ</AU>
<TI>Evaluation of efficacy and safety of diacerein in osteoarthritis of knee joint</TI>
<SO>International Journal of Pharma and Bio Sciences</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schulitz-1994" MODIFIED="2014-01-14 14:54:34 -0500" MODIFIED_BY="[Empty name]" NAME="Schulitz 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-01-14 14:54:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Schulitz KP</AU>
<TI>Clinical investigation of the efficacy and tolerance of diacetylrhein (DAR) in the treatment of osteoarthritis of the knee. Köln, Germany: Madaus AG</TI>
<SO>Unpublished final clinical study report. Madaus Report RDA139.</SO>
<YR>October 27 1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seisenbayev-2012" MODIFIED="2013-12-01 19:41:14 -0500" MODIFIED_BY="[Empty name]" NAME="Seisenbayev 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-01 19:41:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seisenbayev A, Togizbaev</AU>
<TI>Three component treatment of osteoarthiitis</TI>
<SO>Rheumatology</SO>
<YR>2012</YR>
<VL>51 SUPPL 1</VL>
<PG>i29-i30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma--2008" MODIFIED="2013-11-26 21:45:00 -0500" MODIFIED_BY="[Empty name]" NAME="Sharma  2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-26 21:45:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma A, Rathod R, Baliga VP</AU>
<TI>An Open Prospective Study on Postmarketing Evaluation of the Efficacy and Tolerability of Diacerein in Osteo-arthritis of the knee (DOK)</TI>
<SO>Journal of Indian Medical Association</SO>
<YR>2008</YR>
<VL>106</VL>
<PG>31-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2012" MODIFIED="2013-11-26 21:45:08 -0500" MODIFIED_BY="[Empty name]" NAME="Singh 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-26 21:45:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh K, Sharma R, Rai J</AU>
<TI>Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee</TI>
<SO>International journal of rheumatic diseases</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>1</NO>
<PG>69-77</PG>
<IDENTIFIERS MODIFIED="2012-08-28 11:01:27 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22324949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2004" MODIFIED="2013-11-26 21:45:26 -0500" MODIFIED_BY="[Empty name]" NAME="Tang 2004" YEAR="2006">
<REFERENCE MODIFIED="2013-11-26 21:45:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tang FL, Wu DH, Lu ZG, Huang F, Zhou YX</AU>
<TI>The efficacy and safety of diacerein in treatmnet of painful osteoarthritis of the knee</TI>
<SO>11º Asia Pacific League of Associations for Rheumatology Congress, Jeju Island, Korea</SO>
<YR>2004</YR>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valat-1997" MODIFIED="2013-11-26 21:45:37 -0500" MODIFIED_BY="Dolores Matthews" NAME="Valat 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-26 21:45:37 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valat-JP</AU>
<TI>Diacerein Pragmatic Study: Clinical, Life quality and socio- economic analysis</TI>
<TO>Étude pragmatique de la diacerheine: résultats sur les signes cliniques, la qualité de vie et les coûts médico-économiques</TO>
<SO>La Revue du Praticien</SO>
<YR>1997</YR>
<VL>47</VL>
<PG>S39-S45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vignon--2002" MODIFIED="2013-11-26 21:45:51 -0500" MODIFIED_BY="Dolores Matthews" NAME="Vignon  2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-26 21:45:51 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vignon E</AU>
<TI>Results of ECHODIAH study in hip osteoarthritis</TI>
<TO>Résultats de l'essai thérapeutique ECHODIAH dans l"arthrose de hanche</TO>
<SO>La Presse Médicale</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villani--1998" MODIFIED="2013-11-26 21:46:03 -0500" MODIFIED_BY="Dolores Matthews" NAME="Villani  1998" YEAR="1998">
<REFERENCE MODIFIED="2013-11-26 21:46:03 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villani P, Bouvenot G</AU>
<TI>Assessment of the placebo effect of symptomatic slow-acting drugs given for osteoarthritis</TI>
<TO>Approche de l'intensité de l'effet placebo dans l'évaluation des anti-arthrosiques symptomatiques d'action lente</TO>
<SO>La Presse Médicale</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>5</NO>
<PG>211-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villermay-1994" MODIFIED="2013-11-26 22:11:14 -0500" MODIFIED_BY="Dolores Matthews" NAME="Villermay 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-26 22:11:14 -0500" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villermay D</AU>
<TI>A new medicine for Arthrosis</TI>
<TO>Un Nouveau Médicament Pour L'Arthrose</TO>
<SO>revue de L'Infirmière</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>10-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-12-01 19:41:52 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Shin-2013" MODIFIED="2013-12-01 19:41:52 -0500" MODIFIED_BY="[Empty name]" NAME="Shin 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-12-01 19:41:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kichul Shin, Joon Wan Kim, Ki won Moon, Ji Ae Yang,Eun Yeong Lee, MD, Yeong Wook Song, MD, Eun Bong Lee</AU>
<TI>The Efficacy of Diacerein in Hand Osteoarthritis:A Double-Blind, Randomized, Placebo-Controlled Study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2013</YR>
<VL>35</VL>
<PG>431-439</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-07 20:47:43 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-10-08 14:05:55 -0400" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-01-23 14:14:32 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-01-23 14:14:32 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACR-2000" MODIFIED="2013-12-01 19:42:35 -0500" MODIFIED_BY="[Empty name]" NAME="ACR 2000" TYPE="JOURNAL_ARTICLE">
<AU>American College of Rheumatology Siubcommittee on Osteoarthritis Guidelines</AU>
<TI>ACR recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update.</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>9</NO>
<PG>1905-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1986" NAME="Altman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Asch E, Bloch D, et al</AU>
<TI>The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1986</YR>
<VL>29</VL>
<PG>1039-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1990" NAME="Altman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Alarcon G, Appelrough D, et al</AU>
<TI>The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>1601-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bartels-2010" MODIFIED="2014-01-14 14:55:05 -0500" MODIFIED_BY="[Empty name]" NAME="Bartels 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bartels EM, Bliddal H, Schondorff PK, Altman RD, Zhang W, Christensen R</AU>
<TI>Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: meta-analysis of randomized placebo-controlled trials</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>289-296</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1988" NAME="Bellamy 1988" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW</AU>
<TI>Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee</TI>
<SO>Journal of Rheumatology</SO>
<YR>1988</YR>
<VL>15</VL>
<PG>1833-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1997" MODIFIED="2013-12-01 19:43:05 -0500" MODIFIED_BY="Dolores Matthews" NAME="Bellamy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Kirwan J, Boers M</AU>
<TI>Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III</TI>
<SO>Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>700-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2006" MODIFIED="2013-01-18 04:59:37 -0500" MODIFIED_BY="[Empty name]" NAME="Bellamy 2006" TYPE="COCHRANE_REVIEW">
<AU>Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA</AU>
<TI>Viscosupplementation for the treatment of osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-12-06 19:15:39 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-06 19:15:39 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005321.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berembaum-2010" MODIFIED="2014-01-14 14:55:25 -0500" MODIFIED_BY="[Empty name]" NAME="Berembaum 2010" TYPE="JOURNAL_ARTICLE">
<AU>Berembaum F, Sellam J</AU>
<TI>The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis</TI>
<SO>Nature Reviews Rheumatology</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>625-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bijlsma-2012" MODIFIED="2013-12-01 19:43:34 -0500" MODIFIED_BY="[Empty name]" NAME="Bijlsma 2012" TYPE="BOOK">
<AU>Bijlsma JWJ</AU>
<SO>Textbook on Rheumatic Diseases</SO>
<YR>2012</YR>
<EN>First</EN>
<PB>BMJ Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsson-1983" MODIFIED="2014-01-14 14:55:41 -0500" MODIFIED_BY="Dolores Matthews" NAME="Carlsson 1983" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson AM</AU>
<TI>Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale</TI>
<SO>Pain</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>87-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-2004" MODIFIED="2013-11-26 21:47:26 -0500" MODIFIED_BY="[Empty name]" NAME="Dougados 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M</AU>
<TI>Outcome Measures for Clinical Trials of Disease Modifying Osteoarthritis Drugs in Patients with Hip Osteoarthritis.</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>66-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2011" MODIFIED="2013-11-26 21:47:39 -0500" MODIFIED_BY="[Empty name]" NAME="Dworkin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Pierce-Sandner S, Turk DC, McDermott MP, Gibofsky A, Simon LS, Farrar JT, Katz NP.</AU>
<TI>Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database.</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>2011</YR>
<VL>19</VL>
<PG>483-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zahner T, Scheider M, Junker C, Lengeler Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grade-2008" MODIFIED="2013-12-01 19:44:10 -0500" MODIFIED_BY="[Empty name]" NAME="Grade 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grading Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>British Medical Journal</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-1051</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hellio-2009" MODIFIED="2013-11-26 21:47:53 -0500" MODIFIED_BY="[Empty name]" NAME="Hellio 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hellio Le Graverand-Gastineau MP</AU>
<TI>OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>2009</YR>
<VL>17</VL>
<PG>1393-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-12-10 19:56:46 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-01-14 14:56:01 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). www.cochrane-handbook.org</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<CY>UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2001" MODIFIED="2013-12-01 19:45:59 -0500" MODIFIED_BY="Dolores Matthews" NAME="Hochberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg M C, Dougados M</AU>
<TI>Pharmacological therapy of osteoarthritis</TI>
<SO>Best Practice &amp; Research Clinical Rheumatology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>4</NO>
<PG>583-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2011" MODIFIED="2013-12-01 19:46:20 -0500" MODIFIED_BY="[Empty name]" NAME="Hunter 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hunter DJ</AU>
<TI>Pharmacologic therapy for osteoarthritis - the era of disease modification.</TI>
<SO>Nature Reviews Rheumatology</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>1</NO>
<PG>13-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kellgren-1957" MODIFIED="2013-11-26 21:48:50 -0500" MODIFIED_BY="[Empty name]" NAME="Kellgren 1957" TYPE="JOURNAL_ARTICLE">
<AU>Kellgren JH, Lawrence JJ</AU>
<TI>Radiological assessment of osteoarthritis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>1957</YR>
<VL>16</VL>
<PG>494-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawrence-1998" MODIFIED="2014-01-14 14:56:26 -0500" MODIFIED_BY="[Empty name]" NAME="Lawrence 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al</AU>
<TI>Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>4</NO>
<PG>778-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lequesne-1987" MODIFIED="2013-12-01 19:47:02 -0500" MODIFIED_BY="Dolores Matthews" NAME="Lequesne 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lequesne MG, Mery C, Samson M, Gerard P</AU>
<TI>Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests.</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>(Suppl 65)</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lingetti--1982" MODIFIED="2013-11-26 21:49:14 -0500" MODIFIED_BY="Dolores Matthews" NAME="Lingetti  1982" TYPE="JOURNAL_ARTICLE">
<AU>Lingetti M, D'Ambrosio PL, Di Grezia F, et al</AU>
<TI>A controlled study in the treatment of osteoarthritis with diacetylrhein (arthrodar)</TI>
<SO>Current Therapeutic Research</SO>
<YR>1982</YR>
<VL>31</VL>
<NO>3</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-2012" MODIFIED="2014-01-14 14:56:50 -0500" MODIFIED_BY="[Empty name]" NAME="Murphy 2012" TYPE="JOURNAL_ARTICLE">
<AU>Murphy L, Helmick CG</AU>
<TI>The impact of osteoarthritis in the United States: a population-health perspective</TI>
<SO>American Journal of Nursing</SO>
<YR>2012</YR>
<VL>112</VL>
<NO>Suppl 1</NO>
<PG>S13-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pelletier-2010" MODIFIED="2012-12-06 19:42:54 -0500" MODIFIED_BY="[Empty name]" NAME="Pelletier 2010" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier JM, Pelletier JP</AU>
<TI>Effects of diacerein at the molecular level in the osteoarthritis disease process</TI>
<SO>Therapeutical Advances in Muskuloskeletal Disease</SO>
<YR>2010</YR>
<VL>2</VL>
<NO>2</NO>
<PG>95-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2003" MODIFIED="2013-11-26 21:49:59 -0500" MODIFIED_BY="Dolores Matthews" NAME="Pham 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Heijde DV, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al</AU>
<TI>Outcome Variables for Osteoarthritis Clinical Trials: The OMERACT-OARSI Set of Responder Criteria</TI>
<SO>Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<PG>1648-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Picavet-2003" MODIFIED="2013-11-26 21:50:11 -0500" MODIFIED_BY="[Empty name]" NAME="Picavet 2003" TYPE="JOURNAL_ARTICLE">
<AU>Picavet HS, Hazes JM</AU>
<TI>Prevalence of self reported musculoskeletal diseases is high</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>7</NO>
<PG>644-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PRAC-2013" MODIFIED="2014-01-23 14:14:32 -0500" MODIFIED_BY="[Empty name]" NAME="PRAC 2013" TYPE="OTHER">
<AU>The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC)</AU>
<TI>PRAC recommends suspension of diacerein-containing medicines</TI>
<SO>Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Diacerein-containing_medicines_for_oral_administration/human_referral_prac_000010.jsp&amp;mid=WC0b01ac05805c516f</SO>
<YR>8 November 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rintelen-2006" MODIFIED="2013-12-01 19:47:26 -0500" MODIFIED_BY="[Empty name]" NAME="Rintelen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rintelen B, Neumann K, Leeb BF</AU>
<TI>A Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>1899-1902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-1997" MODIFIED="2013-11-26 21:50:32 -0500" MODIFIED_BY="Dolores Matthews" NAME="Spencer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Spencer CM, Wilde MI</AU>
<TI>Diacerein</TI>
<SO>Drugs</SO>
<YR>1997</YR>
<VL>53</VL>
<NO>1</NO>
<PG>98-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2007" MODIFIED="2013-12-01 19:47:54 -0500" MODIFIED_BY="[Empty name]" NAME="Sun 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sun BH, Wu CW, Kalunian KC.</AU>
<TI>New developments in osteoarthritis.</TI>
<SO>Rheumatic Diseases Clinic of North America</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>135-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed--2008" MODIFIED="2014-01-16 12:19:52 -0500" MODIFIED_BY="[Empty name]" NAME="Towheed  2008" TYPE="COCHRANE_REVIEW">
<AU>Towheed T, Maxwell L, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC, Wells GA</AU>
<TI>Glucosamine therapy for treating osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-01-16 11:37:35 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-16 11:37:35 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002946.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Towheed-2006" MODIFIED="2014-01-16 12:20:00 -0500" MODIFIED_BY="[Empty name]" NAME="Towheed 2006" TYPE="COCHRANE_REVIEW">
<AU>Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G</AU>
<TI>Acetaminophen for osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-01-16 11:35:37 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-16 11:35:37 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004257.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woolf-2003" MODIFIED="2013-11-26 21:51:19 -0500" MODIFIED_BY="[Empty name]" NAME="Woolf 2003" TYPE="JOURNAL_ARTICLE">
<AU>Woolf A, Pfleger B</AU>
<TI>Burden of major musculoskeletal conditions</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>9</NO>
<PG>646-656</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2001" MODIFIED="2014-01-14 14:57:05 -0500" MODIFIED_BY="[Empty name]" NAME="Zhang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Xu L, Nevitt MC, Aliabadi P, Yu W, Qin M, et al</AU>
<TI>Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and whites in the United States: the Beijing Osteoarthritis Study</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>9</NO>
<PG>2065-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-01-14 14:52:38 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brahmachari-2009">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Single-blind (participants were blinded)</P>
<P>Placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]">
<P>Individuals between 35 and 70 years of age, with primary, symptomatic, tibiofemoral OA fulfilling ACR criteria and Kellgren-Lawrence grades II and III with pain score &#8805; 35 mm on a 100-mm VAS scale</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 50-mg capsules twice daily or placebo capsules twice daily</P>
<P>Duration eight weeks with evaluation and after 12 weeks without treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]">
<P>Pain on movement in 0 to 100 mm VAS</P>
<P>WOMAC stiffness and physical function</P>
<P>Clinical global impression by investigator on a 5-point Likert scale</P>
<P>Use of rescue medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]">
<P>The study drug was provided by Macleods Pharmaceuticals Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chantre-2000">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Double-blind<BR/>Multi-centre (30 centres)<BR/>Parallel-group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with OA of hip or knee</P>
<P>Country: France</P>
<P>N = 122</P>
<P>Mean age, years: 61.5 </P>
<P>Female 63%; male 37%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 50 mg BID + six capsules of placebo per day versus six capsules of Harpadol(R) + two capsules of placebo per day.</P>
<P>Duration: 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (0 to 100 VAS scale)<BR/>Lequesne Functional Index<BR/>Use of NSAIDs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Arkopharma Laboratories is represented as the first author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougados-2001">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Double-blind</P>
<P>Multi-centre (26 centres)</P>
<P>Parallel-group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with hip OA</P>
<P>Country: France</P>
<P>N = 507<BR/>Mean age, years: 62 ± 7 </P>
<P>Female 60%; </P>
<P>male 40%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 50 mg BID versus placebo BID</P>
<P>Duration: three years of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Radiography once a year (JWS measurement)</P>
<P>Pain (100-mm VAS)</P>
<P>Functional Lequesne Index</P>
<P>Analgesic use</P>
<P>Need for signal hip joint replacement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Supported in part by a grant from Negma Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lequesne-1998">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Double-blind</P>
<P>Parallel-group</P>
<P>Multi-centre (35 centres)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with knee or hip OA</P>
<P>Country: France</P>
<P>N = 183</P>
<P>Mean age, years: 61.5 ± 10.9 </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]">
<P>Zero to two months: diacerein 50 mg BID + diclofenac 50 mg BID versus placebo + diclofenac 50 mg BID</P>
<P>Two to six months: diacerein 50 mg BID versus placebo</P>
<P>Six to eight months: without treatment (carry-over effect evaluation)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (0 to 100-mm VAS scale)<BR/>Functional Lequesne Impairment Index<BR/>Global efficacy evaluation for participant and physician (participant scale 0 to 7 and physician scale 0 to 5)<BR/>Safety scale 0 to 4 at the end of the study<BR/>Analgesic and NSAID use<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-30 18:28:37 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Louthrenoo-2007">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Multi-centre (five medical schools in Thailand)</P>
<P>Double-blind</P>
<P>Piroxicam-controlled</P>
<P>Parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]">
<P>Participants with tibiofemoral X-ray confirmed Kellgren-Lawrence grade II or III OA according to ACR criteria between 40 and 65 years of age, with knee pain of at least 40 mm on at least two items of the WOMAC A, on a 0 to 100-mm VAS scale, for at least 15 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 100 mg/ d (N = 86) versus piroxicam 20 mg/d (N = 85). 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]">
<P>WOMAC A, B, C</P>
<P>SF-36</P>
<P>Paracetamol consumption</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]">
<P>Supported by a grant from TRB Chemedica International</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-14 14:52:30 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nguyen-1994">
<CHAR_METHODS MODIFIED="2013-11-26 20:47:46 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Allocation concealment</P>
<P>Double-blind<BR/>Placebo-controlled</P>
<P>Parallel-group<BR/>Multi-centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:47:46 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with hip OA</P>
<P>Country: France<BR/>N = 288; included in this review: 221</P>
<P>Mean age, years: 60 ± 16</P>
<P>Female 57%;</P>
<P>male 43%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:47:46 -0500" MODIFIED_BY="[Empty name]">
<P>One capsule (50-mg capsule of diacerein or matching placebo capsules) twice daily and one tablet (20-mg tablet of tenoxicam or matching placebo tablets)</P>
<P>Duration: eight weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:47:46 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (100-mm VAS scale)</P>
<P>Functional Lequesne Impairment Index</P>
<P>Analgesic consumption</P>
<P>Participant overall assessment (0 to 4 scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-14 14:52:30 -0500" MODIFIED_BY="[Empty name]">
<P>Supported in part by Negma Pharma Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavelka-2007">
<CHAR_METHODS MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Double-blind</P>
<P>Placebo-controlled</P>
<P>Multi-centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with tibiofemoral OA (knee) according to ACR criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 50 mg twice a day (N = 82) versus placebo (N = 83)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]">
<P>WOMAC for pain (A), WOMAC B, WOMAC C and total WOMAC</P>
<P>Tenderness of target knee on palpation 100 mm VAS</P>
<P>Acetaminophen intake, tablets/d</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:48:20 -0500" MODIFIED_BY="[Empty name]">
<P>Supported by a joint grant from TRB Chemedica International and Glynn Brothers Chemicals AG</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-14 14:52:32 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelletier-2000">
<CHAR_METHODS MODIFIED="2013-11-26 20:48:52 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Double-blind</P>
<P>Parallel-group four-arm trial</P>
<P>Multi-centre (25 centres)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:48:52 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with knee OA<BR/>Country: Canada and Israel, N = 484; included in this review: 236<BR/>Mean age, years: 63.5 ± 8.9<BR/>Female 79.6%;</P>
<P>male 20.4%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:48:52 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 25 mg twice daily versus diacerein 50 mg twice daily versus diacerein 75 mg twice daily versus placebo (one capsule twice daily)</P>
<P>Duration 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:48:52 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (0 to 100-mm VAS scale)<BR/>WOMAC Index<BR/>Handicap (0 to 100-mm VAS)<BR/>Participant and physician overall assessment on a 0 to 100-mm VAS at the end of the study<BR/>Knee joint swelling (0 to 3)<BR/>Duration of morning stiffness in minutes<BR/>Joint mobility assessed with a goniometer</P>
<P>Safety evaluation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-14 14:52:32 -0500" MODIFIED_BY="[Empty name]">
<P>Supported by a grant from Les Laboratoires Negma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pham-2004">
<CHAR_METHODS MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>Double-blind</P>
<P>Three arms</P>
<P>Multi-centre (46 centres)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with knee OA<BR/>Country: France and UK<BR/>N = 301</P>
<P>Mean age, years: 65<BR/>Female 70%;</P>
<P>male 30%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 50 mg BID + 3 × 3 intra-articular injections of saline solution versus 3 × 3 HA intra-articular injections (NRD101) and placebo capsules versus 3 × 3 intra-articular injections of saline solution and daily placebo capsules</P>
<P>Duration: one year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (0 to 100-mm VAS)<BR/>Lequesne Impairment Index<BR/>Participants' global assessment (0 to 100 VAS)<BR/>Percentage of painful days (0 to 100 VAS)<BR/>Assessment of treatment efficacy by participant and investigator (0 to 5 scale) at the end of the study</P>
<P>Radiography after one year (JWS measurement)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:49:41 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2006">
<CHAR_METHODS MODIFIED="2013-11-26 20:50:10 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Double-blind</P>
<P>Parallel-group</P>
<P>Multi-centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:50:10 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with knee OA<BR/>Country: China</P>
<P>N = 184<BR/>Mean age, years: 58.5</P>
<P>82% female;</P>
<P>18% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:50:10 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein 2 × 50 mg capsules and three tablets of placebo versus diclofenac 3 × 25 mg tablets and two tablets of placebo<BR/>Duration: three months with a follow-up period of one month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:50:10 -0500" MODIFIED_BY="[Empty name]">
<P>Pain on walking 20 m on a 100-mm VAS<BR/>WOMAC Index<BR/>Effusion or swelling of soft tissue/tenderness of target joint<BR/>Efficacy judgements by participants and investigators<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]">
<P>Diacerein and diclofenac were provided by Kunming Jida Pharmaceutical Co</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BID: twice a day.<BR/>HA: hyaluronic acid.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-01-14 14:52:38 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-01-14 14:52:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adami--1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-14 14:52:34 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial<BR/>
<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-14 14:52:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascherl-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-14 14:52:36 -0500" MODIFIED_BY="[Empty name]">
<P>Unpublished study. Diacerein versus placebo for knee OA. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-14 14:52:37 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baliga-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-14 14:52:37 -0500" MODIFIED_BY="[Empty name]">
<P>Inappropriate inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:51:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogliola--1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:51:22 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial<BR/>The study describes diacerein 50 mg/d every 60 days versus a 30-day interval compared with falgo balneo therapy for one year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:51:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carrabba--1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:51:06 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial. Study analysed use of diacerein 100 mg/d in a group of 31 participants with OA without defined joint for four weeks, in another group of 20 OA participants using diacerein 100 mg/d in a cross-over arm with naproxen 500 mg/d and in a third group of 20 fibromyalgia participants using diacerein 100 mg/d five days/wk for 12 weeks. The three cohorts were analysed for outcomes on a 0 to 3 scale</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:51:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delcambre--1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:51:06 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial. Study evaluated 1,221 participants with radiological OA of hip, knee or cervical or lumbar spine using diacerein 100 mg/d for three months as isolated therapy or associated with analgesic or NSAIDs. Outcome measurements inadequate for analysis (VAS 0 to 100 in five grades)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:51:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delcambre--1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:51:38 -0500" MODIFIED_BY="[Empty name]">
<P>Duplication of the <LINK REF="STD-Delcambre--1994" TYPE="STUDY">Delcambre 1994</LINK> publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:32:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fagnani--1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:32:09 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised non blinded study using diacerein and standard therapy for OA including other slow acting anti osteoarthritic drugs plus several procedures that could cause confusion on improvement of end point measurements</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:32:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fioravanti-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:32:13 -0500" MODIFIED_BY="[Empty name]">
<P>Report of diacerein effectiveness. Symposium presentation not published. Unsuccessfull TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:27:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kay-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:27:59 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:51:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leblan--2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:51:58 -0500" MODIFIED_BY="[Empty name]">
<P>Duplication of the publication of <LINK REF="STD-Chantre-2000" TYPE="STUDY">Chantre 2000</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:32:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linguetti--1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:32:19 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-14 14:52:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantia-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-14 14:52:38 -0500" MODIFIED_BY="[Empty name]">
<P>Clinical study report. Diacerein versus diclofenac for knee and hip OA. Data not available. Unsuccessfull TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcolongo--1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:08 -0500" MODIFIED_BY="[Empty name]">
<P>Review on diacerein treatment. No specific data are available for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:27:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathieu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:27:56 -0500" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattara-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Data not available. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazzaro--1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not a trial<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mordini-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Clinical study. Data not available. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pietrogrande-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Data not available. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Portioli-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Data not available. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Renapurkar--2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulitz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Data not available. Unsuccessful TRB Chemedica contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seisenbayev-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:26 -0500" MODIFIED_BY="[Empty name]">
<P>Data not available. Unsuccessful personal contact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 21:32:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma--2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 21:32:41 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Inappropriate inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Congress abstract later published by Zheng (<LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>) with additional data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valat-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Duplication of the Fagnani study (<LINK REF="STD-Fagnani--1998" TYPE="STUDY">Fagnani 1998</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vignon--2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Comments about ECHODIAH study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villani--1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:41 -0500" MODIFIED_BY="[Empty name]">
<P>Comment about placebo effects in trials using slow-acting drugs for OA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-26 20:52:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villermay-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-26 20:52:40 -0500" MODIFIED_BY="[Empty name]">
<P>Comment about the large trial involving 1,221 participants described by Delcambre</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-11-26 20:53:00 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-11-26 20:53:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shin-2013">
<CHAR_METHODS MODIFIED="2013-11-26 20:52:53 -0500" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, controlled study; allocation concealment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:52:53 -0500" MODIFIED_BY="[Empty name]">
<P>84 participants &gt; 40 years of age, had at least one tender joint and had a joint pain visual analogue scale of 30 mm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:52:53 -0500" MODIFIED_BY="[Empty name]">
<P>Participants received diacerein (50 mg) or placebo BID for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:52:53 -0500" MODIFIED_BY="[Empty name]">
<P>The primary end point was the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score at four weeks. Secondary end points were AUSCAN pain score at 12 weeks and AUSCAN physical function and stiffness score, participant and physician global assessments, functional index of hand OA scores and multi-dimensional health assessment questionnaire results at four weeks and 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:53:00 -0500" MODIFIED_BY="[Empty name]">
<P>The following additional information is pending:</P>
<UL>
<LI>Description of the process used for allocation concealment</LI>
<LI>Details of outcomes</LI>
</UL>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-08 14:05:55 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-01-14 14:52:32 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-26 22:09:25 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Diacerein and placebo arms were randomly assigned using a computer-generated random number list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>Randomisation in blocks of four to ensure uniform distribution to the treatment groups at each study centre. Trial samples were numbered consecutively and were handed out to participants in the order of inclusion. Treatment groups were matched with respect to age, gender, weight and duration of arthrosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>The centralised allocation schedule was prepared using a blocked randomisation technique (blocking factor of 4)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>Randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>Each participant was randomly assigned to a treatment group using a randomisation table generated by a validated computer software</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:48:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 22:09:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>The centralised allocation schedule was prepared by using a blocked randomisation technique (blocking factor eight). Treatments were divided between the two countries (treatments 1 to 500 in Israel and 600 to 1000 in Canada) and were allocated to each centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>The randomised allocation schedule was centralised (Cassene Laboratories)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-11-26 22:09:28 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-20 09:06:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Opaque sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>Allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:48:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 22:09:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-14 14:52:32 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:47:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Blinding only for the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>Double blind. Medications were packaged individually and labelled with the study number, the participant number and the randomisation number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>Double-blind. Participants were randomly assigned to receive one indistinguishable capsule of placebo or diacerein</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:48:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>Pills were unidentifiable and all participants were allowed to take analgesics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-14 14:52:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>Double-blind for participants and personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:49:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>Double-blinding of participants and personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>The same packaging boxes were used for both groups with the medications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-08-16 17:44:35 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-01-14 14:52:29 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Clinical outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Radiographic outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Single blind. Each participant was followed up at monthly intervals for 12 weeks. Outcomes assessed were pain, WOMAC subscores for stiffness and physical function, clinical global assessment by the physician and use of rescue medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>No reference was made to assessors' blinding in evaluating clinical outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>A central reader expert radiologist was unaware of participants' identity, study group, signal hip and sequence of radiographs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-14 14:52:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:47:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:48:02 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>The same investigator did the clinical evaluation and applied questionnaires</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:48:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 22:09:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>Blinding for assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 22:09:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:49:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:49:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>No reference about assessors' blinding to evaluate clinical outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>Two observers who were unaware of participants' identity, study group, signal knee and sequence of radiographs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Analysis used a modified intention-to-treat method, including all participants who attended at least one postbaseline visit. Missing values were dealt with by the last observation carried forward method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>ITT participants and per-protocol participants were described without disparities</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>252 participants were randomly assigned to placebo and 255 to diacerein. ITT analysis in 247 placebo and 246 diacerein participants. PP analysis in 138 placebo and 131 diacerein</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>93 participants in the placebo group and 90 in the diacerein group. ITT analysis was done for only some outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:47:27 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>A good description of withdrawals and the reasons for them were provided. 171 were randomly assigned (diacerein 86 and control 85); however, ITT analysis was performed in only 161 (82 diacerein, 79 control). 10 participants (four diacerein, six control) were excluded from ITT because they did not take any dose of medication. 150 participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:48:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>Withdrawn participants were well described, and all randomly assigned participants were evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:48:31 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>168 participants were randomly assigned; however, 165 participants were included in the ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:49:30 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>Three populations were evaluated: one for safety and two for efficacy</P>
<P>Safety population received the medications at least once. An intention-to-treat population was evaluated with at least one postbaseline visit. A per-protocol population with all postbaseline visits completed was also evaluated. Four participants were excluded from ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>Intention-to-treat analysis was done for efficacy outcomes. Structural evaluation was analysed only in participants with X-rays in the baseline table. Nine participants were excluded from the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brahmachari-2009">
<DESCRIPTION>
<P>Appropriate methods to compare results were used and well described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chantre-2000">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:10 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dougados-2001">
<DESCRIPTION>
<P>Outcomes were analysed at baseline and at the end of the study. One evaluation described in the baseline table was not reported at the end of the study: participant assessment on the Likert scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lequesne-1998">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:47:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louthrenoo-2007">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:48:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nguyen-1994">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:48:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavelka-2007">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-2000">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:49:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 20:50:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zheng-2006">
<DESCRIPTION>
<P>All data were properly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-02-06 16:07:40 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-02-06 16:07:40 -0500" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-11-26 21:30:01 -0500" MODIFIED_BY="Grade Profiler">Diacerein compared with placebo for osteoarthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Diacerein compared to placebo for osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with osteoarthritis<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> diacerein<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Diacerein</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain overall visual analogue scale for pain</B>
<BR/>Scale from: 0 to 100<BR/>Follow-up: three to 36 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain overall visual analogue scale for pain in control groups was<BR/>
<B>43 mm </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean pain overall visual analogue scale for pain in the intervention groups was<BR/>
<B>8.65 points lower</B>
<BR/>(15.62 to 1.68 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1,283<BR/>(six studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>NNTB 6 (4 to 30)<SUP>5</SUP>
</P>
<P>Absolute risk difference -9% (-16% to -2%)</P>
<P>Relative percentage change -19% (-34% to -4%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Physical function</B>&#8212;<B> Lequesne Impairment Index</B>
<BR/>Scale from: 0 to 24<BR/>Follow-up: two to 36 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean physical function&#8212;Lequesne Impairment Index in control groups was<BR/>
<B>9 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean physical function&#8212;Lequesne Impairment Index in intervention groups was<BR/>
<B>0.29 points lower</B>
<BR/>(0.87 lower to 0.28 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1,006<BR/>(four studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>NNTB: non&#8211;statistically significant<SUP>5</SUP> Absolute risk difference 0% (-4% to 1%)</P>
<P>Relative percentage change -4% (-11% to 4%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Radiographic progression</B>&#8212;<B> minimum joint space width</B>
<BR/>
</P>
<P>(decreased over 0.50 mm during the study period)</P>
<P>Follow-up: 12 to 36 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>494 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>420 per 1000</B>
<BR/>(355 to 489)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.72 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>616<BR/>(two studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>NNTB 14 (8 to 203)<SUP>5</SUP>
</P>
<P>Absolute risk difference -6% (-15% to 2%)</P>
<P>Relative percentage change -15% (-28% to -1%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of Life </B>not measured</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This outcome was not measured.<SUP>6</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse event: diarrhoea</B>
<BR/>Follow-up: two to 36 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>359 per 1000</B>
<BR/>(247 to 521)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.52 </B>
<BR/>(2.42 to 5.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1.462<BR/>(seven studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>NNTH 4 (7 to 3)<SUP>7</SUP>
</P>
<P>Absolute risk difference 24% (12<B>% </B>to 35%)</P>
<P>Relative percentage change 252% (142% to 411%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Withdrawal due to adverse events</B>
<BR/>Follow-up: two to 36 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>153 per 1000</B>
<BR/>(98 to 238)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.29 </B>
<BR/>(0.83 to 2.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1,476<BR/>(seven studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>NNTH: non&#8211;statistically significant<SUP>7</SUP>
</P>
<P>Absolute risk difference 0% (-3% to 4%)</P>
<P>Relative percentage change 0% (-29% to 41%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Total number of serious adverse events </B>not measured</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This outcome was not measured in any of our studies<SUP>8</SUP>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>High heterogeneity (I<SUP>2</SUP> = 84%). Reduction of heterogeneity could be explained by post hoc sensitivity analysis between studies, with follow-up lasting longer than six months.</P>
<P>
<SUP>2</SUP>No allocation concealment in most studies.<BR/>
<SUP>3</SUP>Total number of events is less than 300.<BR/>
<SUP>4</SUP>Unexplained heterogeneity.<BR/>
<SUP>5</SUP>NNTB: number needed to treat for an additional beneficial outcome.</P>
<P>
<SUP>6</SUP>One study<SUP> </SUP>compared diacerein versus non-steroidal anti-inflammatory drugs (NSAIDs) and there was no difference in the quality of life of participants in the two groups (MD -40.70, 95% CI -85.20 to 3.80).</P>
<P>
<SUP>7</SUP>NNTH: number needed to treat for an additional harmful outcome.</P>
<P>
<SUP>8</SUP>Although diacerein is known to cause diarrhoea as a side effect, the PRAC (http://www.ema.europa.eu) on 8 November 2013, concluded that there was a high number of cases, particularly of severe diarrhoea, which sometimes led to complications. The Committee was also concerned about liver problems that had been reported in some patients taking the medicine.</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-09-15 14:32:25 -0400" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-01-16 16:58:30 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-01-15 11:30:15 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>DIACEREIN VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="30.898722080323836" CI_END="-1.6762164284176206" CI_START="-15.622142935876003" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.649179682146812" ESTIMABLE="YES" I2="83.81810099782743" I2_Q="85.69437982051674" ID="CMP-001.01" MODIFIED="2013-12-01 19:50:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="9.808612799533378E-6" P_Q="1.2701892694311212E-5" P_Z="0.015052405629697653" Q="27.961038737325733" RANDOM="YES" SCALE="72.11" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="62.11809796058731" TOTALS="YES" TOTAL_1="638" TOTAL_2="645" UNITS="" WEIGHT="100.0" Z="2.4311157331507878">
<NAME>Visual analogic Scale for Pain</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.11103321613488859" CI_START="-16.11103321613489" DF="0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2013-03-06 17:08:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0532197261604856" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="15.972452064802665" Z="1.9331337276648721">
<NAME>Hip</NAME>
<CONT_DATA CI_END="0.11103321613488859" CI_START="-16.11103321613489" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="48.0" ORDER="2206" SD_1="26.0" SD_2="24.0" SE="4.138358296434875" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" WEIGHT="15.972452064802665"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.231410134149888" CI_START="-5.231410134149888" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2013-11-26 21:55:09 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="252" WEIGHT="18.27959452521712" Z="0.0">
<NAME>Hip change score</NAME>
<CONT_DATA CI_END="5.231410134149887" CI_START="-5.231410134149887" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-3.0" MODIFIED="2013-07-08 17:10:56 -0400" MODIFIED_BY="[Empty name]" ORDER="2205" SD_1="30.2" SD_2="29.9" SE="2.6691358491352815" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" WEIGHT="18.27959452521712"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.2239118857746725" CI_START="-18.97608811422533" DF="0" EFFECT_SIZE="-11.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2013-12-01 19:50:09 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.002053828400929149" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="86" WEIGHT="16.592869417591565" Z="3.082336038911654">
<NAME>Hip and/or knee</NAME>
<CONT_DATA CI_END="-4.223911885774672" CI_START="-18.97608811422533" EFFECT_SIZE="-11.600000000000001" ESTIMABLE="YES" MEAN_1="38.5" MEAN_2="50.1" MODIFIED="2012-08-28 09:43:30 -0400" MODIFIED_BY="[Empty name]" ORDER="2207" SD_1="23.9" SD_2="25.3" SE="3.763379415339757" STUDY_ID="STD-Lequesne-1998" TOTAL_1="85" TOTAL_2="86" WEIGHT="16.592869417591565"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-18.88501236788" CI_START="-38.314987632119994" DF="0" EFFECT_SIZE="-28.599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" MODIFIED="2013-07-08 17:12:01 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="7.929616717286648E-9" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="14.60104260679953" Z="5.769947639718537">
<NAME>Knee</NAME>
<CONT_DATA CI_END="-18.88501236788" CI_START="-38.314987632119994" EFFECT_SIZE="-28.599999999999998" ESTIMABLE="YES" MEAN_1="30.7" MEAN_2="59.3" MODIFIED="2013-07-08 17:12:01 -0400" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="16.4" SD_2="20.1" SE="4.956717423764201" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="14.60104260679953"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.7834357976358435" CI_END="3.7011013628295073" CI_START="-11.777690967366333" DF="1" EFFECT_SIZE="-4.038294802268413" ESTIMABLE="YES" I2="64.07317888023981" ID="CMP-001.01.05" MODIFIED="2013-11-26 21:55:26 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.09524373848154277" P_Z="0.30645999760759723" STUDIES="2" TAU2="20.50341724167675" TOTAL_1="195" TOTAL_2="209" WEIGHT="34.554041385589116" Z="1.0226782816849445">
<NAME>Knee change score</NAME>
<CONT_DATA CI_END="-2.4454280045817063" CI_START="-12.354571995418294" EFFECT_SIZE="-7.4" ESTIMABLE="YES" MEAN_1="-18.3" MEAN_2="-10.9" MODIFIED="2013-07-08 17:11:01 -0400" MODIFIED_BY="[Empty name]" ORDER="2208" SD_1="19.3" SD_2="19.3" SE="2.5278893053644484" STUDY_ID="STD-Pelletier-2000" TOTAL_1="110" TOTAL_2="124" WEIGHT="18.47545909113558"/>
<CONT_DATA CI_END="8.586207787919037" CI_START="-7.386207787919034" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="-33.9" MEAN_2="-34.5" MODIFIED="2013-07-08 17:11:04 -0400" MODIFIED_BY="[Empty name]" ORDER="2209" SD_1="25.7" SD_2="27.4" SE="4.074670683192764" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" WEIGHT="16.078582294453536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1507906785065285" CI_END="0.28133124978653645" CI_START="-0.8699849214073422" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29432683581040286" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-12-01 19:51:18 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7080480115755337" P_Q="0.5518221142028801" P_Z="0.31629276924780025" Q="2.1004483712000606" RANDOM="YES" SCALE="12.422429584671304" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="505" TOTAL_2="501" UNITS="" WEIGHT="99.99999999999999" Z="1.0021052640541432">
<NAME>Lequesne Impairment Index</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.05034230730646816" CI_END="0.4023605710049978" CI_START="-1.976509344390382" DF="1" EFFECT_SIZE="-0.7870743866926921" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2013-03-06 17:11:23 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8224687017674651" P_Z="0.1946484539697794" STUDIES="2" TAU2="0.0" TOTAL_1="106" TOTAL_2="110" WEIGHT="23.42328601358821" Z="1.2969498172961125">
<NAME>Hip</NAME>
<CONT_DATA CI_END="1.2077816206383454" CI_START="-3.2077816206383454" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="9.2" ORDER="2211" SD_1="4.5" SD_2="4.9" SE="1.126439892800605" STUDY_ID="STD-Lequesne-1998" TOTAL_1="31" TOTAL_2="39" WEIGHT="6.798560879869008"/>
<CONT_DATA CI_END="0.7118461447816693" CI_START="-2.1118461447816697" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="8.4" ORDER="2212" SD_1="4.6" SD_2="4.1" SE="0.720342902174801" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" WEIGHT="16.624725133719203"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7140972117062575" CI_START="-0.7140972117062575" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2013-12-01 19:50:43 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="255" TOTAL_2="252" WEIGHT="64.98521251519125" Z="0.0">
<NAME>Hip - change score</NAME>
<CONT_DATA CI_END="0.7140972117062575" CI_START="-0.7140972117062575" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.5" MODIFIED="2013-03-06 17:11:23 -0500" MODIFIED_BY="[Empty name]" ORDER="2210" SD_1="4.0" SD_2="4.2" SE="0.3643420069649061" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" WEIGHT="64.98521251519125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7086748807595586" CI_START="-2.908674880759558" DF="0" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" MODIFIED="2013-03-06 17:11:31 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.23325694714036582" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="54" WEIGHT="10.129971045574909" Z="1.1920110164236135">
<NAME>Knee</NAME>
<CONT_DATA CI_END="0.7086748807595584" CI_START="-2.9086748807595577" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="8.6" ORDER="2213" SD_1="4.9" SD_2="4.9" SE="0.9228102633651203" STUDY_ID="STD-Lequesne-1998" TOTAL_1="59" TOTAL_2="54" WEIGHT="10.129971045574909"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.861685181606639" CI_START="-4.661685181606643" DF="0" EFFECT_SIZE="0.09999999999999787" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" MODIFIED="2013-12-01 19:51:18 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9671674318375414" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="1.461530425645621" Z="0.04116114169225066">
<NAME>Knee - change score</NAME>
<CONT_DATA CI_END="4.861685181606639" CI_START="-4.661685181606643" EFFECT_SIZE="0.09999999999999787" ESTIMABLE="YES" MEAN_1="-18.8" MEAN_2="-18.9" MODIFIED="2013-03-06 17:11:31 -0500" MODIFIED_BY="[Empty name]" ORDER="2214" SD_1="14.7" SD_2="16.9" SE="2.4294758572944226" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" WEIGHT="1.461530425645621"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.4925707462409714" CI_END="56.52230593986092" CI_START="-173.897653421545" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-58.68767374084204" ESTIMABLE="YES" I2="59.8807776466087" I2_Q="59.8807776466087" ID="CMP-001.03" MODIFIED="2013-11-26 22:02:31 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.114385023527934" P_Q="0.114385023527934" P_Z="0.31808509711239663" Q="2.4925707462409714" RANDOM="YES" SCALE="244.31" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4905.433304810184" TOTALS="YES" TOTAL_1="192" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="0.9984007217714461">
<NAME>WOMAC total</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.33967213097381" CI_START="-306.3396721309738" DF="0" EFFECT_SIZE="-148.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2013-03-06 17:16:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06695481708011962" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="30.224745110032842" Z="1.8319772032367667">
<NAME>Knee</NAME>
<CONT_DATA CI_END="10.33967213097381" CI_START="-306.3396721309738" EFFECT_SIZE="-148.0" ESTIMABLE="YES" MEAN_1="834.0" MEAN_2="982.0" MODIFIED="2008-08-25 14:51:28 -0400" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="507.5" SD_2="530.1" SE="80.78703148626043" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="30.224745110032842"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.622052790931338" CI_START="-33.377947209068665" DF="0" EFFECT_SIZE="-20.000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2013-11-26 21:55:49 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0033880757176303965" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="124" WEIGHT="69.77525488996716" Z="2.93014160380515">
<NAME>Knee change score</NAME>
<CONT_DATA CI_END="-6.622052790931338" CI_START="-33.377947209068665" EFFECT_SIZE="-20.000000000000004" ESTIMABLE="YES" MEAN_1="-36.7" MEAN_2="-16.7" MODIFIED="2013-03-06 17:16:24 -0500" MODIFIED_BY="[Empty name]" ORDER="2215" SD_1="52.3" SD_2="51.9" SE="6.825608692094449" STUDY_ID="STD-Pelletier-2000" TOTAL_1="110" TOTAL_2="124" WEIGHT="69.77525488996716"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.40318102560404423" CI_END="-10.200423283334228" CI_START="-48.45321623766527" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-29.326819760499752" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-11-26 22:02:50 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5254510121485647" P_Q="0.5254510121485647" P_Z="0.00265366860579537" Q="0.40318102560404423" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="3.005245163682573">
<NAME>WOMAC subscore (Pain)</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.097955754976304" CI_START="-70.90204424502369" DF="0" EFFECT_SIZE="-38.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2013-03-06 17:21:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.023595801619923307" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="33.79251725572332" Z="2.2636475368483118">
<NAME>Knee</NAME>
<CONT_DATA CI_END="-5.097955754976304" CI_START="-70.90204424502369" EFFECT_SIZE="-38.0" ESTIMABLE="YES" MEAN_1="153.0" MEAN_2="191.0" MODIFIED="2008-08-25 14:57:01 -0400" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="103.3" SD_2="112.2" SE="16.787065734141454" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="33.79251725572332"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3939521353635662" CI_START="-48.406047864636434" DF="0" EFFECT_SIZE="-24.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2013-11-26 21:56:04 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03787606046491976" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="124" WEIGHT="66.20748274427669" Z="2.076193475657342">
<NAME>Knee change score</NAME>
<CONT_DATA CI_END="-1.3939521353635662" CI_START="-48.406047864636434" EFFECT_SIZE="-24.9" ESTIMABLE="YES" MEAN_1="-58.8" MEAN_2="-33.9" MODIFIED="2013-03-06 17:21:52 -0500" MODIFIED_BY="[Empty name]" ORDER="2216" SD_1="92.5" SD_2="90.5" SE="11.993101939652533" STUDY_ID="STD-Pelletier-2000" TOTAL_1="110" TOTAL_2="124" WEIGHT="66.20748274427669"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6003244743239484" CI_END="-5.3681910218305084" CI_START="-26.214145060319503" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.791168041075005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-11-26 21:56:30 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7406980757000312" P_Q="0.44307044588277944" P_Z="0.0029836955022703037" Q="0.5883179366484633" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="234" UNITS="" WEIGHT="100.00000000000001" Z="2.969412728933593">
<NAME>WOMAC subscore (stiffness)</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.012006537675485296" CI_END="34.654704490801656" CI_START="-38.70974601122759" DF="1" EFFECT_SIZE="-2.0275207602129646" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2013-03-06 17:17:57 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9127469571287755" P_Z="0.9137321484620402" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="110" WEIGHT="8.073692670167228" Z="0.10833224104403988">
<NAME>Knee</NAME>
<CONT_DATA CI_END="36.37637761870928" CI_START="-39.37637761870928" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="52.7" MEAN_2="54.2" MODIFIED="2010-06-04 17:35:40 -0400" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="64.9" SD_2="77.6" SE="19.32503756062525" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="7.572629082509291"/>
<CONT_DATA CI_END="137.24662810846553" CI_START="-157.24662810846553" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="85.0" MODIFIED="2008-08-25 14:43:05 -0400" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="476.0" SD_2="489.0" SE="75.12721114771911" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="0.5010635876579361"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.128940499359112" CI_START="-27.87105950064089" DF="0" EFFECT_SIZE="-17.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2013-11-26 21:56:30 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002176974228112448" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="124" WEIGHT="91.92630732983278" Z="3.0649623190100863">
<NAME>Knee change score</NAME>
<CONT_DATA CI_END="-6.128940499359112" CI_START="-27.87105950064089" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-10.3" MODIFIED="2013-03-06 17:17:57 -0500" MODIFIED_BY="[Empty name]" ORDER="2217" SD_1="42.3" SD_2="42.4" SE="5.546560848255589" STUDY_ID="STD-Pelletier-2000" TOTAL_1="110" TOTAL_2="124" WEIGHT="91.92630732983278"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3867484631196468" CI_END="-47.965397623381115" CI_START="-173.88131285239294" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-110.92335523788702" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-11-26 21:57:02 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8241735462368398" P_Q="0.8919164649645367" P_Z="5.539989204874614E-4" Q="0.0184632671454659" RANDOM="YES" SCALE="559.86" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="234" UNITS="" WEIGHT="100.0" Z="3.4531898674633834">
<NAME>WOMAC subscore (Physical Function)</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36828519597418086" CI_END="-14.473394263560294" CI_START="-218.5032264339665" DF="1" EFFECT_SIZE="-116.48831034876339" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2013-03-06 17:19:13 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5439407402681227" P_Z="0.025218811033919045" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="110" WEIGHT="38.08674940065899" Z="2.2380344136421506">
<NAME>Knee</NAME>
<CONT_DATA CI_END="43.455512374220575" CI_START="-397.4555123742206" EFFECT_SIZE="-177.0" ESTIMABLE="YES" MEAN_1="601.0" MEAN_2="778.0" MODIFIED="2010-06-04 17:39:21 -0400" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="402.0" SD_2="431.0" SE="112.4793690665469" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="8.155664211605757"/>
<CONT_DATA CI_END="15.07722995318646" CI_START="-215.07722995318647" EFFECT_SIZE="-100.0" ESTIMABLE="YES" MEAN_1="606.0" MEAN_2="706.0" MODIFIED="2008-08-25 14:59:08 -0400" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="368.8" SD_2="385.3" SE="58.71395130772859" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="29.93108518905323"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.211766453617042E-31" CI_END="-27.48731805142957" CI_START="-187.5126819485705" DF="0" EFFECT_SIZE="-107.50000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.02" MODIFIED="2013-11-26 21:57:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.008456356365896579" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="124" WEIGHT="61.91325059934101" Z="2.6332841645463714">
<NAME>Knee- change score</NAME>
<CONT_DATA CI_END="-27.487318051429554" CI_START="-187.51268194857047" EFFECT_SIZE="-107.50000000000001" ESTIMABLE="YES" MEAN_1="-193.3" MEAN_2="-85.8" MODIFIED="2013-03-06 17:19:13 -0500" MODIFIED_BY="[Empty name]" ORDER="2218" SD_1="318.0" SD_2="304.4" SE="40.82354705479299" STUDY_ID="STD-Pelletier-2000" TOTAL_1="110" TOTAL_2="124" WEIGHT="61.91325059934101"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.13172017017212984" CI_END="0.9935087184760096" CI_START="0.7190383243933314" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.845204616766352" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.0028283174123362106" LOG_CI_START="-0.1432479613153403" LOG_EFFECT_SIZE="-0.07303813936383828" METHOD="MH" MODIFIED="2014-01-15 11:30:15 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7166552199843272" P_Q="0.7214292057399303" P_Z="0.0414581369201926" Q="0.12712750569539644" RANDOM="YES" SCALE="6.11" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="306" TOTAL_2="310" WEIGHT="100.00000000000001" Z="2.038918753416347">
<NAME>Radiographic Progression</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9914177807117223" CI_START="0.7090584123399122" DF="0" EFFECT_SIZE="0.8384349214799042" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="136" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.0037432964498928124" LOG_CI_START="-0.14931798609767546" LOG_EFFECT_SIZE="-0.07653064127378412" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.039325874270854946" STUDIES="1" TAU2="0.0" TOTAL_1="221" TOTAL_2="225" WEIGHT="93.04306082773279" Z="2.0607607129136154">
<NAME>Hip</NAME>
<DICH_DATA CI_END="0.9914177807117223" CI_START="0.7090584123399122" EFFECT_SIZE="0.8384349214799042" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="136" LOG_CI_END="-0.0037432964498928124" LOG_CI_START="-0.14931798609767546" LOG_EFFECT_SIZE="-0.07653064127378412" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2224" O_E="0.0" SE="0.08551129330544308" STUDY_ID="STD-Dougados-2001" TOTAL_1="221" TOTAL_2="225" VAR="0.0073121812827695145" WEIGHT="93.04306082773279"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7372376875481232" CI_START="0.5098974971232251" DF="0" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.23985924235531197" LOG_CI_START="-0.2925171198000103" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8462839433350345" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="6.956939172267226" Z="0.19386199431563353">
<NAME>Knee</NAME>
<DICH_DATA CI_END="1.7372376875481232" CI_START="0.5098974971232251" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.23985924235531197" LOG_CI_START="-0.2925171198000103" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2225" O_E="0.0" SE="0.3127205104355306" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="0.09779411764705882" WEIGHT="6.956939172267226"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="66.83172473852323" CI_END="3.0101540738194004" CI_START="1.8437380331784932" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3558301194330653" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="142" I2="73.06668341955206" I2_Q="90.27618610129936" ID="CMP-001.08" LOG_CI_END="0.4785887253935347" LOG_CI_START="0.2656992145336756" LOG_EFFECT_SIZE="0.37214396996360516" METHOD="MH" MODIFIED="2013-12-01 19:52:26 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.5408131415206583E-7" P_Q="2.518941433216071E-8" P_Z="7.268445638615988E-12" Q="41.136122530425105" RANDOM="YES" SCALE="257.98" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5151424964825524" TOTALS="SUB" TOTAL_1="2195" TOTAL_2="2197" WEIGHT="500.0" Z="6.852275391553358">
<NAME>Adverse Effects</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.278736826193876" CI_END="5.1130644550519015" CI_START="2.418980134920115" DF="6" EFFECT_SIZE="3.5168738028733264" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="75" I2="46.802553402385215" ID="CMP-001.08.01" LOG_CI_END="0.7086812674570152" LOG_CI_START="0.383632301875728" LOG_EFFECT_SIZE="0.5461567846663715" MODIFIED="2013-12-01 19:52:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08013443841427204" P_Z="4.506864859469202E-11" STUDIES="7" TAU2="0.10518413061613976" TOTAL_1="726" TOTAL_2="736" WEIGHT="100.00000000000001" Z="6.586377692013246">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2012-09-17 19:39:50 -0400" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="1.3494074143355588"/>
<DICH_DATA CI_END="5.322483012045283" CI_START="2.613694190537657" EFFECT_SIZE="3.7297912713472487" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="31" LOG_CI_END="0.726114283959723" LOG_CI_START="0.4172547725592328" LOG_EFFECT_SIZE="0.5716845282594779" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2238" O_E="0.0" SE="0.18142560587588685" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" VAR="0.03291525046743263" WEIGHT="26.398609295642654"/>
<DICH_DATA CI_END="6.065441781934146" CI_START="1.7822521940580154" EFFECT_SIZE="3.287878787878788" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="11" LOG_CI_END="0.7828624385857345" LOG_CI_START="0.25096915802758735" LOG_EFFECT_SIZE="0.5169157983066609" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2239" O_E="0.0" SE="0.3124367459140575" STUDY_ID="STD-Lequesne-1998" TOTAL_1="90" TOTAL_2="93" VAR="0.09761672019736535" WEIGHT="17.976411788073808"/>
<DICH_DATA CI_END="30.579764413235388" CI_START="3.1292547029407913" EFFECT_SIZE="9.782222222222222" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" LOG_CI_END="1.4854341352808142" LOG_CI_START="0.49544091360315673" LOG_EFFECT_SIZE="0.9904375244419855" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2240" O_E="0.0" SE="0.5815269189589383" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" VAR="0.33817355747387556" WEIGHT="8.22277746191945"/>
<DICH_DATA CI_END="4.472054498715589" CI_START="0.7901544987886164" EFFECT_SIZE="1.8797909407665505" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6505070874425959" LOG_CI_START="-0.10228798287272159" LOG_EFFECT_SIZE="0.27410955228493716" MODIFIED="2008-08-25 15:32:14 -0400" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.4421955506989141" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" VAR="0.1955369050579159" WEIGHT="12.122968375071387"/>
<DICH_DATA CI_END="3.7003241305780237" CI_START="1.291410572629229" EFFECT_SIZE="2.1860095389507155" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="17" LOG_CI_END="0.568239767838878" LOG_CI_START="0.11106433760314716" LOG_EFFECT_SIZE="0.33965205272101257" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2241" O_E="0.0" SE="0.26854711077534604" STUDY_ID="STD-Pelletier-2000" TOTAL_1="111" TOTAL_2="125" VAR="0.07211755070578599" WEIGHT="20.56174300217682"/>
<DICH_DATA CI_END="15.241596038533594" CI_START="3.063619080730928" EFFECT_SIZE="6.833333333333333" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="6" LOG_CI_END="1.183030446953372" LOG_CI_START="0.4862347657188118" LOG_EFFECT_SIZE="0.8346326063360918" MODIFIED="2012-09-04 08:18:27 -0400" MODIFIED_BY="[Empty name]" ORDER="2242" O_E="0.0" SE="0.40930123235143057" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="0.16752749880439977" WEIGHT="13.36808266278034"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.296950727245053" CI_END="1.5816098795968307" CI_START="0.6133810338270469" DF="3" EFFECT_SIZE="0.9849515232021194" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="9.00682939514799" ID="CMP-001.08.02" LOG_CI_END="0.1990993691539885" LOG_CI_START="-0.21226965683674243" LOG_EFFECT_SIZE="-0.006585143841376976" MODIFIED="2012-09-06 06:19:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34806733840600956" P_Z="0.9499658077769477" STUDIES="4" TAU2="0.021571794758869185" TOTAL_1="526" TOTAL_2="533" WEIGHT="99.99999999999999" Z="0.06274971593221232">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="1.3377773703011435" CI_START="0.30565000206175147" EFFECT_SIZE="0.639446366782007" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.12638384519976273" LOG_CI_START="-0.5147755969446826" LOG_EFFECT_SIZE="-0.19419587587245996" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2243" O_E="0.0" SE="0.3766202301060721" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" VAR="0.14184279772515068" WEIGHT="35.73119537265173"/>
<DICH_DATA CI_END="2.1656511453801133" CI_START="0.3168267024792126" EFFECT_SIZE="0.8283333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3355884994553147" LOG_CI_START="-0.49917822275593776" LOG_EFFECT_SIZE="-0.0817948616503115" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2244" O_E="0.0" SE="0.4903461047888073" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" VAR="0.240439302481556" WEIGHT="22.28531078372924"/>
<DICH_DATA CI_END="6.5533983577688915" CI_START="0.5926299527441239" EFFECT_SIZE="1.9707207207207207" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8164665679748446" LOG_CI_START="-0.2272164021594577" LOG_EFFECT_SIZE="0.2946250829076934" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2245" O_E="0.0" SE="0.6130645429709125" STUDY_ID="STD-Pelletier-2000" TOTAL_1="111" TOTAL_2="125" VAR="0.3758481338481338" WEIGHT="14.692264555668006"/>
<DICH_DATA CI_END="3.2482475981352215" CI_START="0.5820446080173766" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5116491259895466" LOG_CI_START="-0.23504372965698372" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2246" O_E="0.0" SE="0.4386110795960187" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="0.19237967914438503" WEIGHT="27.291229287951015"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.172483791864113" CI_END="4.2303191622632905" CI_START="0.9366726751164159" DF="3" EFFECT_SIZE="1.9905839259657934" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" I2="5.436869127793518" ID="CMP-001.08.03" LOG_CI_END="0.6263731345572694" LOG_CI_START="-0.028412148948175203" LOG_EFFECT_SIZE="0.2989804928045471" MODIFIED="2012-09-17 19:48:07 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.36578878506764834" P_Z="0.07347445398353018" STUDIES="4" TAU2="0.04260633770854735" TOTAL_1="443" TOTAL_2="435" WEIGHT="100.0" Z="1.7898722306029853">
<NAME>Rash or Pruritus</NAME>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2012-09-17 19:48:07 -0400" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="7.5099796725252554"/>
<DICH_DATA CI_END="5.687540199564877" CI_START="1.0127400946441956" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.7549244792717626" LOG_CI_START="0.005498004151449391" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2247" O_E="0.0" SE="0.4402168212065535" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" VAR="0.19379084967320265" WEIGHT="62.579302588152366"/>
<DICH_DATA CI_END="3.6665131972514864" CI_START="0.1086321562585614" EFFECT_SIZE="0.6311111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5642532525344609" LOG_CI_START="-0.9640415999910731" LOG_EFFECT_SIZE="-0.19989417372830603" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2248" O_E="0.0" SE="0.8977279615550283" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" VAR="0.8059154929577464" WEIGHT="17.43452034526227"/>
<DICH_DATA CI_END="48.779291273021116" CI_START="0.7380181027745047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.688235486046344" LOG_CI_START="-0.13193298527905675" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2249" O_E="0.0" SE="1.0691759700357846" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="1.143137254901961" WEIGHT="12.476197394060105"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.554657008155325E-7" CI_END="28.403209359620533" CI_START="5.960002960812442" DF="1" EFFECT_SIZE="13.010888204881095" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="6" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="1.4533674149915994" LOG_CI_START="0.775246475489261" LOG_EFFECT_SIZE="1.1143069452404302" MODIFIED="2013-11-26 21:58:07 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9995242937743765" P_Z="1.1842850928801357E-10" STUDIES="2" TAU2="0.0" TOTAL_1="340" TOTAL_2="337" WEIGHT="100.0" Z="6.441333258332625">
<NAME>Urine Descolouration</NAME>
<DICH_DATA CI_END="29.293671335155935" CI_START="5.7796108526027625" EFFECT_SIZE="13.011764705882353" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="6" LOG_CI_END="1.4667738046170973" LOG_CI_START="0.7618985978916762" LOG_EFFECT_SIZE="1.1143362012543867" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2250" O_E="0.0" SE="0.4140471856190584" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" VAR="0.171435071919063" WEIGHT="92.55285927603462"/>
<DICH_DATA CI_END="227.19734249530424" CI_START="0.7438467287683742" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.356403247169373" LOG_CI_START="-0.1285165425556999" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2251" O_E="0.0" SE="1.459654185035848" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="2.1305903398926653" WEIGHT="7.447140723965381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8516281461576309" CI_END="2.0902973445587936" CI_START="0.4400014923427461" DF="1" EFFECT_SIZE="0.9590276070301358" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.32020806884595626" LOG_CI_START="-0.356545850524902" LOG_EFFECT_SIZE="-0.018168890839472863" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3560922319712885" P_Z="0.9161863553674733" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="156" WEIGHT="100.0" Z="0.1052387601020814">
<NAME>Epigastralgia</NAME>
<DICH_DATA CI_END="1.944552535258242" CI_START="0.2592370176993208" EFFECT_SIZE="0.71" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2888196808157256" LOG_CI_START="-0.586302983377575" LOG_EFFECT_SIZE="-0.14874165128092473" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2252" O_E="0.0" SE="0.514051384874197" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" VAR="0.2642488262910798" WEIGHT="59.803099905687915"/>
<DICH_DATA CI_END="5.126255284061417" CI_START="0.4389168848058959" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7098002299595318" LOG_CI_START="-0.3576177118481694" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2253" O_E="0.0" SE="0.6270065828218717" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="0.3931372549019607" WEIGHT="40.196900094312085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.779944643358252" CI_END="1.0154627619401932" CI_START="0.6481753367603009" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8112939773523097" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="204" I2="61.21015720421136" I2_Q="69.27659235306822" ID="CMP-001.09" LOG_CI_END="0.006664002009250629" LOG_CI_START="-0.1883074980071177" LOG_EFFECT_SIZE="-0.09082174799893357" METHOD="MH" MODIFIED="2013-12-01 19:53:00 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.004047707793868316" P_Q="0.038586781166230155" P_Z="0.06785277185747458" Q="6.50969457224167" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.16607903551956266" TOTALS="SUB" TOTAL_1="1479" TOTAL_2="1504" WEIGHT="300.0" Z="1.8259833368050038">
<NAME>Drop Out</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.12145542327790385" CI_END="0.8701896340279334" CI_START="0.4876519893025077" DF="1" EFFECT_SIZE="0.6514212969378134" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="94" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.06038609446467846" LOG_CI_START="-0.31188999980594917" LOG_EFFECT_SIZE="-0.18613804713531382" MODIFIED="2013-12-01 19:52:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7274613562213503" P_Z="0.003718091528182092" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="384" WEIGHT="100.00000000000001" Z="2.9011387957797092">
<NAME>Ineffective intervention</NAME>
<DICH_DATA CI_END="0.9235670103648992" CI_START="0.48360892952533147" EFFECT_SIZE="0.6683152349209762" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="71" LOG_CI_END="-0.03453158839276073" LOG_CI_START="-0.3155056887712027" LOG_EFFECT_SIZE="-0.17501863858198172" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2229" O_E="0.0" SE="0.16504557740652495" STUDY_ID="STD-Dougados-2001" TOTAL_1="262" TOTAL_2="259" VAR="0.02724004262145322" WEIGHT="80.12294199571419"/>
<DICH_DATA CI_END="1.1248603662620558" CI_START="0.3068896723686076" EFFECT_SIZE="0.5875440658049353" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="0.05109861495795312" LOG_CI_START="-0.5130177264550912" LOG_EFFECT_SIZE="-0.23095955574856908" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2230" O_E="0.0" SE="0.3313647313669479" STUDY_ID="STD-Pelletier-2000" TOTAL_1="111" TOTAL_2="125" VAR="0.10980258519388955" WEIGHT="19.877058004285825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.876975466449508" CI_END="2.0060578914198737" CI_START="0.8286942129553021" DF="6" EFFECT_SIZE="1.2893442385464655" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="88" I2="49.48208812126447" ID="CMP-001.09.02" LOG_CI_END="0.3023434618655661" LOG_CI_START="-0.08160569396715339" LOG_EFFECT_SIZE="0.11036888394920634" MODIFIED="2013-12-01 19:53:00 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06477036598508812" P_Z="0.2598224801108533" STUDIES="7" TAU2="0.1407724973748849" TOTAL_1="733" TOTAL_2="743" WEIGHT="99.99999999999999" Z="1.1268108512189154">
<NAME>Adverse effect</NAME>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2010-06-05 10:18:47 -0400" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="2.459617967744888"/>
<DICH_DATA CI_END="3.3139922692254036" CI_START="1.4814130702408428" EFFECT_SIZE="2.215714661753093" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="29" LOG_CI_END="0.520351490976298" LOG_CI_START="0.1706761720345137" LOG_EFFECT_SIZE="0.3455138315054059" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2231" O_E="0.0" SE="0.20540101326714874" STUDY_ID="STD-Dougados-2001" TOTAL_1="262" TOTAL_2="259" VAR="0.04218957625117141" WEIGHT="27.801073402660695"/>
<DICH_DATA CI_END="1.317248520995168" CI_START="0.5897274187701824" EFFECT_SIZE="0.8813725490196078" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.11966771961985126" LOG_CI_START="-0.2293486796772289" LOG_EFFECT_SIZE="-0.054840480028688805" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2232" O_E="0.0" SE="0.20501396060614474" STUDY_ID="STD-Lequesne-1998" TOTAL_1="90" TOTAL_2="93" VAR="0.04203072404341787" WEIGHT="27.825231958804657"/>
<DICH_DATA CI_END="4.823378698974418" CI_START="0.41804720836635556" EFFECT_SIZE="1.42" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.683351361117054" LOG_CI_START="-0.37877467235094114" LOG_EFFECT_SIZE="0.15228834438305647" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2233" O_E="0.0" SE="0.6238980896677596" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="71" VAR="0.3892488262910798" WEIGHT="9.596863015999508"/>
<DICH_DATA CI_END="5.8223349011543295" CI_START="0.5388990213170031" EFFECT_SIZE="1.771341463414634" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7650971824734899" LOG_CI_START="-0.26849260511618656" LOG_EFFECT_SIZE="0.24830228867865164" MODIFIED="2008-08-25 15:28:12 -0400" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.60713575758214" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" VAR="0.368613828134839" WEIGHT="9.985627379555368"/>
<DICH_DATA CI_END="1.8678702147419324" CI_START="0.4191376465912996" EFFECT_SIZE="0.8848133848133848" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2713466968514773" LOG_CI_START="-0.3776433294487053" LOG_EFFECT_SIZE="-0.053148316298614016" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2234" O_E="0.0" SE="0.38121995400116887" STUDY_ID="STD-Pelletier-2000" TOTAL_1="111" TOTAL_2="125" VAR="0.14532865332865333" WEIGHT="17.778824119626638"/>
<DICH_DATA CI_END="6.9362988648102615" CI_START="0.1441691050933911" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8411277973490133" LOG_CI_START="-0.8411277973490133" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2235" O_E="0.0" SE="0.9881652636251156" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" VAR="0.9764705882352942" WEIGHT="4.552762155608241"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4105895671573779" CI_END="1.6103157009784286" CI_START="0.4875057516795293" DF="1" EFFECT_SIZE="0.8860237955308181" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.20691102743067719" LOG_CI_START="-0.3120202560517096" LOG_EFFECT_SIZE="-0.052554614310516175" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5216704311417235" P_Z="0.6913751593414279" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="377" WEIGHT="100.0" Z="0.3969895612335008">
<NAME>Other</NAME>
<DICH_DATA CI_END="1.6330455415241465" CI_START="0.34972727309041074" EFFECT_SIZE="0.7557251908396947" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.21299829628403277" LOG_CI_START="-0.45627049840046147" LOG_EFFECT_SIZE="-0.12163610105821432" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2236" O_E="0.0" SE="0.3931318029316359" STUDY_ID="STD-Dougados-2001" TOTAL_1="262" TOTAL_2="252" VAR="0.1545526144762786" WEIGHT="60.119942041120446"/>
<DICH_DATA CI_END="2.90037866455474" CI_START="0.43723947753508974" EFFECT_SIZE="1.1261261261261262" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4624547017579143" LOG_CI_START="-0.3592806333151163" LOG_EFFECT_SIZE="0.051587034221399" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2237" O_E="0.0" SE="0.48269140347740913" STUDY_ID="STD-Pelletier-2000" TOTAL_1="111" TOTAL_2="125" VAR="0.232990990990991" WEIGHT="39.88005795887955"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-01-15 15:55:59 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>DIACEREIN VS NSAIDs</NAME>
<CONT_OUTCOME CHI2="0.030334356718907877" CI_END="82.16879382678522" CI_START="-23.16513768822903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="29.50182806927809" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-11-26 22:03:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8617337756602869" P_Q="1.0" P_Z="0.2722526629351867" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="171" UNITS="" WEIGHT="100.0" Z="1.097889723894639">
<NAME>WOMAC subscore (Physical Function)</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.030334356718907877" CI_END="82.16879382678522" CI_START="-23.16513768822903" DF="1" EFFECT_SIZE="29.50182806927809" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2010-05-08 23:51:02 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8617337756602869" P_Z="0.2722526629351867" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="171" WEIGHT="100.0" Z="1.097889723894639">
<NAME>Knee</NAME>
<CONT_DATA CI_END="122.10524033730943" CI_START="-50.90524033730938" EFFECT_SIZE="35.60000000000002" ESTIMABLE="YES" MEAN_1="301.0" MEAN_2="265.4" MODIFIED="2008-09-29 16:57:33 -0400" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="299.1" SD_2="260.2" SE="44.13613771459664" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="37.06736913599689"/>
<CONT_DATA CI_END="92.29964628262516" CI_START="-40.479646282625225" EFFECT_SIZE="25.909999999999968" ESTIMABLE="YES" MEAN_1="656.17" MEAN_2="630.26" MODIFIED="2010-05-08 23:51:02 -0400" MODIFIED_BY="[Empty name]" ORDER="2256" SD_1="216.11" SD_2="242.6" SE="33.8728909338632" STUDY_ID="STD-Zheng-2006" TOTAL_1="92" TOTAL_2="92" WEIGHT="62.9326308640031"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.801886679565669" CI_START="-85.20188667956576" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-40.700000000000045" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-11-26 21:58:39 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0730496643132095" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="82" TOTAL_2="79" UNITS="" WEIGHT="0.0" Z="1.792520275492256">
<NAME>Quality of Life</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.801886679565669" CI_START="-85.20188667956576" EFFECT_SIZE="-40.700000000000045" ESTIMABLE="YES" MEAN_1="517.9" MEAN_2="558.6" MODIFIED="2013-01-16 07:46:08 -0500" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="146.7" SD_2="141.4" SE="22.70546144245043" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="41.32768073215015" CI_END="3.253494617924116" CI_START="1.282091795808478" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0423708667496085" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="74" I2="73.38345678942795" I2_Q="70.23326943107682" ID="CMP-002.03" LOG_CI_END="0.5123500926411698" LOG_CI_START="0.10791912111560889" LOG_EFFECT_SIZE="0.3101346068783893" METHOD="MH" MODIFIED="2013-12-01 19:53:37 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.1163322382444782E-5" P_Q="0.009323325163922758" P_Z="0.0026473952355059146" Q="13.43782109606638" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8260292881226216" TOTALS="SUB" TOTAL_1="995" TOTAL_2="991" WEIGHT="500.0" Z="3.0059649366033465">
<NAME>Adverse Effects</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.955221477208105" CI_END="6.486273806356481" CI_START="1.5812191559846511" DF="2" EFFECT_SIZE="3.202533433638491" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="23" I2="59.63853464069885" ID="CMP-002.03.01" LOG_CI_END="0.811995277682599" LOG_CI_START="0.19899206704712583" LOG_EFFECT_SIZE="0.5054936723648624" MODIFIED="2013-12-01 19:53:37 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08394361095781466" P_Z="0.001227360254693479" STUDIES="3" TAU2="0.23154030792770888" TOTAL_1="253" TOTAL_2="252" WEIGHT="100.0" Z="3.232444382211162">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="6.712367507738481" CI_START="1.7266471306964437" EFFECT_SIZE="3.404392764857881" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="9" LOG_CI_END="0.8268757264579356" LOG_CI_START="0.23720359127340995" LOG_EFFECT_SIZE="0.5320396588656728" MODIFIED="2008-09-29 19:06:46 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3463763311315353" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="86" TOTAL_2="85" VAR="0.11997656276814302" WEIGHT="36.88540267502948"/>
<DICH_DATA CI_END="15.07804691507192" CI_START="2.5494018035967" EFFECT_SIZE="6.2" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="5" LOG_CI_END="1.178345090277795" LOG_CI_START="0.4064382887187128" LOG_EFFECT_SIZE="0.7923916894982539" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2265" O_E="0.0" SE="0.4534218762360969" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="0.20559139784946237" WEIGHT="29.661177972965728"/>
<DICH_DATA CI_END="3.6148315446241828" CI_START="0.7684390665199228" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5580880634715479" LOG_CI_START="-0.11439056423883529" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2266" O_E="0.0" SE="0.39501727473997283" STUDY_ID="STD-Zheng-2006" TOTAL_1="92" TOTAL_2="92" VAR="0.15603864734299516" WEIGHT="33.453419352004786"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8494848900168166" CI_END="1.6065903032028332" CI_START="0.2946366569311505" DF="2" EFFECT_SIZE="0.6880119155899018" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" I2="48.04499674263527" ID="CMP-002.03.02" LOG_CI_END="0.20590514139110397" LOG_CI_START="-0.5307132218092347" LOG_EFFECT_SIZE="-0.1624040402090654" MODIFIED="2008-09-29 19:08:12 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14591346767801328" P_Z="0.38745824501715975" STUDIES="3" TAU2="0.275678325709671" TOTAL_1="253" TOTAL_2="252" WEIGHT="100.0" Z="0.8642360431272414">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="1.1052299756544546" CI_START="0.4069859652199003" EFFECT_SIZE="0.6706810631229236" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" LOG_CI_END="0.04345265518473899" LOG_CI_START="-0.39042056702206934" LOG_EFFECT_SIZE="-0.17348395591866522" MODIFIED="2008-09-29 19:08:12 -0400" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.2548592784313669" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="86" TOTAL_2="85" VAR="0.064953251802557" WEIGHT="54.963626610536096"/>
<DICH_DATA CI_END="4.214689801499144" CI_START="0.46504015534021936" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6247656163380669" LOG_CI_START="-0.33250954498159085" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2267" O_E="0.0" SE="0.5623081683476385" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="0.31619047619047624" WEIGHT="31.632596240980085"/>
<DICH_DATA CI_END="1.1380949639987872" CI_START="0.017931863254715075" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.05617850161964101" LOG_CI_START="-1.7463745816481546" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2268" O_E="0.0" SE="1.0588286038931702" STUDY_ID="STD-Zheng-2006" TOTAL_1="92" TOTAL_2="92" VAR="1.12111801242236" WEIGHT="13.403777148483812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.922561028335374" CI_END="4.145922219156149" CI_START="0.17648989030859483" DF="2" EFFECT_SIZE="0.8554024536362019" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="31.566869584271583" ID="CMP-002.03.03" LOG_CI_END="0.6176211501196007" LOG_CI_START="-0.7532801668140582" LOG_EFFECT_SIZE="-0.06782950834722877" MODIFIED="2013-11-26 21:59:00 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23193913486823636" P_Z="0.8462147605651458" STUDIES="3" TAU2="0.6896779096131725" TOTAL_1="253" TOTAL_2="252" WEIGHT="100.0" Z="0.19395034756693685">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="4.444208047182261" CI_START="0.34345243007023807" EFFECT_SIZE="1.2354651162790697" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.647794381418319" LOG_CI_START="-0.46413340646075624" LOG_EFFECT_SIZE="0.09183048747878142" MODIFIED="2008-09-29 19:12:27 -0400" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.6531518867314883" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="86" TOTAL_2="85" VAR="0.42660738714090285" WEIGHT="58.09147273540771"/>
<DICH_DATA CI_END="72.48563796148957" CI_START="0.12416252726894049" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.860251965578492" LOG_CI_START="-0.9060094561391671" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2270" O_E="0.0" SE="1.6249156523318318" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="2.6403508771929824" WEIGHT="19.473302194339464"/>
<DICH_DATA CI_END="2.034693908793341" CI_START="0.006067585379300212" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3084990849516475" LOG_CI_START="-2.2169841038302973" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2271" O_E="0.0" SE="1.483481326433918" STUDY_ID="STD-Zheng-2006" TOTAL_1="92" TOTAL_2="92" VAR="2.2007168458781363" WEIGHT="22.43522507025282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.31053393679524" CI_END="22.8880176063985" CI_START="2.108067217841161" DF="1" EFFECT_SIZE="6.9461845352265135" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="1.3596081788743983" LOG_CI_START="0.3238844546771708" LOG_EFFECT_SIZE="0.8417463167757845" MODIFIED="2013-11-26 21:59:48 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5773528334287983" P_Z="0.0014436577459783972" STUDIES="2" TAU2="0.0" TOTAL_1="161" TOTAL_2="160" WEIGHT="100.0" Z="3.1857771072657592">
<NAME>Bowel Motility Disorders</NAME>
<DICH_DATA CI_END="23.7971359639551" CI_START="1.2417713510290254" EFFECT_SIZE="5.436046511627907" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3765246919348157" LOG_CI_START="0.0940416359951219" LOG_EFFECT_SIZE="0.7352831639649688" MODIFIED="2008-09-29 19:11:17 -0400" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.7533368954524886" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="86" TOTAL_2="85" VAR="0.5675164780499938" WEIGHT="65.22056798631809"/>
<DICH_DATA CI_END="83.08264109094112" CI_START="1.4563812417512714" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.919510293748843" LOG_CI_START="0.16327507656760715" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2269" O_E="0.0" SE="1.03162126007679" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="1.064242424242424" WEIGHT="34.77943201368192"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.42270830169518" CI_START="0.2440864961934055" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.03.05" LOG_CI_END="2.0103962554363837" LOG_CI_START="-0.6124562467643462" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2961937310981523" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.0446306329638646">
<NAME>Rash or Pruritus</NAME>
<DICH_DATA CI_END="102.42270830169518" CI_START="0.2440864961934055" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0103962554363837" LOG_CI_START="-0.6124562467643462" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2272" O_E="0.0" SE="1.540676543121987" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="2.373684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5167555037496245" CI_END="2.4350345551014967" CI_START="0.3804137049662213" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9624554622562722" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="43.129398735067994" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.3865051285828584" LOG_CI_START="-0.4197438453518985" LOG_EFFECT_SIZE="-0.016619358384520087" METHOD="MH" MODIFIED="2013-11-26 22:00:12 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17232423834303645" P_Q="1.0" P_Z="0.9355992614882439" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2950412013311497" TOTALS="YES" TOTAL_1="267" TOTAL_2="267" WEIGHT="100.0" Z="0.0808021961773287">
<NAME>Drop Out</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5838694852422042" CI_START="0.1132838464218674" EFFECT_SIZE="0.42358803986710963" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19971939178982867" LOG_CI_START="-0.9458320134375675" LOG_EFFECT_SIZE="-0.37305631082386936" MODIFIED="2010-06-05 10:42:44 -0400" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.6729025660014821" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="86" TOTAL_2="85" VAR="0.452797863331379" WEIGHT="29.991998547778646"/>
<DICH_DATA CI_END="14.390718876174342" CI_START="0.6254030863531523" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1580824892915473" LOG_CI_START="-0.20383997985222232" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2273" O_E="0.0" SE="0.8" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" VAR="0.64" WEIGHT="23.98737949664668"/>
<DICH_DATA CI_END="2.145951762365302" CI_START="0.3846102801816226" EFFECT_SIZE="0.9084905660377358" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.33161995547987555" LOG_CI_START="-0.414979111760347" LOG_EFFECT_SIZE="-0.04167957814023574" MODIFIED="2010-06-05 10:42:26 -0400" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.4385559878218935" STUDY_ID="STD-Zheng-2006" TOTAL_1="106" TOTAL_2="107" VAR="0.1923313544544368" WEIGHT="46.02062195557467"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.483120214539968" CI_START="-6.483120214539968" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-12-01 19:54:10 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6440199145146446" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="0.4620856324022614">
<NAME>Pain VAS 0 to 100</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diacerein</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.483120214539968" CI_START="-6.483120214539968" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="38.0" MODIFIED="2013-04-13 14:13:13 -0400" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="26.0" SD_2="27.0" SE="4.328202090167848" STUDY_ID="STD-Nguyen-1994" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="38.148268692976416" CI_START="-10.148268692976416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2014-01-15 15:55:59 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.255834201723419" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="79" UNITS="" WEIGHT="100.0" Z="1.1362924660326315">
<NAME>Womac Pain</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diacerein</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="38.148268692976416" CI_START="-10.148268692976416" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="84.7" MEAN_2="70.7" MODIFIED="2014-01-15 15:55:59 -0500" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="85.8" SD_2="70.0" SE="12.32077164858889" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.407592249378272" CI_START="-3.8075922493782706" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2014-01-14 14:57:43 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6178808156060678" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="107" UNITS="" WEIGHT="99.99999999999999" Z="0.4988560275562766">
<NAME>Pain on walking 20 m</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diacerein</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.407592249378272" CI_START="-3.8075922493782706" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="28.6" MEAN_2="27.3" MODIFIED="2013-04-13 14:55:11 -0400" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="19.7" SD_2="18.3" SE="2.605962298116857" STUDY_ID="STD-Zheng-2006" TOTAL_1="106" TOTAL_2="107" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-01-14 14:58:09 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>DIACEREIN VS OTHER SYSADOA(Symptom modifier slow acting drug for OA)</NAME>
<CONT_OUTCOME CHI2="0.6693577503269372" CI_END="7.232582744170955" CI_START="-4.215644685392501" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5084690293892271" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2013-12-01 20:22:27 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4132759394463307" P_Q="0.4132759394463307" P_Z="0.6055003328848336" Q="0.6693577503269372" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="0.5165070291601844">
<NAME>Visual analogue scale for pain</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>SYSADOA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.67199342092408" CI_START="-4.671993420924087" DF="0" EFFECT_SIZE="4.4999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" MODIFIED="2013-12-01 20:22:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.33624789582622805" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="52" WEIGHT="38.948347538555666" Z="0.9616053485504609">
<NAME>Knee and/or hip</NAME>
<CONT_DATA CI_END="13.67199342092408" CI_START="-4.671993420924087" EFFECT_SIZE="4.4999999999999964" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="31.3" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2285" SD_1="22.8" SD_2="22.9" SE="4.679674470179859" STUDY_ID="STD-Chantre-2000" TOTAL_1="44" TOTAL_2="52" WEIGHT="38.948347538555666"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.925875625212395" CI_START="-7.725875625212392" DF="0" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" MODIFIED="2013-12-01 20:22:27 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9147763202932353" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="61.051652461444334" Z="0.10701595739871565">
<NAME>Knee-change score</NAME>
<CONT_DATA CI_END="6.925875625212395" CI_START="-7.725875625212392" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="-33.9" MEAN_2="-33.5" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2286" SD_1="25.7" SD_2="28.5" SE="3.7377603277396756" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" WEIGHT="61.051652461444334"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1675110269332965" CI_END="1.7337137324587046" CI_START="-0.9981895980828884" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.36776206718790816" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-12-01 19:55:28 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6823336307090158" P_Q="0.6823336307090158" P_Z="0.597713819820249" Q="0.1675110269332965" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="0.5276910046633332">
<NAME>Lequesne Impairment Index</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>SYSADOA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7139529849230561" CI_START="-1.173952984923057" DF="0" EFFECT_SIZE="0.2699999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2013-12-01 19:55:13 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.714001568369723" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="52" WEIGHT="89.48794976474102" Z="0.3664871926934744">
<NAME>Knee and/or hip</NAME>
<CONT_DATA CI_END="1.7139529849230561" CI_START="-1.173952984923057" EFFECT_SIZE="0.2699999999999996" ESTIMABLE="YES" MEAN_1="7.42" MEAN_2="7.15" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2287" SD_1="3.2" SD_2="3.98" SE="0.7367242440742654" STUDY_ID="STD-Chantre-2000" TOTAL_1="43" TOTAL_2="52" WEIGHT="89.48794976474102"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.413001542355625" CI_START="-3.0130015423556262" DF="0" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2013-12-01 19:55:28 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5766657974938176" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="10.51205023525898" Z="0.5582615524353709">
<NAME>Knee-change score</NAME>
<CONT_DATA CI_END="5.413001542355625" CI_START="-3.0130015423556262" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" MEAN_1="-18.8" MEAN_2="-20.0" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2288" SD_1="14.7" SD_2="16.5" SE="2.1495300809541624" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" WEIGHT="10.51205023525898"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.908561213197437" CI_START="0.6022585019376441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0721227621483376" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.2807060936157644" LOG_CI_START="-0.22021706045615747" LOG_EFFECT_SIZE="0.03024451657980342" METHOD="MH" MODIFIED="2013-12-01 19:55:43 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8129084063001146" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="131" WEIGHT="100.0" Z="0.23667567667566103">
<NAME>Radiographic progression</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>NRD101</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.908561213197437" CI_START="0.6022585019376441" EFFECT_SIZE="1.0721227621483376" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.2807060936157644" LOG_CI_START="-0.22021706045615747" LOG_EFFECT_SIZE="0.03024451657980342" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2291" O_E="0.0" SE="0.29424474031145015" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.08657996720095273" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="54.581355005527385" CI_END="1.882467244040864" CI_START="1.0678709060434832" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4178265061322195" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="213" I2="83.51085274616473" I2_Q="84.42607303728343" ID="CMP-003.04" LOG_CI_END="0.2747274279770839" LOG_CI_START="0.028518754395124666" LOG_EFFECT_SIZE="0.15162309118610431" METHOD="MH" MODIFIED="2013-12-01 20:24:50 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.4634287781589705E-8" P_Q="8.864099223515609E-7" P_Z="0.01577778382375801" Q="38.52592871639753" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4925576633251794" TOTALS="SUB" TOTAL_1="775" TOTAL_2="1103" WEIGHT="700.0" Z="2.4140156691146917">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>SYSADOA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.635597347943292" CI_END="3.3447314189257176" CI_START="0.5969346530111402" DF="1" EFFECT_SIZE="1.4130060470400976" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="117" I2="84.92976671783813" ID="CMP-003.04.01" LOG_CI_END="0.5243612497685379" LOG_CI_START="-0.2240732088873773" LOG_EFFECT_SIZE="0.15014402044058037" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0099961053533697" P_Z="0.43164501684481116" STUDIES="2" TAU2="0.33491046582877054" TOTAL_1="145" TOTAL_2="193" WEIGHT="100.0" Z="0.786379806953474">
<NAME>Total</NAME>
<DICH_DATA CI_END="4.215940118287216" CI_START="1.1169276289230254" EFFECT_SIZE="2.17" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6248944336840633" LOG_CI_START="0.048025034012995786" LOG_EFFECT_SIZE="0.3364597338485295" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2292" O_E="0.0" SE="0.33885594091636706" STUDY_ID="STD-Chantre-2000" TOTAL_1="60" TOTAL_2="62" VAR="0.11482334869431644" WEIGHT="42.97612071027723"/>
<DICH_DATA CI_END="1.1581814783290352" CI_START="0.9029782020566639" EFFECT_SIZE="1.022649807586586" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="107" LOG_CI_END="0.06377661540324868" LOG_CI_START="-0.044322733452574425" LOG_EFFECT_SIZE="0.009726940975337144" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2293" O_E="0.0" SE="0.0634980926183173" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.0040320077661644025" WEIGHT="57.02387928972277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7541907608686648" CI_START="0.16058176402289284" DF="0" EFFECT_SIZE="0.34800759013282734" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="31" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-0.12251879217480825" LOG_CI_START="-0.7943037755822804" LOG_EFFECT_SIZE="-0.4584112838785443" MODIFIED="2013-12-01 20:23:11 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007475766354470561" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="100.0" Z="2.674872552081878">
<NAME>Knee pain after intra-articular injection</NAME>
<DICH_DATA CI_END="0.7541907608686648" CI_START="0.16058176402289284" EFFECT_SIZE="0.34800759013282734" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="31" LOG_CI_END="-0.12251879217480825" LOG_CI_START="-0.7943037755822804" LOG_EFFECT_SIZE="-0.4584112838785443" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2294" O_E="0.0" SE="0.3946098246428482" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.1557169137046594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.403616114586952" CI_END="7.160382461262037" CI_START="2.5359959301237547" DF="1" EFFECT_SIZE="4.2613027092533615" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="16" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.8549362201262285" LOG_CI_START="0.40414855223563606" LOG_EFFECT_SIZE="0.6295423861809323" MODIFIED="2013-12-01 20:23:28 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5252276426190761" P_Z="4.3916805994970464E-8" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="193" WEIGHT="100.00000000000001" Z="5.474330783846999">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="8.459600177666537" CI_START="1.2925013256903648" EFFECT_SIZE="3.3066666666666666" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9273498376564644" LOG_CI_START="0.11143099721256804" LOG_EFFECT_SIZE="0.5193904174345162" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2295" O_E="0.0" SE="0.4792747657401429" STUDY_ID="STD-Chantre-2000" TOTAL_1="60" TOTAL_2="62" VAR="0.22970430107526885" WEIGHT="30.524610439702368"/>
<DICH_DATA CI_END="8.878732262930829" CI_START="2.5557963381438955" EFFECT_SIZE="4.763636363636364" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="11" LOG_CI_END="0.948350960089633" LOG_CI_START="0.4075262435613701" LOG_EFFECT_SIZE="0.6779386018255016" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2296" O_E="0.0" SE="0.3176831156142246" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.10092256194636079" WEIGHT="69.47538956029764"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3046955757974845" CI_END="3.1346885995953118" CI_START="0.7425448724876205" DF="1" EFFECT_SIZE="1.5256627892410886" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="0.4961944044348212" LOG_CI_START="-0.12927729650917658" LOG_EFFECT_SIZE="0.18345855396282232" MODIFIED="2013-12-01 20:23:52 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5809536791327119" P_Z="0.25024145361267747" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="193" WEIGHT="100.0" Z="1.1497631559677053">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="4.919638352365202" CI_START="0.2170439575633492" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6919331785102621" LOG_CI_START="-0.6634523002810415" LOG_EFFECT_SIZE="0.014240439114610285" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2297" O_E="0.0" SE="0.7961601395083375" STUDY_ID="STD-Chantre-2000" TOTAL_1="60" TOTAL_2="62" VAR="0.6338709677419354" WEIGHT="21.29558983052261"/>
<DICH_DATA CI_END="3.8173368808899535" CI_START="0.7528866943120528" EFFECT_SIZE="1.6952941176470588" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.5817604882319458" LOG_CI_START="-0.12327037803255277" LOG_EFFECT_SIZE="0.22924505509969656" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2298" O_E="0.0" SE="0.41413862080283986" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.1715107972404784" WEIGHT="78.7044101694774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9025496838850469" CI_START="0.19975088660135698" DF="0" EFFECT_SIZE="0.6164705882352941" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-003.04.05" LOG_CI_END="0.27933600691718197" LOG_CI_START="-0.6995112843783141" LOG_EFFECT_SIZE="-0.2100876387305661" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.4001660610578316" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="100.0" Z="0.8413247074811951">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.9025496838850469" CI_START="0.19975088660135698" EFFECT_SIZE="0.6164705882352941" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.27933600691718197" LOG_CI_START="-0.6995112843783141" LOG_EFFECT_SIZE="-0.2100876387305661" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2299" O_E="0.0" SE="0.5749797442792115" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.33060170633138747" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.496457180722505" CI_START="0.46020339768634483" DF="0" EFFECT_SIZE="0.8298642533936652" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" I2="0.0" ID="CMP-003.04.06" LOG_CI_END="0.1750642945527649" LOG_CI_START="-0.33705017925498165" LOG_EFFECT_SIZE="-0.08099294235110839" MODIFIED="2013-12-01 20:24:32 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5352892540145876" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="100.0" Z="0.6199522104102656">
<NAME>Influenza-like and respiratory symptoms</NAME>
<DICH_DATA CI_END="1.496457180722505" CI_START="0.46020339768634483" EFFECT_SIZE="0.8298642533936652" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="0.1750642945527649" LOG_CI_START="-0.33705017925498165" LOG_EFFECT_SIZE="-0.08099294235110839" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2300" O_E="0.0" SE="0.30081857692219977" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.0904918162214974" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="349.6710496308564" CI_START="1.1386178485052305" DF="0" EFFECT_SIZE="19.953488372093027" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.04.07" LOG_CI_END="2.5436596771876196" LOG_CI_START="0.05637798735061818" LOG_EFFECT_SIZE="1.300018832269119" MODIFIED="2013-12-01 20:24:50 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.04048020271373614" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="131" WEIGHT="100.0" Z="2.0488150585294327">
<NAME>Urine discolouration</NAME>
<DICH_DATA CI_END="349.6710496308564" CI_START="1.1386178485052305" EFFECT_SIZE="19.953488372093023" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.5436596771876196" LOG_CI_START="0.05637798735061818" LOG_EFFECT_SIZE="1.3000188322691189" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2301" O_E="0.0" SE="1.4610415768531886" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="2.1346424892936517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5895844387541489" CI_END="2.5758824966815395" CI_START="0.7812089005771632" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4185564258246988" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.4109260480485161" LOG_CI_START="-0.10723281729211034" LOG_EFFECT_SIZE="0.15184661537820293" METHOD="MH" MODIFIED="2014-01-14 14:58:09 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.44258000625215654" P_Q="1.0" P_Z="0.25066483440920695" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="145" TOTAL_2="193" WEIGHT="100.00000000000001" Z="1.1487361009251043">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>SYSADOA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.934841392605523" CI_START="0.8186132327468247" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.46758463567648584" LOG_CI_START="-0.08692123933590289" LOG_EFFECT_SIZE="0.1903316981702915" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2302" O_E="0.0" SE="0.3257194958306268" STUDY_ID="STD-Chantre-2000" TOTAL_1="60" TOTAL_2="62" VAR="0.10609318996415772" WEIGHT="87.31996687993632"/>
<DICH_DATA CI_END="4.115181141173122" CI_START="0.14429649825922974" EFFECT_SIZE="0.7705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.6143889566516902" LOG_CI_START="-0.8407442080967096" LOG_EFFECT_SIZE="-0.11317762572250965" MODIFIED="2009-04-28 22:57:35 -0400" MODIFIED_BY="[Empty name]" ORDER="2303" O_E="0.0" SE="0.8547524239985445" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="131" VAR="0.7306017063313875" WEIGHT="12.680033120063694"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-12-01 20:26:39 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Diacerein versus Placebo/ Sensitivity</NAME>
<CONT_OUTCOME CHI2="0.10789292661196548" CI_END="4.856518099949126" CI_START="-3.895692992318773" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4804125538151766" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2013-12-01 20:26:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7425559157343771" P_Q="1.0" P_Z="0.8296375104075703" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="340" TOTAL_2="337" UNITS="" WEIGHT="100.0" Z="0.2151664975335207">
<NAME>Pain on VAS (0 to 100 mm)</NAME>
<GROUP_LABEL_1>Diacerein</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.10789292661196548" CI_END="4.856518099949126" CI_START="-3.895692992318773" DF="1" EFFECT_SIZE="0.4804125538151766" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" MODIFIED="2013-12-01 20:26:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7425559157343771" P_Z="0.8296375104075703" STUDIES="2" TAU2="0.0" TOTAL_1="340" TOTAL_2="337" WEIGHT="100.0" Z="0.2151664975335207">
<NAME>Longer studies (longer than six months)</NAME>
<CONT_DATA CI_END="5.231410134149887" CI_START="-5.231410134149887" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-3.0" MODIFIED="2013-05-22 14:41:50 -0400" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="30.2" SD_2="29.9" SE="2.6691358491352815" STUDY_ID="STD-Dougados-2001" TOTAL_1="255" TOTAL_2="252" WEIGHT="69.97421538655149"/>
<CONT_DATA CI_END="9.586207787919037" CI_START="-6.386207787919034" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="-33.9" MEAN_2="-35.5" MODIFIED="2013-05-22 12:53:54 -0400" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="25.7" SD_2="27.4" SE="4.074670683192764" STUDY_ID="STD-Pham-2004" TOTAL_1="85" TOTAL_2="85" WEIGHT="30.02578461344851"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-01-16 16:58:30 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Subgroup Analysis_Carry over effect</NAME>
<CONT_OUTCOME CHI2="13.437782461218621" CI_END="-2.130496141475801" CI_START="-24.25434691896337" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.192421530219587" ESTIMABLE="YES" I2="85.11659192450846" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2013-12-01 20:25:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0012078798894500364" P_Q="1.0" P_Z="0.019415921998233693" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="79.06924712522832" TOTALS="YES" TOTAL_1="224" TOTAL_2="227" UNITS="" WEIGHT="100.0" Z="2.3374476105590074">
<NAME>Pain on VAS 0 to 100 mm</NAME>
<GROUP_LABEL_1>diacerein carry over</GROUP_LABEL_1>
<GROUP_LABEL_2>control carry over</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-15.137741083623421" CI_START="-38.06225891637658" EFFECT_SIZE="-26.6" ESTIMABLE="YES" MEAN_1="33.4" MEAN_2="60.0" MODIFIED="2010-06-05 22:55:39 -0400" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="20.8" SD_2="22.5" SE="5.848198745889932" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="28.122101830873483"/>
<CONT_DATA CI_END="-4.122258399909339" CI_START="-19.277741600090668" EFFECT_SIZE="-11.700000000000003" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="48.5" MODIFIED="2010-06-05 22:51:27 -0400" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="25.5" SD_2="26.8" SE="3.866265737464016" STUDY_ID="STD-Lequesne-1998" TOTAL_1="90" TOTAL_2="93" WEIGHT="33.88111447080872"/>
<CONT_DATA CI_END="-0.321881374890685" CI_START="-8.878118625109314" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="5.7" MODIFIED="2010-06-05 22:52:29 -0400" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="14.2" SD_2="17.5" SE="2.182753692850771" STUDY_ID="STD-Zheng-2006" TOTAL_1="106" TOTAL_2="107" WEIGHT="37.996783698317806"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.6204767666868705" CI_END="-7.473670498327493" CI_START="-153.2583398981769" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-80.3660051982522" ESTIMABLE="YES" I2="86.87746146840145" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2014-01-16 11:28:11 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005770978293649032" P_Q="1.0" P_Z="0.03070154949634386" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2404.490125568653" TOTALS="YES" TOTAL_1="164" TOTAL_2="162" UNITS="" WEIGHT="100.0" Z="2.1609196140907225">
<NAME>WOMAC A (Pain)</NAME>
<GROUP_LABEL_1>diacerein carry over</GROUP_LABEL_1>
<GROUP_LABEL_2>control carry over</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-77.98294364655473" CI_START="-158.81705635344528" EFFECT_SIZE="-118.4" ESTIMABLE="YES" MEAN_1="82.9" MEAN_2="201.3" MODIFIED="2010-06-05 22:35:41 -0400" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="88.3" SD_2="161.5" SE="20.621326040809866" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="48.879039244962634"/>
<CONT_DATA CI_END="-9.98795141182162" CI_START="-78.01204858817837" EFFECT_SIZE="-44.0" ESTIMABLE="YES" MEAN_1="148.0" MEAN_2="192.0" MODIFIED="2010-06-05 22:41:24 -0400" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="109.8" SD_2="113.1" SE="17.353404887263785" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="51.120960755037366"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1021176377258473" CI_END="-10.314979475634761" CI_START="-30.519443143830284" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-20.417211309732522" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2014-01-16 16:58:21 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9502227806367904" P_Q="1.0" P_Z="7.457285762830423E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="189" UNITS="" WEIGHT="100.0" Z="3.9612037705125154">
<NAME>WOMAC B (Stiffness)</NAME>
<GROUP_LABEL_1>diacerein carry over</GROUP_LABEL_1>
<GROUP_LABEL_2>control carry over</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.159146144681856" CI_START="-50.75914614468185" EFFECT_SIZE="-14.799999999999997" ESTIMABLE="YES" MEAN_1="47.2" MEAN_2="62.0" MODIFIED="2010-06-05 22:56:59 -0400" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="50.7" SD_2="81.3" SE="18.34684026253697" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="7.892524161234482"/>
<CONT_DATA CI_END="-6.021254112507513" CI_START="-35.57874588749248" EFFECT_SIZE="-20.799999999999997" ESTIMABLE="YES" MEAN_1="36.1" MEAN_2="56.9" MODIFIED="2010-06-05 22:37:39 -0400" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="37.2" SD_2="56.2" SE="7.5403150282685525" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="46.726096135466896"/>
<CONT_DATA CI_END="-6.003894635967729" CI_START="-35.996105364032275" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="88.0" MODIFIED="2010-06-05 22:40:37 -0400" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="46.8" SD_2="51.4" SE="7.6512147581892505" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="45.38137970329861"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.194519684707361" CI_END="-103.30193703429217" CI_START="-363.2972569842562" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-233.29959700927418" ESTIMABLE="YES" I2="52.31873610483404" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2014-01-16 16:58:30 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12279249039453721" P_Q="1.0" P_Z="4.357328838868747E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="6752.676209328377" TOTALS="YES" TOTAL_1="192" TOTAL_2="189" UNITS="" WEIGHT="100.0" Z="3.5174387587736975">
<NAME>WOMAC C (Physical function)</NAME>
<GROUP_LABEL_1>diacerein carry over</GROUP_LABEL_1>
<GROUP_LABEL_2>control carry over</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="80.22518270619003" CI_START="-432.22518270619" EFFECT_SIZE="-176.0" ESTIMABLE="YES" MEAN_1="581.0" MEAN_2="757.0" MODIFIED="2010-06-05 22:58:01 -0400" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="538.0" SD_2="427.0" SE="130.72953621967625" STUDY_ID="STD-Brahmachari-2009" TOTAL_1="28" TOTAL_2="27" WEIGHT="18.45083527908786"/>
<CONT_DATA CI_END="-207.57154250612052" CI_START="-474.82845749387945" EFFECT_SIZE="-341.2" ESTIMABLE="YES" MEAN_1="297.8" MEAN_2="639.0" MODIFIED="2010-06-05 22:43:49 -0400" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="322.9" SD_2="516.5" SE="68.17903724146142" STUDY_ID="STD-Louthrenoo-2007" TOTAL_1="82" TOTAL_2="79" WEIGHT="38.58599984318035"/>
<CONT_DATA CI_END="-45.26548336533487" CI_START="-276.7345166346651" EFFECT_SIZE="-161.0" ESTIMABLE="YES" MEAN_1="544.0" MEAN_2="705.0" MODIFIED="2010-06-05 22:42:16 -0400" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="366.1" SD_2="392.1" SE="59.04930781767636" STUDY_ID="STD-Pavelka-2007" TOTAL_1="82" TOTAL_2="83" WEIGHT="42.96316487773179"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-10-08 14:26:21 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAAA+IElEQVR42u3df8QV+fv48TdJkmRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAroAAAEACAMAAABrmiWlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-01-14 14:52:33 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAALdCAIAAAAajscrAAAh90lEQVR42u3dva4lR9XG8SMhIYIJ
Jpgr4BomQiMiiLgnHE5gCYe+C8QlIAyhcUSGgDHCEzgYQ8aX+j1mXqHNmb1799eqXqvq92iC0faZ
55R717/XWtXVtR4eiGg0TUQ0hjBPhHkiwjwRYZ6IME9EmCcizBMR5okI80SEeaJdM/5y6mOeaBTg
n/wF80SYxzwR5jFPVHHGDws85okwT0SYJ+ptxv9nzsvtifqf7rf+gnkizGOeCPOYJypaz9t7S0SY
JyLME/WU26vniTqf7i4C5gnzmCeCPeaJ1POYJxLkMU+EecwTwR7zRCmKefU8EWGeiDBP1Ed6j3mi
zqf73U8wT4R5zBNhHvNE6nnMExHmiQjzRKeU9HJ7onRkHjs/reFhnrIDfyyZmMc8jcX8ZN0e8zQa
84R5yjsvI4K83B7zNNJE9/485mnMqsHtz4WgpGEZqJingaJxxLM6uT3maSDmpfqYp6GZn6zbE2Wr
56PnJ+aJBrqVyO2JCPNEAjLmiaInZQcrBZgnOp95++0xT2Nhj3nM01j1POYxT+p59TxR18wT5gn2
mCdKVsybopgnIswTEeapj/Q+aKXAuj1Rlkl595NszpgnwjzmiRKQ6XEA5mmsep5cUyLME3VaL9jt
g3kqUNKbn5ingYCHPeYJ80fMeLm9eUYZ5+XRWJrqmKfRMwjME/Wf27u8mKekKf2B6X2cM+aJhGLM
ExHmiVbl4UHmmCfqOdW32wfzNBb2mMc8DR3q5fZESev50JWC0RDAPJE4T0SYJzoxvS9ROGCeaPuk
vPvJTuf/HpsjzhMNxPzkWR0R5jFP1Fs9f/kr5PZEhHmifqsGzBPBHvNEnS4TeD5PRJgnOjsOm6KY
p6SI1r2nYJ5o0bxZ8mHCkX/4d+/SEi3FZu1/3RyQg0Y+4MZ7zFPee8rhQGIe83QYnBFkRuTeV9MH
zBOdSaY3YTBPYzE/eRMG8zQa8+EzXk8LM5g2z55awN/9BPNEJ8Opjw3maSDgjyUT85inI2vjEmSq
5zFPe8mM2NaCTMxTduYnT9ExT5jPNlov1WGeDsP+qFdrkIl5IsI80baJLoPAPOXMwEOdr/4d80Tn
LxM0cBbniTCPeaJlGXgV7O3DwzzliplW2jBPYzFPmKcC2FeZRTIIzNMxufchEyn6KWDoe0GYJ8qb
mIz8XhDmCfOYJ+quariKvdyeiDBPRJgnepKKT2Gn00a8t3Prd2GeaGlhfCA/QVt9PryPqOeJzmf+
lsOxzoPPeczTiMyryDBPuyrkY8/DwzzmacT0IbqexzxRt+nD5Dw8zNPhMdkswjxJwgnzhHnCPCm8
CfNEhHlSNahHME+pcnsTCfM0VjQmzBPmj8kgSjhjnmC/fUYu+TCPM+Zp0GI+7r26/beYOGfMExHm
ibaG5bjul+p5ogPS+8OxPDb3dr495ukwfoKOoMc85ikp8yXIxDzmKSk/l9My4vn8sMBjng7D3izC
PBFhnmjVvIzpUek8PMxTLn6aPRFQzxNt4Sd0meDY32XdHvN5YybmMY/5zr+DJR+Oib29t5gfKENO
/tVYD8M8uVsR5qnTnDPowIwp8s18vaswnxH4QlHUzME8DcS8mIl5Gi7ON7uhlHDGPG35JiT2k54W
mKfRsMc85mm4ej6us32cM+ZpL0IuwrHP6oKcMU+7gs/I73sR5sdlfqqzjOdBHeZpFOath2GeDsO+
6LM6EwnzNMRNCvOYp8FmT/xuOefhYb63aFnrGVL02Fru8BPniVbcpzCPeRo0qw/dhwd7zKuNO8/w
4+4m9uFhPi8/Ix+ASZjHPOwJ811jX3HjbegTtZFrKMx3Xsbbvj55fx7zhHnMY55yJSlTTCdJzGOe
MkbjiHcB1fOYp7GYJ8wT5gnzndbGtbbiHTtgvaswP1zMJMI85l0N6/aYh32/ub2zrjE/aDE/8hmY
XqTFPI3FPGGeCmBfpcOU3lWY77Y2PqUeOfC5WpuqQT1P8uSxVgpK7BfGvFmebrSHj7zWfvurVmnJ
wnz/zJvl1e+AmFfPZyHTO2rqeRJ/Dr4DTgHr9nHOJfIdzFPeu9Xhb+xVdMZ8n/O7TX+IcifnYx7z
1PNcxDzmh669B5yLV6vuQmdjXRqq52npFIxYuj+cee+o9TDlXIhscX7A+NMy62lz5TFPdFoG0SA3
qZL1YD5jcKvyjTQ7376Qc8STf8wPkdvnjz/OvS16NTA/SgUbF41De1pMRfbhYZ72RuP8c5HzjLnc
nvrMOd2nCkcXbAyCvb23mMd8utx+cphkqX145TrkYL7/DLwZmSaSOE9nMh8df0wbzNNYcT5ihD3t
w8M8dTJj2oT6cufbF9rJj3l3kyMjZ3J+vL2D+YGqhkJ1eN3z7UtcZMznCsKFYmbRSqdQL13MU8ba
2LO6qmHGhZBB7M8goj33/MbSJ39jvnNEp7Kn2Rx4HZZ8mMcZ87Sdn+qHWA1Yz5db3cA85o+sHXyV
+bMeXxXmKeommHN1A/N95m/UTZmjnqfz44/7VGPmjz0BwbdlLh7mPPgO2bgHGcfWfZjPWNIXPTc6
89tvDXYrVDlfGPPpgC8XfxpE4wGrbsxjPl38Uc+3nB7Htxt0WTuO83Vnea0OU87MoDPv5X3cAUs7
e6+OssTMoPREv7q433VsboL51DEtYi9XrZ4wVbAv1H0M87my+vkPB2G+4hO1qU5XH8x3noEXjfOE
eUpazwO+MfZye+r8PjWl70WtdxUNF3zyZ7PqEcwPxGT0qhXmb/mk7T6GeTpmmSDzWyWhzs66psOm
Ttr40/5q5Hd2ZgadP2PKxR9qc58yCbplvkH8KXc+d8V1k8MzNcz3j330gIP23pZ7r67ZxMB8n8V8
/t6JLdfA5VMH/iLMD5c+VHzuVY7MuEjgWR2dxvzU5C3dKth7Vke5+KnerWnkeh7zovGIV6OiszhP
HTJfbn+LfRCYH6vqnoKPsnFOjtyeEsXMEm+VzETO/M4tr4a+tHQC81PYk//SN+tmOyz0paUT4rz9
/KcUIzvLNMynmCu6zczcqkqcz93yboJ5kptkqXRa3rUx31tm6Pn8VPOcnPxvGWI+xxdQsPsy5ptl
EJgfIs67IEHwBDkXqhowTwNlEM3Sk8zbk3xVeUE63DkiZkpVyuWAmM9YwQ6+D28q9awuustoUHWD
+VzMT6Oe6F70akR3GVXPYz6F81T5HYFCVyOqikRdKuwHPzPDEzXM0zTmvIyrZksAr3fVEEG+ZMTw
rE6cp1TYV3luTAuvszjf0a23Zr/H0Asype8/33hWyO3pNOYnvaibVDr25FAifvSivuVs7y2dn80W
KsK9VxeKPeb7z8A7WODI71won8J8t8y32QfuWd3VL9E+PDonSkTvAw+qYAnzstmxstmp4BmYhXqB
Yp4yVrCFnKNPELEnh/qvYPt4szhtBoH5pLm9c28n79VhfoRZTh8mDlV2K1TpSoL5zpl3cv4puYln
dXQC9k6n7aMewfwoxXyJt9/aIFTrWV3+U7cwTwPxU3FPgTU8OiCJGJZM6/aYz0jmVOEVd8yfhb3c
vsMkOWiWFxrzVOpZXYN9eMf6Y75z5qOx9/JvUDQOzyhR13Gc96yuYtWN+YHq+XKdJyJmebM9bVW6
9x241oN5yljBXv4l7ingmO8sY34gRCdPBCo/q8P8EJHTLMc85nvGfuZrzjnLQ6vuy18RhFCVmW/v
befAH1twFu1jQ+F3EBeiV+an+LUlajw3MN9nSV+CKzPn6jc4BTwRwDylu0k5zyuuhtLTgvZOGtek
EPPqeRoi/S7Xi7pQJyLMYz5dBtFHL+oDPZd8iHkKx77ZDtnJ+/Oez/dddU9FzmB2ZkbtmQa5JKHY
mRlxeXJjZ2t41BvzU819rBXXTTCP+W6nI+YxP2I9H31ERMVVq1rvBWGe3KfSrUEUuk8d/p415ukw
fir2da5yN5kpAzHfA0JVzmCOm/fl4GzfZRTzYmYP9yn1POYxX6aYP3ajWMXcvnH/ecz3gP3ge0Wq
V93FZpoL0X0GEbGrF/aYp+zMT8e949m4Q1vRDDxhpob5vOVxWuZpSfqQ9skl5jtPZSe74jGP+dGY
bzPsom+/5Wd+cgYm7AeMbLU6SSZ/YwLzSYv5tF1NMd/JZENd9+lDoZMtMI95Ssp8s8SnivOxt5Kg
Z6KYTzfLpyLnSVLRDALzMvAs8QfzbZwxLwPPjlDyDDz03hrxFhPmMd9/ZKuYgceNEPPp6vkSa0tF
T+Powxnz1MlcbHYHLJGBx11qzGM+I/MdXOegm5R6vs/EvtA7nlYKqk421A0SNJLfp0LP24peg9C7
imTOGfPkiv8L+tKa93tDkMtb6Bu0J2eUer5EZHM2FuZpxDw5+nTNEs4t79qYp3OYabl3cPBjcNXz
Q+T2oevVmK/FfMhkQ12qaFzuFPpC7aUqvpmP+SHSb1+Kb1Bub8Z0Hn98g22czYOkJf3gdxNnXWOe
+p+LpZ2nOm9DYx7znCslgPtvK5hP99VOpXrCBAVMzIfPNMglica1zsaKe1PNEzXMY57kgMfkgJjv
n/mKu30obm5gPmmqnL82ptBojHlKxLx99S0zNczT+RlE3MuzFZ3bVGf23nZettVdtB/TeSq1Cov5
dMBXqbpl+NH5VNCYMY95KjM9MI/53lYK6jqH7h3U06Jb7MsBHzfLCzk36F0lt6e9kxLzDZyzzwdg
KAUxP1YMwAbm1fNHOSe/lWAe9nTkRfZ8ntIV877ucsx7r24UOF0TzE/220u/qcpdO+3dBPP9My99
kEFgfiDsG+8PG/k1myp3bcx3Xs9Hn+48E44GcbYPj3Ll9u33t0ScyZHfORpRzGP+/Hoe86ekgZiH
fbo6M+6s64rOCcM+5pMW876U6rfsuI294jzNzUJ3k+rMq+cpdXoyuHOJSg3zqWvj5PGn3NJGdJl9
bFYVlKlhvtvMMPq5MeZrRxcXouNqsOWwYZ9/bmC+c+ZbFvNpT31s4ByxUhCUqWG+83p+8pbuSXft
tM4mwShzscqGM8yr5+lI5qfjdrBG5MkVnRuHeu/V9ZbSj9xHrb+vMuhWop7vMDk8vJ6//LJd6ur1
POb7nDEFNnLFZODlnBt8X87MwPxAuUlR5wI1COqyBc/8s1wfm7t5BOapqwyCc/t4MFm3p3Nnud5V
Lb9B5952ntuXIJMaXGfMjxKNST6FecyPm5vkdy5UQ2G+f+xLbzWt62zdntYFn4pr4CMzP9VZN8G8
OhP2lSKB9+fpzDjvzIzCSSU2Et7UR8s5e7q9yu1p6XRxsoV8auauPdmH1yvz+QPF5MyMhjXUsXMD
890yX65HcmfVWdq5YRJkxN43QpinvAHNmRm1MgjMI5OiLnjqcfrCMsyVqxkd1crAy8w331mGuXK5
thz6fR97nwraNlPIOY75y0HK7ftkPnTqRDyXOvzo9XLOcdgHjRnz6eJ8EOoNGq2PzHzcngLMY35j
2MF8m/usOE/iPOYxT/dywriDH5OPmfP8F2cNjzZ+366DOWASEGGeiDBPRJgnIswTEeZHv8REbYX5
M5nnzDmPM+YxzxnzZMZwxjyZMZwxT+YiZ8yTucgZ85if/4F3/3z3+s3rV1+8ev7r5w+/fHj22bOX
n7/86I8fff2Prwd0/ue7d29ev/7i1atfP3/+y4eHz549+/zlyz9+9NE/vjbmY8aM+ZOZ//Qvn774
zYvHr/PDP49f8yd//mQo5798+ulvXry4ZvzwiNOfPzHmA8aM+TOZf7xhX/1GL/88/swgzo+B8Z7x
w+PPGPPOMWP+NOYf7+J3v9T3f27d0XtyfoyWy4wfbkVOYz6S+c2nf4TeTbaZX/1Xt06Y3/Ph/G98
rNNupW1XE7m3f3/bsfNjPXwrPb6aMP/9rTFvGfM65rfBlpD5eZ+rLcE2fHh3nK/fvF74pc5kcd04
v3n9eo3x9WzZmFsw/+RwxQ/D3dUmDR9+uCqczpvPD+PunaIZ86++eHXl+3uva9/ry89fduz8xatX
q/j5/KUxbxnzMczf5eFqV827PzCD1rZ/u7CnZzPm3z96Wf69PvvsWcfO7x9xLf/z2TNj3jLmA+r5
uxXsKkjmgfnwv277t/PXYk/Cf+tKXv/w6jd6qQ++2o6dP5zJL+4YG/OWMR+W21+9Nexkft5qz789
nPlL2sV5cb6fOL8qfu5k/u6Hh6ff8+uUO9N49bx6vqt6fluRvxCt+Yp9w79djqV1e2vgo6/bL6nn
P0xxd+b202zb1uX/dh7Lmf87z+c96x70+TxF7COwD+9S9uG1GTPmz2R+st/+f2W/fZsxY/5M5t/f
0a+v0/4nbfv4y4+Hcn6MnLfWwx8///JjYz5gzJg/mfnp9jvSV+u07p1vvYt+tR42ZsyXZJ4z55bO
mMc8Z8yTGcMZ82TGcMY8mYucMU/mImfMY55IX1pxnjNncR7znDljHvOcOWMe85w5Yx7znDljHvOc
OWM+I/P//ve7b755/fbtqy+/fP6nPz28efPsq69evnv30b///XVa57gerxXHXMsZ8ycz/7e/ffrl
ly8eJ/eHfx4n/V//+klC57gerxXHXM4Z82cy/xi+rs7vyz+PP5PKOe78lopjruiM+dOYf4xpd6f4
+z+34lt757hz2iqOuaLzyczfOkO2/aJI+760j1XrZRL7q189/PCHD9/73rd/fvKTh9/+9mla+69/
vT3dOe481opjruh8MvOrOliFMn9KX9pvvnl9OY+///1vv4Vf/OLh5z//9i8/+MGinLaxc9y56xXH
XNH5TOZnekhs6DZ7tTHu3Z658wOLZv7t21dXE9ff//7bQX73u08//+qrl6c7x/VXqTjmis65mH8y
oIWwre1aO6XpS/v+QdSTP7/73cOPfvTtsH/2s6f/6c2bZ6c7x/VRqzjmis55mV+I0MKW1VOrvrSr
mL8a1n7842+/i5/+9Pra1enOcf1SK465onMx5tc2vb31b5MwfzWyfec73w7vD3+4MsV3xvlDnBvH
+eRjFucPruf3f7h2XXBzX9pj6/lbf/bX8/ud29fzmcesng9Zt99QpW/L7dv3pX2yUv3+z3st34vS
2LnZun2JMVu3D3k+v6Hb7NWGtvPr9qf0pX3yRHp+lu95Pn+gc7Pn8yXG7Pk8rV68sA+v+pjtw6PV
C5b221cfs/32tO7qT///Jtnz22+SfZzQOa7Ha8Uxl3PG/MnMT7ffGL9atSZxjuvxWnHMtZwxfz7z
nDm3dMY85jljnswYzpgnM4Yz5slc5Ix5Mhc5Yx7zRPrSivOcOYvzmOfMGfOY58wZ85jnzBnzmOfM
GfOY58wZ8xmZ1+O1+pj/+e7dm9evv3j16tfPn//y4eGzZ88+f/nyjx999I+vMzpj/mTm9XitPua/
fPrpb168uHqqxSOof/4knTPmz2TemTPVx/wYcu8eYPX4M6mcMX8a886Wqz7mxzi88HDaWzG5vfPB
zC/c+pdwLWT/EbcLW2Vc1pZ6vJYe82OlfSvxvpqK//3t+c4hzLdZkzyW+f1H2S9vj/Nf6fFafcxv
Xr9eY3w9D2/sHM78dKOB1Dxs040z6mei7vKfjOtLu5Z5PV6rj/mLV69Wkfn5y/OdmzK/rfnU4T85
BfSl3Zbb6/FafczvH54t//PZs/OdszM/7etLe+vDtUl+EPN6vFYf84fsvbhjfL5zMebX9qVdkvCf
yLwer9XHLM7HMh/dMXLa0Zd2G/N6vFYfs3p+KTbLC/KdH+68EUQzr8dr9TFbt7//fH7twvvOD1v2
pc38fF5fWs/nA5lP9dQ9//+FPW3Vx2wf3mGEnLKT75Q7l73r1cdsvz2tzlb0eK0+5seYfGul/fHz
Lz9O54z58ysUPV6rj/nWW+5XK+3TnTFfeFWCM2fMY54zZ8xjnjNnzGOeM+YJ85wxT2YMZ8zThqtP
pC+tOM+ZsziPec6cMY95zpwxj3nOnDGPec6cMY95zpwxn5H5uE6snC9VsS9txJgxfzLzcZ1YOV+q
Yl/aoDFj/kzm406G4XypiufkxI0Z86cxH3cCHOcn0bLceXhxYw5hvugdZNVBvaua4TXuxMr5ST1c
7tzbuDFj/ulVuPV/EdFFI64TK+dLVTzfPm7MrZlfeL79quZTt3rdrj3fftrRx2Yb83GdWDlfqmIf
m7gxN2U+orHsrQ+v+i+5JbVkPq4TK+dLVexXFzfmRMxPx3Wb3dyL+hbzd7tlbavn4zqxcv6fDwv2
pY0bc2vm9zSWXd5eatU/X7KGN93rlnVgnD+kEytncT5dnN8Z/Od/6eb+86sbyMfU8/s7sXJWz1et
548t8rPV83GdWDlbtz+B+VuZ/P6+tAvX7Rcu++d5Pn9gJ1bOns9PJfbhdbwX0G65c53tw8N8ov81
u+LbONtvn5H5jnVWJ1bOTyJnub60QWPG/PkpTFwnVs5P6uRyfWkjxoz5wmULZ86YxzxnzpjHPGfO
mMc8Z8wT5jljnswYzpinDVefSF9acZ4zZ3Ee85w5Yx7znDljHvOcOWMe85w5Yx7znDljPiPzcf1S
9aVtc531paUV32tcv1R9adtcZ31pacXVjzsLxTk5ba6zc3JoxdWPO/PMeXhtrvOI5+HtvFmsOn8+
GsvNR9ze3fDY+GxTfWnbXOdBz73tg/noo+wbn2GuL22b6zzo+fbLW9Deah17eY79rQ6z856HHEF/
CPOrzreP61WiL22b6zxoH5ujOlJt7mOzsAXtkj42O33Wtr6K60mmL22b6zxov7oDmV8OWFDvqs2/
cRvzcb1H9aVtc50H7UvbkvmdbW2zMd84zutLK84XjvMRa2/Tjh6Vy+uFc+t5fWnV8+cwv78Ij4jz
8wtyEcw3W7fXl9a6/cHM72lBe6v/7K3Au6cF7fzz86sP2Fc9tF/LfLPn8/rSej5/JPO054mmfXht
nO3Dw3wW5if77Vs522+P+SzMT5H9UvWlbXOd9aWldd/rFNkvVV/aNtdZX1pa971y5tzSGfOY54x5
MmM4Y57MGM6YJ3ORM+bJXOSMecwT6UsrznPmLM5jnjNnzGOeM2fMY54zZ8xjnjNnzGOeM2fMZ2Re
j9dL1erxWtEZ8yczr8frpcr1eK3ojPkzmXfmzKUqnjlT0RnzpzHvbLknEb7c2XIVnU9mfnnLt7MG
s/b83OVXX4/XJzV8uTNkKzqnYH7VodFnjWRhH5tVzOvxeqmKZ8VXdM4S5+ePqZ9HbqZ35ZIOtres
GjCvx+ulKvaEqeicmvmF3WlX3QVWZeAb+tisYl6P10tV7P1W0TlRPb+nm9XdXGDa16/ubp/sbczr
8Xqpij1eKzrnWsPbjO7VflhLOtguXMNbXnHsj/N6vIrzo8T5Y5lf8ovWXqP5JGX+oAI9XtXz6vn7
y2AbUuug3H65z551ez1erdsPtG4/Q9qS1Hra0cE2z/N5PV49nx/i+fzmW8PaH8g5fvvwLmUfXhvn
vMwvOcqvBPCT/faLne23b+Nsv/3JeYoer0+ifa0erxWdMX9+baLH65PavlCP14rOmD+fec6cWzpj
HvOcMU9mDGfMkxnDGfNkLnLGPJmLnDGPeSJ9acV5zpzFecxz5ox5zHPmjHnMc+aMecxz5ox5zHPm
jPmMzMd1Na3Yl7aic61eupg/mfm4rqYV+9JWdC7XSxfzZzIfdxZKxXNyKjpXPNsH86cxH3fmWcXz
8Co6VzzD70zmF+4T3IDWBrflR9xePVR3w/n2cWebVuxLW9G54lm95zN/7ALmZubX9s+Y+S3LP4w7
w7xiX9qKzhXP5M/L/JLOUzOH2C/8+eU3joieFnG9Sir2pa3oXLH3TlLm9zSfvfuXu1nAZubXtr6K
60lWsS9tReeKPfYK1PPbms9u6BI7j3QE83G9Ryv2pa3oXLGXbq44f+t2cIv5meaz82tvSZhvHOeT
96UV50eJ82tX1BY2n92W2+/pUbmwXji3ns/cl1Y9P2I9f2vVbUMQnv/LwqX1aOabrduX6Etr3X7E
dfsPxzRtbT47s24/zfafvfXgfclD+7X/p82ez5foS+v5/BDP58eRfXi9OtuHR6szGvvtqzvbb0/r
rv4U2dW0Yl/ais7leuli/mTmp8iuphX70lZ0rtVLF/PnM8+Zc0tnzGOeM+bJjOGMeTJjOGOezEXO
mCdzkTPmMU+kL604z5mzOI95zpwxj3nOnDGPec6cMY95zpwxj3nOnDGfkfmKfWkrOutLi/kUzFfs
S1vRWV9azKdgvuI5ORWdnZOD+RTMVzwPr6Kz8/DOZ35VR9qFnSf3NKWd9vWlne41w+umL21FZ+fe
ZmF+eUmzlvmd49nQr25bs9qKfWkrOjvfPjvzy0+tf9K16taR+FfdlvSZima+Yl/ais762KRmfm13
mm0/dnhf2m3MV+xLW9FZv7rU9Xwb5tcm+UHMV+xLW9FZX9qMcX7+XjDTdnbPj53OfMW+tBWdxfns
zC9Jtg/5sbWrDB3U8/v70lZ0Vs+XYb5xbr+nL23ydfsD+9JWdLZun5r5zev20+1WtjNLBkvWFzp4
Pn9gX9qKzp7Pp2B+NNmHd66zfXiYz8L8ZL99K2f77TGfhfmpZl/ais760mI+C/NTzb60FZ31pcV8
FuY5c27pjHnMc8Y8mTGcMU9mDGfMk7nIGfNkLnLGPOaJ9KUV5zlzFucxz5kz5jHPmTPmMc+ZM+Yx
z5kz5jHPmTPmMzJfsS+tMV9KX1pa8b1W7EtrzJfSl5ZWXP2K5+QY86Wck0Mrrn7F8/CM+UmEdx7e
kZzc7XUT8eu2fTg/tm760hrzkxreubeBsXFnq+nlv2vzUfZrz7qu2JfWmC/lfPumzC8Jvx/+5OZ2
9xHMV+xLa8yX0semHfMbWtBuaFm3ivn5Ftfd9KU15kvpV3dCPb+wcd2Sf7XwnxzIfMW+tMZ8KX1p
G611z1A304I2lPkNzfCmmn1pjVmcz8L8hpi8vJpYWESsXc+v2JfWmNXz6ZjfHOf39KXd9qyuYl9a
Y7Zuny633xbn9/el3cB8xb60xnwpz+dp9f3LnrbqY7YPj6a1V9/e9epjtt+e1l39qWZfWmN+Eu31
paUV3+tUsy+tMT+p7fWlpRXfK2fOLZ0xj3nOmCczhjPmyYzhjHkyFzljnsxFzpjHPJG+tOI8Z87i
POY5c8Y85jlzxjzmOXPGPOY5c8Y85jlzxnxG5uM6sXK+lL60mE/BfFwnVs6X0pcW8ymYjzsZhvOl
nJOD+RTMx50Ax/lJtHQeXmrmr24hjB7hzr6087sdG3di5fykHnbubaU4H9qO9urV2dAnY8Ph+VNk
J1bOl3K+fSXm55vM3gqw8z85BfSoXN7r9lJxnVg5X0ofm8LMb2tHO/Nfj2V+bW4f14mV86X0qyvD
/J7ucRvS7/kf23CXuXv14zqxcv6fD/WlLcH88u5xC9vRtulLu4r5uE6snMX5npnfsyAXmllsrmD3
d2LlrJ6v96wubml9eXvJxuv2B3Zi5WzdvhLzt474mW9Hu6QF7cy6/f6+tPufzx/YiZWz5/OTfXgL
r0Xj32i3XBtn+/BGZH7JwYCn3GXsim/jbL/90HE+W2YR14mV85PIqS8t5rNUE3GdWDk/qZP1pcV8
7RUEzpwxj3nOnDGPec6cMY95zpgnzHPGPJkxnDFPG64+kb60RHRqEHIhiDBPRJgnIswTEeaJCPNE
hHkiOod5IhpH/wcpnGhStNWwtQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-01-17 09:25:48 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-10-05 12:03:22 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-10-05 12:01:53 -0400" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-05 12:03:22 -0400" MODIFIED_BY="[Empty name]">
<P>1. exp osteoarthritis/<BR/>2. osteoarthr$.tw.<BR/>3. (degenerative adj2 arthritis).tw.<BR/>4. arthrosis.tw.<BR/>5. or/1-4<BR/>6. Diacetylrhein/<BR/>7. Diacerein.tw.<BR/>8. Diacerhein.tw.<BR/>9. Rhein.tw.<BR/>10. Diacetylrhein.tw.<BR/>11. Anthraquinone Derivative/<BR/>12. Anthraquinone$.tw.<BR/>13. or/6-12<BR/>14. 5 and 13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-10-05 12:02:37 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-10-05 11:41:51 -0400" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-05 12:02:37 -0400" MODIFIED_BY="[Empty name]">
<P>CDSR, ACP, DARE, HTA</P>
<P>1. exp osteoarthritis/</P>
<P>2. osteoarthr$.tw.</P>
<P>3. (degenerative adj2 arthritis).tw.</P>
<P>4. arthrosis.tw.</P>
<P>5. or/1-4</P>
<P>6. Diacetylrhein.tw.</P>
<P>7. Diacerein$.tw.</P>
<P>8. Diacerhein.tw.</P>
<P>9. Rhein.tw.</P>
<P>10. Anthraquinone Derivative.tw.</P>
<P>11. exp Anthraquinones/</P>
<P>12. Anthraquinone$.tw.</P>
<P>13. or/6-12</P>
<P>14. 5 and 13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-10-05 12:03:12 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-10-05 11:51:33 -0400" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-05 12:03:12 -0400" MODIFIED_BY="[Empty name]">
<P>1. 'osteoarthritis'/exp</P>
<P>2. osteoarthr*:ab,ti</P>
<P>3. (degenerative NEAR/2 arthritis):ab,ti</P>
<P>4. arthrosis:ab,ti</P>
<P>5. #1 OR #2 OR #3 OR #4</P>
<P>6. 'diacerein'/exp</P>
<P>7. diacerein*:ab,ti</P>
<P>8. diacerhein:ab,ti</P>
<P>9. diacetylrhein:ab,ti</P>
<P>10. 'anthraquinone derivative'/exp</P>
<P>11.'anthraquinone derivative':ab,ti</P>
<P>12. anthraquinon*:ab,ti</P>
<P>13. rhein:ab,ti</P>
<P>14. #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13</P>
<P>15. #6 AND #14</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-01-17 09:25:48 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-10-05 11:52:02 -0400" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-17 09:25:48 -0500" MODIFIED_BY="[Empty name]">
<P>((TW:Osteoarthritis) OR (TW:Osteoartrite) OR (TW: 'Arthritis, Degenerative') OR (MH:C05.550.114.606$) OR (MH:C05.799.613$) OR (TW:osteoarthr$) OR (TW: 'degenerative arthritis') OR (TW: 'artrite degenerativa') OR (TW:arthrosis) OR (TW:artrose)) AND ((TW:Diacetylrhein) OR (TW:Diacerein$.) OR (TW:Diacerhein) OR (TW:rhein) OR (TW: 'Anthraquinone Derivative') OR (TW:Anthraquinone$) OR (TW:Antraquinonas) OR (TW:Antraquinonas) OR (TW:Anthracenediones) OR (MH:D02.455.426.559.847.117.159$) OR (MH:D02.806.100$) OR (MH:D04.615.117.159$))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-12-21 11:32:58 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-12-21 11:32:25 -0500" MODIFIED_BY="[Empty name]">International Clinical Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-21 11:32:58 -0500" MODIFIED_BY="[Empty name]">
<P>Keywords CONTAINS: (Osteoarthritis) OR (degenerative arthritis OR (arthrosis)) AND ((Diacetylrhein) OR (Diacerhein) OR (rhein) OR (Anthraquinone Derivative) OR (Anthraquinone))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;40 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;272 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;272 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;324 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt; 09 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;232 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;30 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>